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ABSTRACT 
Insulin resistance is a common factor in metabolic disorders, such as obesity and Type 
II diabetes mellitus.  In skeletal muscle, insulin can induce the translocation of both 
glucose transporters and the α-subunit of the Na+K+-ATPase to the plasma membrane. 
Whilst the detrimental effects of insulin resistance upon insulin-mediated glucose uptake 
is well recognized, little is known about the effect on Na+K+-ATPase function and the 
potential benefits antidiabetic therapies, such as exercise training and Rosiglitazone can 
have on Na+K+-ATPase function in insulin resistant skeletal muscle.  Therefore the 
primary aim of this dissertation was to determine the effect of insulin resistance on 
Na+K+-ATPase content and activity in rat skeletal muscle, and the possible beneficial 
effects of Rosiglitazone treatment and exercise training.  Since Na+K+-ATPase is a 
membrane-bound enzyme and its function is dependant upon the membrane lipid 
milieu surrounding it, a second focus of this thesis was to examine a possible link 
between changes in enzyme activities and membrane phospholipids.  The first study 
examined the effects of insulin resistance on maximal in vitro Na+K+-ATPase activity 
and content.  The results demonstrated depression in Na+K+-ATPase activity and 
content with insulin resistance in rat skeletal muscle.  This was shown in both, the 
genetically predisposed obese Zucker and high fat diet induced Sprague Dawley rat 
models of insulin resistance.  The findings indicate compromised Na+K+-ATPase 
function, causing a reduced reserve for Na+K+-ATPase activation in insulin resistant 
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skeletal muscle.  This may predispose diabetics to early muscle fatigue with associated 
impaired exercise tolerance and may further progress the development of type II 
diabetes and its associated complications.  Membrane phospholipids influence the 
function and intrinsic activity of transmembrane proteins, such as the Na+K+-ATPase.  
Therefore, the second study investigated Na+-K+-ATPase function and membrane 
phospholipid composition in skeletal muscle of more mature obese Zucker rats.  Insulin 
sensitising agents, Thiazolidinediones (TZD) have also been found to alter membrane 
phospholipids however their effect on Na+-K+-ATPase function has never been 
addressed.  Hence, another purpose of the second study was to evaluate the effects of 
Rosiglitazone, a TZD derivative, on Na+-K+-ATPase function and membrane 
phospholipids in skeletal muscle.  In this study, the Na+K+-ATPase activity, but not 
content, was found to be altered in the obese Zucker rats, which may have been due to 
the altered membrane phospholipid composition and desaturase activity found with this 
phenotype.  Despite insulin sensitivity increasing through Rosiglitazone, Na+K+-ATPase 
activity was reduced in the lean rats only.  Rosiglitazone had either no effect on Na+K+-
ATPase in skeletal muscle of obese Zucker rats or, its effect was not seen because it was 
not additive to the decrease already observed with insulin resistance alone.  The 
reduction in the lean group was not due to a decrease in enzyme content or alterations 
in membrane lipids but may possibly be due to elevated leptin levels or AMPK 
activation, leading to inhibition of the membrane bound Na+K+-ATPase.  Therefore, 
treatment of insulin resistance with Rosiglitazone may increase insulin sensitivity but 
may also affect Na+K+-ATPase, which may limit skeletal muscle function.  This 
apparent lack in pump capacity might lead to a decrease in specific muscle tension and a 
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reduced resistance to muscle fatigue during prolonged contractile activity.  The final 
study for this dissertation investigated the effect of a more therapeutic dose of 
Rosiglitazone, and exercise training in high fat fed rats.  The most important finding was 
the positive effect exercise training had on the reduced Na+K+-ATPase capacity found 
with insulin resistance.  Exercise training significantly increased skeletal muscle Na+K+-
ATPase content and its corresponding maximal activity but had a mixed effect on the 
membrane phospholipid profile.  Rosiglitazone did not have the same desired effect, 
furthermore at more therapeutic doses, did not appear to have any effect.  The other 
disappointing result from this study was that there was no correlation between the 
Na+K+-ATPase function and membrane phospholipids.  In summary, the results of the 
studies undertaken for this thesis repeatedly demonstrated that insulin resistance has a 
detrimental effect on Na+K+-ATPase function in rat skeletal muscle.  This may be due 
to changes in the phospholipid profile however this may depend on the insulin resistant 
animal model used.  More therapeutic doses of the insulin sensitising drug, 
Rosiglitazone do not have an effect on Na+K+-ATPase in skeletal muscle and for the 
first time, it was shown that chronic exercise training increased Na+K+-ATPase activity 
and content, reversing the negative effect of insulin resistance on Na+K+-ATPase 
function. 
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C h a p t e r  1  
 
INTRODUCTION 
The Na+K+-ATPase is an enzyme located in the cytoplasmic membrane of all excitable 
animal cells and is responsible for restoring Na+ and K+ gradients, maintaining the 
membrane potential and consequently the excitability of a cell (Clausen et al., 1998).  
Skeletal muscles contain the majority of Na+K+-ATPase in the body and the ability of a 
muscle to contract resides in the excitability of the cell (Clausen & Everts, 1989).  
Na+K+-ATPase is responsible for re-accumulating the K+ lost, back into the muscle cell 
whilst removing Na+ (Nielsen & Clausen, 2000).   
 
The activity and concentration of the Na+K+-ATPase enzyme is subject to regulation by 
a variety of hormonal and non-hormonal factors.  The major physiological stimuli for 
the Na+K+-ATPase are excitation and hormonal activators.  Excitation is indisputably 
the most effective stimulus (Nielsen & Harrison, 1998), whereby repetitive high-
frequency stimulation often induces a net loss of K+, and a net gain of  Na+, that 
exceeds the maximum capacity for K+ influx and Na+ efflux via the Na+K+-ATPase 
(Lindinger et al., 1995; Hallen, 1996).  The membrane potential of skeletal muscle must 
be restored for the ability of subsequent action potentials to occur.  Under these 
conditions, hormonal induced stimulation of the enzyme can help to restore membrane 
excitability and can also lead to temporary hyperpolarisation of the membrane 
(Overgaard et al., 1997).  A number of hormones can influence the Na+K+-ATPase in an 
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acute or chronic manner, such as insulin, adrenaline, aldosterone and thyroid hormone 
(Ewart & Klip, 1995) but important control of Na+K+-ATPase rate is achieved by its 
sensitivity to insulin.  Two determinants of insulin sensitivity are physical activity and 
lipid metabolism.   
 
In addition to insulin’s important function of regulating blood glucose concentrations, 
the hormone also plays a central role in Na+ and K+ homeostasis.  Insulin has been 
shown to act as a regulator of Na+K+-ATPase in a variety of tissues (Deachapunya et al., 
1999; Feraille et al., 1999; Sweeney & Klip, 2001; Al-Khalili et al., 2003; McKenna et al., 
2003), skeletal muscle being the main target tissue.  Independent of other hormones, 
insulin has been shown to promote the uptake of K+ into skeletal muscle cells primarily 
through stimulation of the Na+K+-ATPase (Brodal et al., 1974), countering the 
hyperkalemia induced by exercise (Kanbe & Kitasato, 1986).  However the mechanisms 
by which insulin exerts its control and the signalling pathways involved remain unclear.  
 
Insulin resistance is the lack of tissue response to insulin and has long been known to be 
a precursor of type II diabetes and is associated with obesity (Cleland et al., 1998).  
Several skeletal muscle defects have been shown to occur with insulin resistance and 
their effect on Na+K+-ATPase and K+ homeostasis has been investigated.  Several 
studies have found a decrease in the Na+K+-ATPase activity and expression with 
diabetes (Kjeldsen et al., 1987; Ng et al., 1993; Takeda et al., 1996; Kuwahara et al., 1997; 
Djurhuus et al., 2001).  Diabetes can cause serious health complications including heart 
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disease, blindness and kidney failure.  Impairment of the Na+K+-ATPase through 
insulin resistance may contribute to these diabetic complications.  
 
The intrinsic activity of Na+-K+-ATPase, is dependant upon the membrane lipid milieu 
surrounding it.  Irregular Na+ ion transport has been seen in disease states with 
abnormal lipid metabolism such as atherosclerosis, obesity and diabetes (Hughes & 
York, 1983; Chen et al., 1995; Makar et al., 1995).  Therefore, the effect of the membrane 
lipid composition on Na+K+-ATPase function may offer an explanation for this 
detrimental effect. 
 
Often treatment for type II diabetes is hindered by the persistence of obesity and a 
pharmacological approach is commonly used to reinstate normoglycemia. Rosiglitazone 
is an oral antidiabetic drug, belonging to a class of insulin sensitizers called 
Thiazolidinediones (TZD) (Cuzzocrea et al., 2004).  Studies have shown Rosiglitazone 
improves hyperglycaemia and hyperinsulinemia in insulin resistant and Type II diabetic 
patients (Lebovitz et al., 2001; Hung et al., 2005).  However TZDs have been shown to 
cause excessive weight gain, fluid retention and repress the gene expression of stearoyl-
CoA desaturase 1, an enzyme which catalyses the desaturation of membrane 
phospholipids (Kurebayashi et al., 1997).  This can cause alterations in the membrane 
structure and function including fluidity, permeability, enzyme activity, ion channels and 
transport (Komers & Vrana, 1998).  TZDs are also known to increase the risk of heart 
failure (Delea et al., 2003). 
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It has been well documented that with regular exercise emerge physiological and 
biochemical benefits.  Exercise training has been shown to decrease insulin resistance 
and increase Na+K+-ATPase concentrations in skeletal muscle suggesting regular 
physical activity could be an important therapeutic strategy in the treatment of type II 
diabetes (McKenna, 1995; McKenna et al., 1996; Green et al., 1999; Juel et al., 2000).   
 
However, very few studies have investigated the effects of insulin resistance on the 
concentration and function of Na+K+-ATPase and none have explored the effects of 
Rosiglitazone or exercise on Na+K+-ATPase in insulin resistant skeletal muscle.  Type II 
diabetes is a major health concern and prevalence is expected to double in the next 25 
years (Dunstan et al., 2002; Agarwal et al., 2005).  Therefore, research that can help 
elucidate mechanisms that contribute to the aetiology as well as the treatments options 
for this disease are vital. 
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C h a p t e r  2  
 
LITERATURE REVIEW 
2.1 Introduction 
 
The Na+K+-pump, also referred to as Na+K+-ATPase, was first identified in 1957 by  a 
Danish researcher, Jens Christian Skou, who isolated an energy-dependant enzyme from 
peripheral nerves which could be activated by the concentration of Na+ and K+ (Skou, 
1957).  Four decades later Skou’s role in demonstrating the molecular basis for active 
transport of Na+ and K+ across the membrane was recognised with the 1997 Danish 
Nobel price in Chemistry (Clausen & Persson, 1998).  Since then, the Na+K+-ATPase 
enzyme has become an area of intense research interest to a diverse group of scientists.  
The critical role of Na+K+-ATPase in specialised tissues has drawn the attention of a 
broad spectrum of disciplines who are intrigued by the electrochemical gradient 
generated while molecular genetics techniques have revealed the primary structure and 
different isoforms of the enzyme (Lingrel, 1992).       
 
Na+K+-ATPase is recognised as one of the most important enzymes of a cell.  It plays a 
vital role in maintaining K+ homeostasis, the cell membrane potential and consequently 
the excitability of the cell.  The Na+K+-ATPase also provides the energy to drive 
essential Na+ coupled transport of various nutrients into the cell and is involved in 
controlling cellular pH, osmotic balance and cell volume (Skou & Esmann, 1992).  
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2.2 Na+K+-ATPase in Skeletal Muscle 
 
The Na+K+-ATPase is a ubiquitous protein found in all excitable tissue, especially nerve 
and muscle cells.  Skeletal muscle contains the largest pool of K+ and a large portion of 
Na+K+-ATPase in the body (Clausen & Everts, 1989) giving this organ the capacity for 
rapid Na+ and K+ exchange and effectively regulate extracellular K+ concentrations.  By 
transporting Na+ and K+ across the sarcolemma, the Na+K+-ATPase plays a key role in 
the prevention of fatigue in skeletal muscle by maintaining membrane excitability during 
muscle contraction (Nielsen & Overgaard, 1996).  
 
2.2.1   Na+K+-ATPase Structure  
The Na+K+-ATPase exists as a functional heterodimer, composed of 2 polypeptide 
chains, a catalytic alpha (∝)-subunit and a heavily glycosylated beta (β)-subunit 
(McDonough & Farley, 1993).  Additional regulatory proteins belonging to a FXYD 
family of proteins have also been associated with the Na+K+-ATPase (Reis et al., 2005).  
A gamma subunit (FXYD2) has been identified, although it’s expression is essentially 
restricted to the kidney (Blanco & Mercer, 1998; Therien et al., 1999) and 
phospholemman (FXYD1) which has been identified in heart, skeletal muscle, and 
neuronal tissues and is associated with the ∝-subunit (Feschenko et al., 2003; Reis et al., 
2005).  The ∝-subunit conveys the channel properties of the enzyme through 10 
transmembrane segments which contain the intracellular binding sites for Na+ and ATP 
and Pi, and extracellular binding sites for K+ and specific cardiac glycosidic inhibitors 
(Hasler et al., 1998).  The β-subunit does not participate in the ion transportation but is 
required for the normal functioning of the enzyme (Blanco & Mercer, 1998).   
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Figure 2.1 Model of the Na+K+-ATPase structure. P denotes phosphorylation. 
(Fambrough et al., 1994) 
 
Unaccompanied, the ∝-subunit promptly degrades in or near the endoplasmic reticulum 
(ER) hence, the primary function of the β-subunit is to act as a chaperone by stabilising 
the correct folding of the ∝-subunit and delivering it from the ER to the plasma 
membrane (Hasler et al., 2001).  This protects the ∝-subunit from proteolysis and 
cellular degradation.  The β-subunit also influences the cation sensitivity of Na+K+-
ATPase, which produces different affinities for Na+ and K+ (Jaisser et al., 1992).  The β-
subunit is comprised of a hydrophobic transmembrane segment, a short sarcoplasmic 
tail and an extracellular portion containing 3 disulfide bridges and polysaccharide chains 
attached.  Studies have suggested that the ∝-subunit interacts with the β-subunit 
through all 3 domains (Hasler et al., 2001).   
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The tertiary structure of Na+K+-ATPase is based upon other P-type pumps.  The 
Na+K+-ATPase ∝-subunit is thought to transverse the cytoplasmic membrane 10 times 
according to a homology model based on the Ca2+-ATPase crystal structure (Toyoshima 
et al., 2000; Tal et al., 2001), refer to Figure 2.2.  The transmembrane helices are woven 
into the membrane to form a pore/channel.  
 
Figure 2.2 Crystallographic structure of the rabbit skeletal muscle Ca2+-ATPase 
(Toyoshima et al., 2000).  The head region is composed of three 
cytoplasmic domains: the P-domain has the phosphorylation site, the N-
domain contains the ATP binding site and the A-domain, or actuator 
domain.  The structure was obtained in the presence of two Ca2+ ions, 
bound in the transmembrane domain.   
                                   P 
 
 
 
A                                   
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      ADP 
cytoplasm 
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2.2.2   Na+K+-ATPase Function 
Na+K+-ATPase translocates positively charged ions across the sarcolemma against their 
concentration gradients.  Specifically, it imports 2 K+ ions whilst simultaneously 
extruding 3 Na+ ions for each ATP molecule hydrolysed.  Steep concentration gradients 
of the two ions are formed and maintained across the sarcolemma.  A high Na+ 
concentration is maintained outside the muscle, 130-145mM in serum (Worth, 1985), 
whilst the concentration remains between 5 and 20mM inside muscle (Sjogaard, 1983). 
On the contrary, approximately 75% of total K+ is located in the intracellular space of 
human skeletal muscle cells, ~160mM, whilst plasma concentration is maintained 
between 3.5 and 5.3mM (Sejersted & Sjogaard, 2000).  Extremely high and low plasma 
K+ concentrations can contribute to muscle fatigue or even lead to possible paralysis 
and cardiac arrest, therefore maintenance of K+ homeostasis is crucial for survival.   
 
Furthermore the enzyme is electrogenic, generating an electrical gradient by transferring 
disproportional numbers of ions across the cytoplasmic membrane.  One net positive 
charge is associated with the third Na+ pumped into the sarcoplasm for each cycle, 
causing positive charges to accumulate outside the cell, and hence creating an electrical 
current (Sturmer et al., 1991; Domaszewicz & Apell, 1999).  Both the concentration 
gradients and the electrical gradient constitute the membrane potential which at rest is 
approximately -75mV across the sarcolemma.  
 
The main function of Na+K+-ATPase is to restore Na+ and K+ gradients following an 
action potential so that subsequent action potentials can occur (Schwartz et al., 1975).  
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During an action potential in the working skeletal muscle, ion channels are opened and 
there is an influx of Na+ during depolarization and efflux K+ during repolarization.  
Extracellular K+ levels can increase to 8mM in plasma and 10mM in interstitial space 
within minutes of intense exercise, dissipating the K+ gradient which could induce 
action potential block (Vyskocil et al., 1983; Klitgaard & Clausen, 1989).  Therefore, 
Na+K+-ATPase are essential for re-accumulating the K+ lost and help maintain 
excitability so that maximal activation of Ca2+-releasing channels in the sarcoplasmic 
reticulum and myosin contractile filaments can occur (Green, 1998; Ortenblad et al., 
2000).  Na+K+-ATPase not only restores ionic concentration gradients but also 
contributes to repolarization of the membrane due to its 3:2 ion exchange ratio. 
 
In addition, the Na+ concentration gradient maintained by the Na+K+-ATPase is a 
central mechanism for controlling multiple cellular processes.  The Na+ gradient 
provides the energy required for Na+-coupled transport of essential substrates into the 
cytoplasm (Lingrel, 1992).  Plasma membrane transporters work by coupling the 
downhill movement of Na+ to the uphill transport of substrates such as glucose, amino 
acids and vitamins into the cell.  The Na+ gradient also moves ions such as H+, Ca2+ and 
Cl- across the sarcolemma which help maintain cellular pH, osmotic balance and cell 
volume (Rosic et al., 1985).  These mechanisms also modulate cell growth, 
differentiation and protein synthesis.  Na+ is also involved in the recycling of 
neurotransmitters released after neuronal activity.  Transmitters are moved back into the 
cytoplasm  by cotransport with Na+ (Rudnick, 1998).  
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2.2.3   Mechanism of Action 
As the name suggests, ATP energises the Na+K+-ATPase and several studies have 
shown that the enzyme preferentially uses glycolytically derived ATP (Okamoto et al., 
2001; Dutka & Lamb, 2007).  Phosphorylation of the enzyme causes a change in 
conformation and its affinity for Na+ and K+ ions.  The kinetic mechanism of Na+K+-
ATPase involves a number of steps based on a simplified version of the Albers-Post 
transport cycle (Apell et al., 1998).  Prior to phosphorylation the binding site of the 
enzyme is exposed to the sarcoplasm and has a greater affinity for Na+ [E1•ATP].  The 
binding of the third Na+ ion at the inner membrane surface activates the enzyme 
ATPase [(Na3)E1•ATP] and in the presence of Mg
2+ ions, ATP is hydrolysed, releasing 
sufficient energy to power the pump.  The phosphate group that binds to the membrane 
protein [(Na3)E1-P] causes the protein to change shape, placing the Na
+ binding sites at 
the outer membrane surface [P-E2(Na3)].  The K
+ binding sites are immediately revealed 
and as the enzyme’s affinity for K+ is now greater than Na+, the Na+ ions are expelled 
[P-E2].  The binding of K
+ ions from the interstitial fluid [P-E2(K2)] causes the release of 
the phosphate [E2(K2)] and this dephosphorylation causes K
+ occlusion.  ATP binds to 
the enzyme which returns to its original conformation [(K2)E1•ATP], carrying the K
+ 
ions to the inner membrane surface and releasing them into the cell [E1•ATP].  Refer to 
figure 2.3 for schematic representation of transport cycle reactions.  
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Figure 2.3 Simplified Albers-Post transport cycle.  The dashed (horizontal) line 
separates Na+- and K+-translocation pathways (Holmgren et al., 2000). 
 
The cations must traverse the lipid bilayer of the membrane.  Three amino acids within 
the transmembrane region of the enzyme, which play a major role in ion transport, are 
Ser775, Asp804 and Asp808 (Lingrel et al., 1998).  The 3 residues are involved with the 
K+ binding site but it is also possible that other amino acids influence Na+ and K+ 
binding. 
 
2.2.4   Subunit Isoforms and Expression 
The Na+K+-ATPase ∝-subunit is known to exist in 4 different isoforms ∝1, ∝2, ∝3 and 
∝4, and is approximately 112-kDa in size, while the smaller β-subunit has only 3 known 
variants, β1, β2 and β3, and varies in size between 40-60-kDa depending on the degree of 
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glycosylation (Blanco & Mercer, 1998).  Since ∝1 isoform is found in almost every 
tissue, it is considered to be of a house-keeping nature while the other 3 ∝ isoforms are 
expressed in particular tissues, for instance ∝2 is mostly confined to skeletal, smooth 
and cardiac muscle and brain glial cells (He et al., 2001).   In mammalian skeletal muscle, 
all subunit isoforms are expressed with the exception of ∝4 (Murphy et al., 2006).  ∝3 
and β3 are present in trivial amounts, therefore Na+K+-ATPase isozymes predominantly 
consist of ∝1, ∝2, β1 and β2 (Fowles et al., 2004). 
  
2.2.4.1 Tissue and Developmental Specificity 
The subunit isoforms are expressed in a tissue- and developmental-specific manner and 
convey different kinetic characteristics of Na+K+-ATPase isozymes.  In rat skeletal 
muscle, mRNA and protein expression of the ∝1 isoform is low but constant 
throughout development whilst ∝2 dominates in adult life (Lingrel, 1992).  The β-
subunits are of distinct but not exclusive tissue distribution with β1 found predominately 
in slow-twitch oxidative muscle fibres and β2 specifically expressed in glycolytic fast-
twitch muscle (Hundal et al., 1993).  In the muscle membranes of red oxidative fibres, 
the abundance of ∝2 was found to always exceed ∝1
 (Lavoie et al., 1997), therefore the 
prevalent isoform complement in the red portions of the gastrocnemius is ∝2β1, while 
∝1β2 and ∝2β2 are predominate in the white portion.   
 
2.2.4.2 Subunit Functional Properties 
Since the establishment of molecular biology techniques, the functional properties of 
distinct isoforms have become clearer.  The diversity of the ∝ isoform enables the 
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Na+K+-ATPase to demonstrate varying affinity for ions (Zahler et al., 1997; Blanco & 
Mercer, 1998) and cardiac glycosidic inhibitors (Repke et al., 1995).  In rodents, the ∝1-
isoform displays ouabain affinity 100-fold lower than ∝2 and is considered to be ouabain 
resistant, however no such difference has been reported in humans.  In addition, the 
associated β-subunit has been shown to influence the interaction of the enzyme with 
Na+ and K+ (Eakle et al., 1994; Eakle et al., 1995; Blanco & Mercer, 1998).  Isoforms 
have also been shown to display differing functional roles in muscle contractility, with a 
reduction in ∝2- and ∝1-subunits causing an increase and decrease, respectively, in 
isometric force (He et al., 2001; Lingrel et al., 2003).  However the mechanisms by which 
the subunits demonstrate these variations are unknown. 
 
2.2.5 Na+K+-ATPase Localisation 
 
The surface of a skeletal muscle fibre is composed of 2 distinct domains, the plasma 
membrane called the sarcolemma and a network of internal tubules called T-tubules.  
The T-tubular system represents a large extension of the sarcolemma forming up to 
85% of the total sarcolemma membrane area in mammalian skeletal muscle (Dulhunty et 
al., 1984).  Na+K+-ATPase are found in the sarcolemma as well as in the T-tubules with 
particular subunit localisation.  The ∝1-isoform is mainly located in the sarcolemma, 
whereas ∝2-isoform can be found in both the sarcolemma and dispersed within the 
muscle fibres, concentrated along the T-tubules (Williams et al., 2001).  The T-tubules 
only contain a minor proportion of the enzyme and due to its narrow structure, it has 
limited diffusional space for the K+ release during muscle contraction (Sejersted & 
Sjogaard, 2000).  This predisposes the site to action potential blockage in which the T-
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tubules fail to propagate an action potential and thus contribute to cell inexcitability.  
The need for local glycolytically produced ATP is also likely to be important in the 
maintance of T-tubule membrane polarisation and excitability by Na+K+-ATPase 
(Dutka & Lamb, 2007).  
 
It has also been suggested that an intracellular pool exists for the 2 subunits and that 
they can translocate to the plasma membrane upon stimulation.  Hundal et al reported 
an increase in the concentration of ∝2-subunits in the sarcolemma that corresponded 
with a decrease in intracellular stores (Hundal et al., 1992).  The Na+K+-ATPase subunit 
stores were later found to be different from the GLUT4 intracellular vesicles (Aledo & 
Hundal, 1995). 
   
2.3 Regulation of the Na+K+-ATPase 
 
The Na+K+-ATPase enzyme demonstrates a high degree of plasticity with up- or down-
regulation depending on the stimulus.  It is known that the Na+K+-ATPase enzyme is 
regulated by a variety of hormonal and non-hormonal factors, however the molecular 
mechanism by which these stimuli exert their effects remain poorly understood.  
Despite this, it is known that excitation elicits the largest activation response of the 
pump, whilst endocrine control through insulin, adrenaline and thyroid hormones are 
also important (Clausen, 1996).  In particular, insulin plays a key role in acute and 
chronic regulation of Na+K+-ATPase activity and concentration (Sweeney & Klip, 
1998).  
 16
 
Strict regulation of plasma K+ concentration is essential as hyperkalemic conditions 
interfere with muscle contraction and in extreme cases can cause paralysis or cardiac 
arrest.  The kidneys are responsible for the long-term control of plasma K+ 
concentration, but skeletal muscles can carry out immediate Na+ and K+ exchange, and 
consequently are responsible for the acute ongoing plasma K+ adjustments (Clausen & 
Everts, 1989).  The function of Na+K+-ATPase in skeletal muscle is inturn controlled by 
short and long-term regulation.  The mechanisms shown to be involved include changes 
in enzyme activity, subcellular distribution or subunit expression (Sweeney & Klip, 
1998).   
 
2.3.1   Acute Control 
Acute activation of the Na+K+-ATPase enzyme can occur within minutes and the three 
major stimuli are excitation, catecholamines and insulin (Clausen & Everts, 1989).   
These activators are essential for reducing exercise-induced hyperkalemia, ensuring 
prompt recovery of excitability.  Na+, insulin, adrenaline and amylin have all been shown 
to increase lactate production in skeletal muscle as a result of stimulated Na+K+-ATPase 
activity and increased glycolytic ATP consumption (James et al., 1999b; McCarter et al., 
2001; Okamoto et al., 2001).  This suggests that ATP consumption by the Na+K+-
ATPase could possibly regulate the rates of aerobic glycolysis and glycogen breakdown.   
 
2.3.1.1 Excitation 
Skeletal muscle uses less than 10% of Na+K+-ATPase maximal activity to uphold ionic 
concentration gradients at rest (James et al., 1999a).  During muscle contraction, a 
pronounced decrease in transmembrane Na+ and K+ gradients occur due to these ions 
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leaking across the sarcolemma with the passing of an action potential.  Plasma K+ levels 
can rise above 8mmol/L (Klitgaard & Clausen, 1989; Medbo & Sejersted, 1990; 
Vollestad et al., 1994) while interstitial K+ concentrations can increase up to 10mmol/L 
(Vyskocil et al., 1983).  When the ion gradient dissipation is unopposed, there is loss of 
membrane excitability (Macdonald et al., 2007).  This creates the urgent need for Na+K+-
ATPase activation to restore the ion gradients so subsequent action potentials can 
occur.  Electrical stimulation has been repeatedly shown to rapidly induce Na+-K+-
ATPase activity in skeletal muscle.  Electrical stimulation can induce Na+K+-ATPase 
activity after 1 second of stimulation, evident by an increase in 86Rb+ uptake that can be 
abolished by ouabain (Buchanan et al., 2002).  The effect was also seen with low 
frequency stimulation (2Hz) for 2 minutes (Buchanan et al., 2002).  The cause of 
excitation-induced activation of Na+K+-ATPase can be partly due to an increase in 
intracellular Na+ concentrations, however Na+K+-ATPase activity has been shown to 
persist beyond normal resting levels, causing an undershoot in intracellular Na+ 
concentrations (Juel, 1986; Nielsen & Clausen, 1997).  Therefore excitation is believed 
to activate Na+K+-ATPase by increasing the apparent affinity of Na+K+-ATPase for 
intracellular Na+.  Another possible explanation for the excitation-induced increase in 
ion transport could involve the translocation of Na+K+-ATPase subunits from an 
intracellular pool to the sarcolemma.  With added functional pumps in the membrane, 
the capacity for ion transport increases (Clausen & Hansen, 1977).   
 
2.3.1.2 Hormonal Control 
Hormones contribute only 5% of the increase in enzyme activity caused by electrical 
stimulation of the muscle (Sweeney & Klip, 1998).  Repetitive high-frequency 
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stimulation often induces a net loss of K+, and a net gain of Na+, that exceeds the 
maximum capacity of the Na+K+-ATPase, concomitantly there is a progressive decline 
in contractile force (Clausen & Everts, 1988; Ortenblad et al., 2000).  In this state, 
Na+K+-ATPase activity is dependant on hormonal control (Clausen et al., 1993; 
Overgaard et al., 1997).   
 
2.3.1.3 Insulin 
Insulin is an anabolic hormone synthesised in the pancreas by the β endocrine cells.  
The main function of insulin is to reduce the blood level of glucose by promoting its 
entry into the skeletal muscle.  In addition to insulin’s important function of regulating 
blood glucose concentration, the hormone also plays a central role in K+ homeostasis by 
promoting K+ entry into skeletal muscle (Sweeney & Klip, 1998).  There is a negative 
feedback relationship between plasma K+ concentrations and insulin secretion (Clausen 
& Everts, 1989).  Elevated plasma K+ concentration stimulates insulin secretion, and 
insulin in turn enhances K+ uptake by Na+K+-ATPase, therefore counter-balancing 
hyperkalemia.   
 
Insulin has been shown to act as a regulator of the Na+K+-ATPase in a variety of 
tissues.  However, skeletal muscle is the main peripheral insulin target tissue, since up to 
85% of all glucose up-take occurs here (Galuska et al., 1998), and it is the main storage 
tissue for glucose and K+ in the body .   
 
The underlying mechanisms resulting in the acute insulin-induced activation of Na+K+-
ATPase differ with respect to the type of tissue involved.  In some tissues, insulin 
activates the Na+K+-ATPase secondary to an insulin-induced elevation of intracellular 
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Na+.  For example through the Na+/H+ exchanger and the Na+/K+/2Cl- cotransporter.  
However, previous studies have shown that this is evident in adipocyctes and 
hepatocytes, but not for skeletal muscle (Weil et al., 1991; Therien & Blostein, 2000).  In 
rat adipocytes and kidney cells, insulin has been shown to upregulate enzyme activity by 
increasing the affinity of the ∝-subunit for Na+ by lowering k0.5 for Na
+ (ie. the 
intracellular Na+ concentrations that stimulates the pump to 50% of its maximum pump 
rate) (McGill & Guidotti, 1991; Feraille et al., 1995).  However, insulin stimulation of 
Na+K+-ATPase in skeletal muscle has been mainly attributed to the translocation of ∝1-, 
∝2- and β1- subunits to the plasma membrane from an intracellular storage 
compartment (Hundal et al., 1992; Al-Khalili et al., 2003).  It has been proposed that 
phosphorylation of the ∝-subunit activates the otherwise latent and inactive Na+K+-
ATPase molecule (Al-Khalili et al., 2004). 
 
It has also been suggested that insulin may act directly upon a Na+ dependent inhibitor 
of the pump (McGill & Guidotti, 1991).  Insulin would increase Na+ affinity of the 
inhibitor and consequently alleviate inhibition of the enzyme.  However, this theory has 
not had further support and the inhibitor remains unknown. 
 
2.3.1.4 Adrenaline 
Catecholamines have been shown to influence Na+K+-ATPase activity.  One of those 
most studied is adrenaline.  Adrenaline is known to stimulate Na+K+-ATPase activity in 
skeletal muscle, primarily after exercise-induced hyperkalemia (Overgaard et al., 1997; 
James et al., 1999).  Na+K+-ATPase activation occurs by the hormone binding to β2-
adrenoreceptors and raising cyclic AMP production (Clausen & Flatman, 1980).  
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Administration of β2-adrenoreceptor agonists, such as Salbutamol has also been shown 
to alleviate hyperkalemia (Overgaard et al., 1997).  Signalling pathways seems to be 
tissue-specific and implicate both PKC- and AMPK-mediated pathways but the mode 
of regulation still remains controversial.    
 
2.3.2 Chronic Control 
The long-term regulation of the Na+K+-ATPase in skeletal muscle involves the cellular 
distribution of the enzyme and changes in membrane concentration.  While adrenal 
steroids such as aldosterone and dexamethasone can cause changes in pump 
concentrations, basal levels of these steroids seem to be of minor importance in skeletal 
muscle (Dorup & Clausen, 1997).  The major endocrine factor stimulating the synthesis 
of Na+K+-ATPase is thyroid hormone (Clausen & Everts, 1989; Azuma et al., 1993).  K+ 
intake has also been shown to modulate Na+K+-ATPase concentrations in skeletal 
muscle (Norgaard et al., 1981). 
 
2.3.2.1 Thyroid Hormone 
The thyroid hormone, Thiiodothyronine (T3) serves as chronic pump regulator, which 
does not alter catalytic properties of the enzyme but regulates the mRNA and protein 
levels of Na+K+-ATPase ∝2 and β2 isoforms (Azuma et al., 1993).  A significant 
correlation exists between thyroid function and the concentration of Na+K+-ATPase, 
whereby hyperthyroidism (increased T3 level) and hypothyroidism (reduced T3 level) 
causes the number of 3H-ouabain binding sites to increase and decrease, respectively 
(Kjeldsen et al., 1984c).  Changes in enzyme concentration are fully reversed when 
thyroid status is normalised by therapy (Kjeldsen et al., 1984c).  Uncontrolled diabetes 
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and starvation are 2 conditions which display hypothyroidism (Clausen, 2003).  The fact 
that both conditions exhibit a down-regulation of the Na+K+-ATPase concentration in 
skeletal muscle may indicate the reduction of the T3 level partly accounts for the 
observed effects.  The decline in ∝2 protein levels is more profound than mRNA, 
indicating a translational or post-translational regulatory effect.  T3 treatment for 
hypothyroidism increases mRNA and protein abundance of Na+K+-ATPase ∝2 and β2 
isoforms in skeletal muscle (Azuma et al., 1993).   
 
Thyroid hormone has also been shown to increase the passive permeability of Na+ and 
K+ in the skeletal muscle membrane (Ismail-Beigi et al., 1986).  This may be the result of 
T3 induced changes in the fatty acid and phospholipid composition of the sarcolemma, 
increasing its fluidity and permeability (Pilarska et al., 1991; Bangur et al., 1995).  This 
would suggest that the thyroid-induced elevation in Na+K+-ATPase content is an 
adaptation to counter-balance the surplus in Na+ and K+ leaks.   
 
2.3.2.2 Insulin 
There is less research on the effects of prolonged insulin action compared with an acute 
response, however it is important to understand the potential actions of the hormone in 
hyperinsulinemic states such as obesity and type II diabetes.  Insulin has been shown to 
alter gene expression of Na+K+-ATPase subunits.  One study showed long term 
exposure of 3T3-LI fibroblasts to insulin increased ∝2 mRNA but decreased β1 mRNA 
(Russo & Sweadner, 1993) This was again shown by another study which demonstrated 
the same ∝2 mRNA increase in vascular smooth muscle (Russo & Sweadner, 1993; 
Tirupattur et al., 1993).  The changes could be a result of increased transcription, mRNA 
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stabilisation and/or protein translation and stabilisation.  More recently Deachapunya et 
al, showed long-term exposure to insulin for 4 days resulted in enhanced Na+ 
absorption with a further increase in Na+K+-ATPase transport activity in porcine 
glandular endometrial epithelial cells grown in primary culture (Deachapunya et al., 
1999).  
 
It is also known that insulin acts as a long term regulator by promoting muscular K+ 
clearance on the basis of K+ ingested.  Bundgaard and Kjeldsen showed rats on a 2 
week K+ rich diet had increased Na+K+-ATPase concentrations while rats on a K+ 
depleted diet had decreased concentrations (Bundgaard & Kjeldsen, 2003).   
 
2.3.2.3 Exercise Training 
Many longitudinal studies with animals and humans have reported an up-regulation in 
Na+K+-ATPase concentration in skeletal muscle as a result of exercise training.  Various 
types of training, including strength, sprint and endurance training have caused an 
increase in the number of 3H-ouabain binding sites in human skeletal muscle (Klitgaard 
& Clausen, 1989; McKenna et al., 1993; Madsen et al., 1994).  The molecular events 
responsible for increasing Na+K+-ATPase content are currently unknown.  
Furthermore, exercise training alters a wide range of hormones, including adrenaline, 
insulin and aldosterone, which are implicated with Na+K+-ATPase expression 
regulation, making signalling mechanisms as a result of exercise training unclear. Given 
that the effect of training is confined to the working muscle, the signalling mechanism 
must be of a local nature.   Hyperkalemic stress imposed on the muscle may be an 
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important factor in exercise-induced elevation of Na+K+-ATPase content and improved 
K+ uptake in skeletal muscle.  
 
2.3.3 Role of Insulin 
By binding to the insulin receptor, insulin can activate a variety of intracellular signalling 
processes and modulate cell function.  Principally, insulin’s role in both glucose and K+ 
cellular uptake is essential, however control of K+ homeostasis is an important yet often 
underestimated action of insulin.  Independent of other hormones, insulin has been 
shown to promote the uptake of K+ into the skeletal muscle cell primarily through 
stimulation of the Na+K+-ATPase, counter-balancing the hyperkalemia induced by 
exercise (Kanbe & Kitasato, 1986).  Insulin favorably activates subunits demonstrating 
ouabain sensitivity.  ∝2 and β1 subunits are preferentially involved in insulin responses 
(Hundal et al., 1992). 
 
2.3.3.1 Insulin Signalling 
The signalling pathway of insulin generally requires a sequence of events that begins 
with insulin binding to its cell surface receptor protein and in turn activates the intrinsic 
tyrosine kinase activity of the receptor (Saltiel & Kahn, 2001).  The activated receptor 
kinase then phosphorylates tyrosine residues on protein substrates called insulin 
receptor substrates (IRS) inside the cell which act as “docking” sites, binding other 
cellular signalling molecules, eg: phosphatidylinositol-3-kinase (PI 3-kinase), to form 
complexes of intracellular signalling proteins (Kahn, 1998).  The mechanism and the 
signalling pathway involved are still poorly understood and clearly warrant further 
investigation.  Various cellular processes are stimulated through the signalling cascade 
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such as glucose and lipid metabolism as well as cell growth and Na+K+-ATPase 
activation.  Defective insulin signalling is a chief characteristic of obesity and type II 
diabetes and leads to a number of associated complications. 
 
2.3.4 Phosphorylation Signalling Pathways  
Hormones play a significant role in modulating Na+K+-ATPase activity and most 
regulate through signalling mechanisms that modulate the activities of protein kinases.  
Hormone action directly interacts with protein kinase A, C, G, or protein phosphatase 
2B and will inhibit or stimulate Na+K+-ATPase activity depending on tissue type.  
Extracellular regulated kinases (ERK) 1 and 2, and upstream kinase MAP ERK kinase 
(MEK) 1 and 2 have also been implicated in the signalling pathway of Na+K+-ATPase 
phosphorylation (Al-Khalili et al., 2004).  
 
As the name suggests, AMP-activated protein kinase (AMPK), is activated by the build 
up of intracellular AMP.  AMPK is not only tissue specific but also species dependant.  
AMPK has been shown to activate Na+K+-ATPase activity in rat (Li & Sperelakis, 1993) 
and frog (Venosa, 2005) but suppress activity in squirrel (MacDonald & Storey, 1999) 
skeletal muscle.  Very few studies have investigated the mechanism by which AMPK 
alters Na+K+-ATPase activity, however it is thought to be via direct phosphorylation of 
the pump at site Ser-934 (NB numbering of amino acids used includes the post-
translationally cleaved NH2-terminal of 5 amino acids) (Fisone et al., 1994). 
 
The signal transduction of insulin on the Na+K+-ATPase involves an insulin receptor, 
protein kinases and the ∝-subunit of the Na+K+-ATPase.  Studies have shown that 
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insulin’s effect on Na+K+-ATPase is not additive to protein kinase C (PKC) and that 
insulin exerts its control via a PKC-dependent pathway (Sampson et al., 1994).  Chibalin 
et al, also found an insulin receptor tyrosine kinase inhibitor completely abolished 
insulin mediated phosphorylation of the ∝-subunit (Chibalin et al., 2001).  PI 3-kinase 
inhibitor, wortmannin also blocked insulin stimulated ∝-subunit translocation to the 
sarcolemma (Al-Khalili et al., 2003).  Lipid products of PI 3-kinase are known to been 
implicated in the insulin signalling cascade and activate PKC (Sweeney et al., 2001).  
Therefore insulin regulation of Na+K+-ATPase follows a tyrosine kinase, PI 3-kinase 
and PKC activation pathway, refer to figure 2.4.   
 
Recently, a study by Al-Khalili and collaborators found ERK1/2 MAP kinase to be 
involved in insulin stimulated Na+K+-ATPase activity, as an inhibitor of upstream kinase 
MEK1/2 stopped insulin mediated ∝-subunit phosphorylation and translocation to the 
membrane (Al-Khalili et al., 2004).  In addition, a PKC inhibitor completely blocked 
insulin stimulated ERK1/2 phosphorylation, indicating the kinase is most likely 
downstream from PKC, refer to figure 2.4. 
 
Regulation of Na+K+-ATPase by PKC may be dependant on cytosolic Ca2+ 
concentration but this is controversial.  PKC, like AMPK can regulate the pump via 
direct phosphorylation of the ∝ subunit at site Ser-23, which in turn causes endocytosis 
and inhibition of the pump (Chibalin et al., 1998).  However this is not the mechanism 
seen in skeletal muscle as PKC has been shown to activate Na+K+-ATPase activity in 
frog (Venosa, 2005) and rat (Li & Sperelakis, 1993; Sampson et al., 1994).   
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cGMP-dependant protein kinase G (PKG), is activated by intracellular cGMP.  In 
skeletal muscle, cGMP/PKG actions are antagonistic to those of cAMP/AMPK, with 
raised cGMP inhibiting Na+K+-ATPase activity (Li & Sperelakis, 1993).  At present, it is 
unknown whether PKG regulation of Na+K+-ATPase activity is by direct 
phosphorylation or through secondary modulators (Therien & Blostein, 2000).   
 
 
 
 
Figure 2.4 Proposed Na+K+-ATPase signalling pathway diagram. 
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Protein phosphatases 2B or PPB2 is a major participant in protein phosphatase-
dependant regulation of Na+K+-ATPase.  Protein phosphatases can actively reverse the 
effects of protein kinases on Na+K+-ATPase in various tissues, including skeletal muscle 
(MacDonald & Storey, 1999). 
  
2.3.5 Inhibition 
Principal inhibitors of the Na+K+-ATPase enzyme are the digitalis glycosides, digoxin 
and ouabain.  These compounds have been repeatedly associated with a severe rise in 
plasma K+ and are extensively used for treatment of cardiac insufficiency.  The drugs are 
effective by binding to and blocking the K+ binding site, repressing K+ influx and Na+ 
extrusion.  Inhibition of cardiac Na+K+-ATPase causes a rise in intracellular Na+, which 
effectively reduces Ca2+ efflux via the Na+/Ca2+ Exchanger (Clausen, 1998).  Elevated 
levels of cytoplasmic Ca2+ are accumulated in the sarcoplasmic reticulum (SR), leading to 
a greater Ca2+ release from the SR with each electric pulsation of the cardiac muscle. 
 
K+ deficiency induced by diet or diuretics also reduces Na+K+-ATPase content in 
skeletal muscle.   The concentration of 3H-ouabain binding sites has been positively 
correlated with tissue concentration of K+.  K+ deficiency leads to a fall in plasma K+ 
levels, which the body rectifies by releasing stored intracellular K+ from skeletal muscle 
(Thompson & McDonough, 1996).  The hypokalemic state is corrected but there is an 
associated decrease in active Na+K+-ATPase numbers.  Treatment to reinstate normal 
K+ content in skeletal muscle will also restore Na+K+-ATPase concentrations in skeletal 
muscle (Kjeldsen et al., 1984b).   
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Another well known inhibitory regulator of Na+K+-ATPase is dopamine.  This 
catecholamine is a natriuretic factor, known to inhibit Na+K+-ATPase activity in a 
variety of tissues, but particular regions of the kidney (Aperia et al., 1987). 
 
Reduced physical activity as a result of aging or disease causes a reduction in the content 
of Na+K+-ATPase in skeletal muscle (Norgaard et al., 1990; Ng et al., 2003).  
Immobilisation studies in animals and humans have also shown decreased 
concentrations of 3H-ouabain binding sites in skeletal muscle (Kjeldsen et al., 1986; 
Leivseth & Reikeras, 1994).  The reduced Na+K+-ATPase capacity caused by inactivity 
may exacerbate exercise-induced hyperkalemia and fatigue often seen with disease states 
such as type II diabetes (Schneider et al., 1984; Regensteiner et al., 1995; Baldi et al., 
2003).    However, Na+K+-ATPase content will adjust to meet with functional demands 
as seen in training or remobilising studies (Leivseth et al., 1992; Jebens et al., 1995) which 
suggests exercise as a potential treatment for diabetes.  
 
2.4 Membrane Composition and Na+K+-ATPase 
 
Since the Na+K+-ATPase is a membrane-embedded protein, the surrounding membrane 
phospholipids are important for the intrinsic function of the enzyme.  The cell 
membrane is an important barrier that regulates the flow of fluid and molecules in and 
out of the cell.  The phospholipid composition of membranes can influence the 
function of various proteins embedded within.  However it is unclear whether the lipid-
protein interactions are effective via direct contact and binding or indirectly by means of 
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order and fluidity.  Species-crossover experiments have suggested that the molecular 
activity of Na+K+-ATPase is predominately modulated by the physical properties of its 
immediate lipid milieu (Wu et al., 2001).   
 
2.4.1 Membrane Phospholipids   
Membranes are made up of amphiphilic molecules call phospholipids.  The 
phospholipid structure consists of a 3-carbon glycerol backbone molecule to which 2 
fatty acyl chains are attached and a phosphate group esterified to the third carbon of the 
glycerol.   
 
Figure 2.5 Bilayer membrane and Phospholipid structure. Modified from  
 
Since the acyl chains are made up of carbon and hydrogen and share their electrons 
evenly, they have no charge and constitute the hydrophobic portion of the 
phospholipid, whereas electrons in phosphate head group are not shared equally, giving 
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this end of the molecule a hydrophilic nature (Mathews & van Holde, 1990).  Different 
classes of phospholipids are characterised by the head-group esterified to the phosphate 
group and molecular species within the different classes differ by the position, length 
and extent of unsaturation of the acyl chains (Mathews & van Holde, 1990).   
 
Phospholipids are held together only by weak hydrogen bonds between the heads and 
the even weaker interactions between the hydrophobic lipid molecules in the tails but 
these thousands of non-covalent interactions between the lipids make the membrane 
bilayer a sturdy enclosing structure (Mathews & van Holde, 1990).  On the other hand, 
it is a well known phenomenon that the bilayer system is extremely dynamic.  
Phospholipid molecules can travel sideways along the membrane or flip from one side 
to the other, making the cell membrane flexible and continually moving and flowing 
(Mathews & van Holde, 1990). 
 
2.4.2 Membrane Proteins   
Essential components of the lipid membrane are membrane proteins.  Membrane 
proteins contain both hydrophilic and hydrophobic areas and can penetrate completely 
through or partially into the phospholipid bilayer through an ∝ helix.  The ∝-subunit of 
Na+K+-ATPase is thought to contain 10 transmembrane segments, spanning the 
membrane through ∝ helices (Tal et al., 2001).  The membrane is virtually impermeable 
to polar solutes such as glucose, minerals and ions because it is a costly process 
energetically.  Therefore regulation of the translocation of solutes in and out of the cell 
is a significant function of membrane transport proteins with Na+K+-ATPase regulating 
Na+ and K+ counter transport.  
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2.4.3 Membrane Characteristics    
 
Increasing research into the phospholipid composition of cell membranes has indicated 
that they are important for the function of transmembrane proteins (de Lima Santos et 
al., 2005).  Alterations in membrane fatty acyl chains and phospholipid compositions 
have been shown to influence membrane permeability, ion channels and transport, and 
cause a lowering of membrane-bound enzyme activities (Spector & Yorek, 1985).  Past 
experiments have demonstrated that function and intrinsic activity of the membrane ion 
transporter, Na+-K+-ATPase is influenced by the lipid milieu in which it exists 
(Abeywardena et al., 1983; Storch & Schachter, 1984).  Modifications that can affect 
protein function are alteration of the phospholipid head group, acyl chain length and 
unsaturation, and insertion of cholesterol (Cantor, 1999).   The effect of membrane lipid 
composition on Na+K+-ATPase function may explain irregular Na+ ion transport 
observed in disease states with abnormal lipid metabolism such as atherosclerosis, 
obesity and diabetes (Hughes & York, 1983; Chen et al., 1995; Makar et al., 1995). 
 
2.4.3.1 Fluidity and Bilayer Thickness 
Fluidity is considered an important property of the membrane because of its effect on 
transmembrane protein conformation, transport processes and membrane permeability 
(Pilch et al., 1980; Lynch et al., 1987; Lande et al., 1995).  The degree of unsaturation and 
length of acyl chains in adjacent phospholipids affects lateral movement and 
conformational change of an integral protein (Wu et al., 2001).  While the length of acyl 
chains simply increases bilayer thickness, the double bonds in unsaturated acyl chains 
inhibit freedom of rotation about the bond and prevent phospholipids from compacting 
themselves.  This creates a higher degree of conformational flexibility of a protein in the 
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membrane, improving efficiency of ligand binding and activity of membrane-bound 
enzymes (Hollan, 1996).  A study using hepatocyte membranes reported an increase in 
lipid fluidity was accompanied by an increase in Na+K+-ATPase specific activity (Storch 
& Schachter, 1984).   
 
However, there is growing evidence that the bilayer thickness and lipid acyl chain order 
rather than fluidity, are the primary factors determining enzyme activity (Cornelius, 
2001).  One study found Na+K+-ATPase activity measured by labelled Rubidium (K+ 
analogue) uptake was inhibited when short acyl chain phosphatidylcholine (PC) was 
incorporated into erythrocytes compared with longer acyl chain PC (Dwight & Hendry, 
1995), while another showed that increasing the fatty acid chain length in PC-liposomes 
increased the percentage of Na+K+-ATPase incorporated (de Lima Santos et al., 2005) 
supporting the notion that bilayer thickness is an important factor for integral protein 
function.   
 
The type of phospholipid head-group has also been associated with modulating 
membrane protein function.  Negatively charged lipids such as phosphatidylserine and 
phosphatidylglycerol have been found to enhance bilayer thickness and fluidity, and 
increase Na+K+-ATPase activity (Kimelberg & Papahadjopoulos, 1972; Cornelius & 
Skou, 1984).  
 
2.4.3.2 Membrane Permeability and Cholesterol 
Membrane permeability is another important function of the membrane and can be 
seriously altered by the lipid interior.  Excessive fluidity causes non-selective cation 
leakage while closely packed lipids and rigidness make translocation of solutes across the 
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membrane difficult (Armstrong et al., 2003).  Integrated cholesterol is known to 
promote membrane rigidness and bilayer thickness by increasing acyl chain order.  
Cholesterol restricts the bending action of neighbouring phospholipid acyl chains, 
forcing the chain to be elongated (Cornelius, 2001).  A deficiency in cholesterol causes 
excessive fluidity and non-selective cation permeability (Grunze & Deuticke, 1974).   
Polyunsaturated fatty acids (PUFAs) allow a higher incorporation of cholesterol 
(rigidness) in the membranes to balance their fluidity and provide satisfactory 
permeability (Colin et al., 2003).  By increasing bilayer thickness, cholesterol may 
function to compensate for short acyl chains in membranes.  A study by Cornelius, 
found that in the absence of cholesterol, the phospholipid which sustained optimal 
Na+K+-ATPase activity was C22:1 PC, yet in the presence of cholesterol, the 
phospholipid was substituted with a saturated PC of shorter acyl chain length, 18:0 
(Cornelius, 2001).  Optimal Na+K+-ATPase activity was reported as being dependent on 
the hydrophobic thickness of the bilayer, however the class of phospholipids chosen for 
the study was not optimal for Na+K+-ATPase activity.   
 
Obesity and type II diabetes are also associated with changes in membrane phospholipid 
composition with studies suggesting decreased fluidity contributes to the development 
of insulin resistance (Manco et al., 2004).  PUFAs may prevent the pathogenesis of 
insulin resistance by alterations in cell membrane fluidity which alters the expression 
and/or presentation of a wide range of receptors, including the GLUT-4 and insulin 
receptors (Das, 2005).  PUFAs enhance insulin action by increasing the number of 
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insulin receptors and the affinity of insulin to its receptors (Hainault et al., 1993; Mori et 
al., 1997).  
 
2.4.3.3 Omega Fatty Acids  
Membrane fluidity is increased by phospholipids composed of PUFAs, in particular 
omega-3 PUFAs.  Specifically, docosahexaenoic acid (DHA) contains 22 carbons and 6 
double bonds and is the longest and most unsaturated fatty acid commonly present in 
biological membranes.  Mammals must synthesise DHA by elongation of ∝-linolenic 
acid through a series of enzymatic reactions involving elongases and desaturases 
(Petrache et al., 2001).  DHA plays an important structural role in the cytoplasmic 
membrane of cells and has been shown to increase the unsaturation index, disordering 
and fluidity (Hashimoto et al., 1999; Petrache et al., 2001).  Omega-6 PUFAs have been 
associated with inhibiting the absorbance of omega-3 PUFAs, in a competitive nature 
(Iritani & Fujikawa, 1982).  The net result is an increase in omega-6/omega-3 ratio, 
which reflects reduced membrane fluidity (Farkas et al., 2002).  There is also evidence to 
suggest a high omega-6/omega-3 ratio is deleterious on insulin action in skeletal muscle 
(Storlien et al., 1996).  The significance of omega-3 is widely recognised, with deficient 
diets associated with numerous diseases, including insulin resistance in humans and rats 
(Wu et al., 2001) while lard diets high in DHA and eicosapentaenoic acid (EPA) prevent 
insulin resistance and obesity (Hainault et al., 1993; Mori et al., 1997; Taouis et al., 2002).  
However the mechanisms sustaining such a protective effect of omega-3 PUFA remain 
unclear. 
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2.5 Obesity and Type II Diabetes 
 
Diabetes is characterised by excessively high blood glucose and occurs in 2 forms.  In 
Type I diabetes previously known as Insulin Dependent Diabetes Mellitus, the 
pancreatic β-cells produce little or no insulin.  Type II diabetes is characterised by 
varying degrees of insulin resistance and relative insulin deficiency.  There are currently 
150 million people suffering diabetes worldwide, and this number is expected to rise to 
300 million by 2025 (Zimmet et al., 2001).  In Australia, the AusDiab study reported 
7.4% of the population with diabetes, 90% of which have type II diabetes (Dunstan et 
al., 2002), and many others are pre-diabetic or undiagnosed. Research has shown that 
for every person diagnosed with diabetes there is another who has it but has not yet 
been diagnosed (Colagiuri, 2002).  The reason for this is the progressive nature of the 
disease.  It involves a slow and late onset due to a gradual build up of glucose in the 
blood stream as a consequence of insulin resistance.  Most are not diagnosed until after 
the age of 40 years.  The evidence is overwhelming that adverse lifestyle factors are the 
cause of type II diabetes, which is becoming an ever-increasing health problem.  There 
is general agreement that obesity is closely associated with type II diabetes with 80% of 
people with type II diabetes being overweight or obese.   
 
2.5.1 Pathophysiology and Complications  
The pathophysiology of type II diabetes appears to involve defects in both insulin 
action (insulin resistance) and secretion (insulin deficiency).  Depending on the severity, 
the disease does not necessarily involve insulin injections, however it is a dynamic 
disease in which untreated individuals often become more insulin deficient with time.   
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The healthcare problem of type II diabetes is further exacerbated by its association with 
obesity and cardiovascular risk factors, particularly dyslipidaemia and hypertension 
(Stolar & Chilton, 2003).   Complications associated with type II diabetes often set in 
prior to diagnosis as hyperglycemia is often not severe enough for the individual to 
notice symptoms.  The disease-associated complications involve microvascular 
complications such as retinopathy (blindness), neuropathy (decreased nerve activity) and 
nephropathy (kidney disease), and macrovascular complications including cardiovascular 
disease, stroke and premature atherosclerotic vascular disease (Stolar & Chilton, 2003).  
Not all diabetics develop all the complications nor to the same degree.  However, 
cardiovascular disease is undoubtedly the leading cause of mortality and morbidity in 
type II diabetes, even the pre-diabetic state of hyperinsulinemia and impaired glucose 
tolerance poses a considerable cardiovascular risk (Zimmet et al., 2001).   
 
2.5.2 Insulin resistance  
Insulin resistance is defined as a decreased biological response of peripheral target 
tissues to normal concentrations of circulating insulin.  β-cells in the pancreas 
compensate by releasing more insulin to maintain euglycemia, but overtime are unable 
to maintain high rates of insulin secretion and hyperglycemia results (Goldstein, 2002), 
refer to figure 2.6.  The condition is found in both individuals suffering obesity and type 
II diabetes and also in normal individuals as it is the primary defect, preceding type II 
diabetes by up to 20 year.  Insulin resistance is closely associated with a variety of 
cardiovascular risk factors including glucose intolerance, visceral adiposity, dyslipidemia 
and hypertension.   
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Figure 2.6 Progression to Type II diabetes.  Modified from (Rao et al., 2004). 
 
2.5.2.1 Skeletal Muscle 
Skeletal muscle is the primary tissue affected by insulin resistance as it is the main 
insulin target tissue and performs most glucose up-take via glucose transporter 4 
(GLUT4) (Zierath et al., 2000).  Impaired glucose uptake in skeletal muscle is not due to 
abnormal concentrations of GLUT4 in insulin resistant skeletal muscles but presumably 
caused by a reduction in insulin stimulated translocation of GLUT4 from intracellular 
vesicles to the membrane.  The defect in insulin action is at the cellular level though the 
faulty signalling pathway is still unclear.  Insulin resistance also reduces fat oxidation 
capacity in skeletal muscle and therefore increases circulating free fatty acid (FFA) levels 
and lipid storage including triglycerides dispersed within muscle (Kelley & Simoneau, 
1994).  Several studies have shown insulin resistance to have a tighter correlation with 
the amount of intramuscular triglycerides (IMTGs) rather than other common markers, 
such as body mass index, waist-to-hip ratio or total body fat (McGarry, 2002).   
 
2.5.2.2 Adipose Tissue 
Insulin resistance also affects adipose tissue which fails to respond to insulin action 
causing altered fatty acid (F.A) metabolism. Obesity is strongly associated with insulin 
resistance.  Additional visceral adipose tissue causes increased lipolysis and the secretion 
of excessive FFA into circulation (Bjorntorp, 1990; Nielsen et al., 2004).  Increased 
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plasma FFA compete with glucose for utilisation in skeletal muscle, resulting in 
increased blood glucose concentration which provides the stimulus for further increased 
insulin secretion (Karpe & Tan, 2005).  Excessive F.A circulation can also cause 
dyslipidemia and vascular dysfunction (Ginsberg, 2000) and interfere with insulin 
signalling directly and impair hepatic insulin removal, exaggerating the degree of 
hyperinsulinemia (Bergman, 2000; Goodpaster & Kelley, 2002).   
 
2.5.2.3 Hypertension 
Insulin resistance is frequently associated with hypertension.  Non-obese and non-
diabetic patients with essential hypertension (hypertension without a known cause) have 
been shown to exhibit greater insulin resistance and elevated insulin levels when 
compared to normal controls.  However the mechanism by which insulin exerts its 
effect is not fully understood (Shen et al., 1988; Pollare et al., 1990).  Serum digitalis-like 
factor (DLF) is a Na+K+-ATPase inhibitor and functions to increase Na+ removal by 
decreasing renal Na+ reabsorption and increase vascular resistance by increasing cardiac 
output and therefore systolic blood pressure.  Hyperinsulinemia has been shown to 
elevate circulating DLF in healthy controls (Carroll et al., 2001).  This may explain a 
possible mechanism by which chronically elevated insulin levels may cause 
hypertension, however not all individuals with insulin resistance display hypertension 
(Levy et al., 1994; Reaven, 2003). 
 
2.5.2.4 Na+K+-ATPase dysfunction 
Type II diabetes and insulin resistance is frequently accompanied by altered regulation 
of the Na+-K+-ATPase enzyme.  Modification in Na+K+-ATPase activity may be the 
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result of structural changes of binding sites or altered content in the cell membrane.  
Na+K+-ATPase concentration can vary through altered transcriptional, translational or 
post-translation degradation.  However, disagreement exists over the effect of insulin 
resistance on Na+-K+-ATPase function with numerous studies showing conflicting or 
no change with insulin resistance in various tissue types of both humans and rats.   
Na+K+-ATPase activity has been shown to be decreased in human erythrocytes (Baldini 
et al., 1989; Kiziltunc et al., 1997), nerve tissue (Scarpini et al., 1993), platelets (Rabini et 
al., 1998) and retinal cells (Ottlecz et al., 1993) from type II diabetics patients.  While 
other studies have reported no change in human erythrocytes (Jannot et al., 2002) and 
rat skeletal muscle (Banyasz & Kovacs, 1996; Ferrer-Martinez et al., 1996).    
 
Na+K+-ATPase concentration in human skeletal muscle has previously been reported to 
be higher with type II diabetes (Schmidt et al., 1994).  However the author also pointed 
out that the mean concentration for the normal muscle was less than previously 
reported ranges.  If a mean value for normal muscle from previous studies by this group 
was used then this elevated concentration would not have been reported.    Djurhuus 
and colleagues (2001) conducted a study involving identical twins discordant for type II 
diabetes, where the diabetic twin group demonstrated an approximate 20% reduction in 
muscle [3H]-ouabain binding capacity compared to the healthy twin group.  The 3H-
ouabain binding capacity difference within twin pairs was negatively correlated with the 
corresponding difference in waist/hip ratio, indicating the development of abdominal 
fat in type II diabetics is associated with reduced muscle Na+K+-ATPase concentration. 
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As previously mentioned the Na+K+-ATPase has been repeatedly shown to 
preferentially use glycolytically derived ATP in a variety of tissues, including skeletal 
muscle (Okamoto et al., 2001; Dutka & Lamb, 2007), whereby an increase in Na+K+-
ATPase activity is associated with an increase in aerobic glycolysis.  This suggests that 
when glycolysis is inhibited, Na+K+-ATPase activity may be impaired.  This may offer a 
possible explanation for the compromised Na+K+-ATPase activity seen with insulin 
resistance.   
 
Obesity and type II diabetes are also associated with changes in membrane phospholipid 
composition which may explain the different effects seen with Na+K+-ATPase function 
(Borkman et al., 1993; Pan et al., 1994).  Studies of insulin deficiency have demonstrated 
a relationship between insulin and F.A desaturase activity, the enzyme responsible for 
inserting double bonds (Tilvis & Miettinen, 1985; el Boustani et al., 1989), whilst others 
have shown relationships exist between the F.A composition of phospholipids in 
skeletal muscle and the action of insulin (Vessby et al., 1994; Clore et al., 1998).  
Reducing desaturase activity may contribute to impaired insulin action by decreasing the 
amounts of PUFA in the membrane. This may then influence the action of insulin by 
modulating the function of membrane proteins that mediate insulin action such as 
insulin receptors and glucose transporters.  It may alter Na+K+-ATPase function 
through direct effects on the physical properties of the surrounding lipid environment.  
. 
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2.5.2.5 Treatments 
Diabetes has reached epidemic proportions in many populations and the growing 
prevalence is posing a massive health problem worldwide.  Although type II diabetes is 
known to be a lifestyle-related condition, healthcare resources are largely spent on 
treatment with little emphasis on preventive care.  Treatment of the disease is usually 
with dietary and exercise advice as well as anti diabetic medications, which are generally 
needed for the rest of the patient's life and often in increasing doses (Rosenberg et al., 
2005).  Drug medications effective in lowering blood glucose levels include 
sulfonylureas, meglitinides, biguanides (metformin), alpha-glucosidase inhibitors and 
thiazolidinediones, however none are without side-effects and consequences of long 
term use are not clear (Luna & Feinglos, 2001; Mayerson & Inzucchi, 2002).  Current 
evidence strongly suggests that environmental and behavioural factors are major 
determinants of the increasing rates of diabetes (Zimmet et al., 2001).  Obesity and 
physical inactivity are the two main risk factors for the development of insulin resistance 
and ultimately type II diabetes (Franz et al., 2003; Sullivan et al., 2005).  With around 56% 
of the Australian adult population being either overweight or obese (Baur, 2001), 
focusing on these factors offers an opportunity for preventing diabetes.  Two major 
intervention studies, the American and the Finnish prevention study, used moderate 
exercise and modified diet to demonstrate a similar 58% decline in the incidence of type 
II diabetes (Tuomilehto et al., 2001; Knowler et al., 2002).   
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2.6 Thiazolidinediones 
 
Obesity-related insulin resistance is a characteristic feature of type II diabetes and often 
the persistence of obesity interferes with conventional therapy such as diet and exercise.  
In these cases, a pharmacological approach is commonly used to reinstate 
normoglycemia.  Thiazolidinediones (TZDs) are a class of compounds that function as 
insulin sensitizers and are expected to be used by an estimated 50 000 diabetics as an oral 
antidiabetic drug (Burton, 2003; Ferre, 2004).  Many studies have shown administration 
of TZDs improves hyperglycaemia and hyperinsulinemia in insulin resistant rodent 
models and Type II diabetic patients (Saltiel & Olefsky, 1996; Olefsky, 2000).  TZDs 
have additional positive effects on F.A metabolism by decreasing TG, FFA and LDL-
cholesterol levels, whilst increasing plasma HDL-cholesterol concentrations (Komers & 
Vrana, 1998; Wilmsen et al., 2003).  Sensitised skeletal muscle might increase the known 
insulin-induced Na+-K+-ATPase function (Al-Khalili et al., 2003), however, TZDs have 
also been shown to cause undesirable side effects including altered membrane 
phospholipid composition which is integral to normal Na+-K+-ATPase function 
(Komers & Vrana, 1998). 
 
2.6.1 Mechanisms of Action 
TZDs function via agonistic action on the nuclear peroxisome proliferator-activated 
receptor-γ (PPAR-γ ) (Spiegelman, 1998).  These receptors are expressed on intra-
nuclear transcription factors in insulin target tissues; skeletal muscle, adipose tissue and 
liver and are activated by natural ligands, F.As and their derivatives (Ricote et al., 1998; 
Wahli, 2002).  Once TZD bind to the transcription factor, the activated PPAR-γ 
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complex regulates the transcription of genes involving lipids (refer to figure 2.7), 
whereby stimulation or inhibition is dependant on the specific gene and tissue 
concerned (Lebovitz, 2002).   
 
 
Figure 2.7 Activation of PPAR-γ nuclear receptor (Mudaliar & Henry, 2001) 
 
TZDs ameliorate insulin resistance by regulating a series of genes involved in altering 
lipid metabolism, adipose tissue differentiation, and insulin action (Lebovitz, 2002).  
Many of the specific gene changes elicited by TZD are at present still unknown, 
however studies have linked PPAR-γ gene allele variations to obesity and type II 
diabetes (Argmann et al., 2005; Ghoussaini et al., 2005).  
 
Although PPAR-γ is highly expressed in white and brown adipose tissue, the insulin 
sensitising effect of TZDs is largely seen in skeletal muscle (Vidal-Puig et al., 1997).  
There are 3 proposed explanations for this phenomenon (Kliewer et al., 2001).  1. 
PPAR-γ may be responsible for activating the release of signalling molecules from 
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adipocytes which in turn affect glucose metabolism in other tissues, such as skeletal 
muscle.  2. PPAR-γ reduces serum lipid concentrations and this has a secondary effect 
on glucose utilisation in skeletal muscle as high circulating FFA and TG are known to 
inhibit glucose utilisation.  3. PPAR-γ may have direct effect on glucose metabolism in 
skeletal muscle which is why they are expressed at low levels.  Most data supports the 
hypothesis that insulin sensitising effects of TZDs are secondary to altered adipose 
tissue metabolism.  However the mechanism underlying the pharmaceutical action of 
these drugs remains poorly understood (Kahn et al., 2000).   
 
2.6.2 Rosiglitazone 
Rosiglitazone is a TZD derivative and a PPAR-γ agonist that is better known as Avandia 
on the market (Cuzzocrea et al., 2004).  It differs from other members of the TZDs class, 
such as troglitazone and pioglitazone, by carrying a different side chain (see figure 2.8) 
(Mudaliar & Henry, 2001) and displaying a higher affinity for PPAR-γ (Young et al., 
1998).   
 
 
Figure 2.8 Structures of TZD agents.  Modified from (Mudaliar & Henry, 2001) 
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The pharmacokinetic profile of rosiglitazone is not altered by food intake and the 
compound is fully metabolized with no unchanged drug detected in urine (Mudaliar & 
Henry, 2001).  Diabetic patients commence rosiglitazone treatment with a 4 mg oral dose 
daily but may increase to 8 mg daily if an inadequate response is seen after 12 weeks of 
treatment (Mudaliar & Henry, 2001).  Rosiglitazone increases insulin sensitivity by 
enhancing glucose metabolism in muscle and decreasing glucose biosynthesis in the liver.  
Like the other TZDs, rosiglitazone is thought to ameliorate insulin resistance by altering 
lipid metabolism (Miyazaki et al., 2001).  Some of these changes include decreased 
hepatic secretions of lipids into plasma, induced de novo F.A synthesis and lipid uptake 
in muscle (Watkins et al., 2002; Ferrannini, 2005).  A fall in circulating FFA reduces the 
competition with glucose for utilisation in skeletal muscle, resulting in decreased blood 
glucose concentrations (Ferrannini, 2005). 
 
2.6.2.1 Benefits 
The major effect of rosiglitazone treatment is the improvement in insulin action, 
resulting in decreased insulin resistance.  Rosiglitazone has been reported to restore 
insulin’s ability to suppress hepatic gluconeogenesis and improve peripheral glucose 
uptake, without stimulating insulin production (Miyazaki et al., 2001; Carey et al., 2002; 
Wagstaff & Goa, 2002).   In a study by Miyazaki and colleagues, rosiglitazone treatment 
(8 mg/day) for 12 weeks significantly decreased fasting plasma glucose levels and 
glycated haemoglobin 1c without changes in plasma insulin concentrations (Miyazaki et 
al., 2001).  They also showed a decrease in basal endogenous glucose production and an 
increase in whole body glucose clearance rate.  
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Rosiglitazone has also been shown to reduce circulating FFA and TG (Mayerson et al., 
2002).  Rosiglitazone stimulates the differentiation of stem cells within adipose tissue 
into mature adipocytes, promoting FFA and TG uptake and storage.  This action in 
humans is specific to stem cells in peripheral subcutaneous adipose, rosiglitazone has 
little or no effect on stem cells in visceral adipose tissue (Lebovitz, 2002).  Therefore 
redistributed fat in a favourable direction and lessening visceral adiposity, a major driver 
of type II diabetes (Pedersen et al., 1993).  Although it seems rosiglitazone, at least partly 
exerts its insulin-sensitising effect via PPAR-γ action, it may also involve a PPAR-
independent mechanism, involving AMPK via the AMP/ATP-dependent pathway 
(Fryer et al., 2002; Feinstein et al., 2005; Lessard et al., 2006). 
 
In addition to its beneficial effects on glucose and lipid metabolism, rosiglitazone has 
been associated with other advantageous affects.  Bakris et al found that rosiglitazone at 
4 mg twice daily significantly reduced systolic blood pressure and diastolic blood 
pressure in type II diabetic patients  (Bakris et al., 2003). 
 
 
2.6.2.2 Side effects 
In general, TZDs have been shown to cause excessive weight gain and fluid retention 
(and oedema) increasing the risk of heart failure.  Other reported adverse effects include 
reduced hematocrit and white blood cell count, altered liver function and hepatotoxicity 
(Sood et al., 2000).  
 
Haemoglobin and hematocrit counts are reduced in patients with rosiglitazone treatment 
in a dose-related fashion (Mudaliar & Henry, 2001).  Fluid retention is the most common 
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drug-related side effect of rosiglitazone in clinical practice and may be the cause of 
decreased hemoglobin/hematocrit via hemodilution (Wagstaff & Goa, 2002).  However, 
available data is conflicting and does not completely support this concept.  Other 
researchers have suggested fluid retention and tissue oedema seem to be part of a 
vascular 'leak' syndrome (Scheen, 2004).  A large clinical trial with rosiglitazone reported 
peripheral oedema occurred in 4.8% of patients receiving rosiglitazone alone, with a 
higher incidence (14.7%) occurring with combined insulin therapy compared to 1.3% 
receiving placebo (Hollenberg, 2003).  Patients treated with rosiglitazone have also 
shown slight decreases in white blood cell counts (Haffner et al., 2002).  
 
Fluid retention by glitazones can reveal or aggravate congestive heart failure, an issue of 
particular concern in patients with type II diabetes who are insulin-treated or have pre-
existing heart failure.  This may limit the therapeutic application of rosiglitazone in the 
prevention of cardiovascular disease.   
 
Rosiglitazone treatment for 12-52 weeks has been reported to increase mean body 
weight by 1 to 3 kg (Hollenberg, 2003).  The increase in body weight with rosiglitazone is 
due to increased peripheral subcutaneous and not visceral fat masses (Carey et al., 2002).  
Even though the fat is redistributed in a favourable direction, no long-term follow-up is 
yet available and weight gain can only exacerbate the problem of pre-existing obesity, 
furthering the struggle to be physically active (Ferre, 2004).  The mechanism of weight 
gain remains unclear but probably involves a combination of fluid retention and fat 
accumulation. 
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Other TZDs, such as troglitazone and pioglitazone have been shown to repress the gene 
expression of stearoyl-CoA desaturase 1, reducing the biosynthesis of PUFA from 
saturated F.As (Kurebayashi et al., 1997).  Modification of membrane phospholipids can 
alter membrane properties such as fluidity, permeability and membrane ion transport 
(Komers & Vrana, 1998).  The intrinsic activity of Na+-K+-ATPase, is dependant upon 
the membrane lipid milieu surrounding it.   
 
With potential links to congestive heart failure and liver failure, little research has been 
done on the side effects and chronic effects of rosiglitazone.  It is a research area which 
very much requires attention to determine the safe use of these new insulin sensitisers in 
patients with type II diabetes.  
2.7 Exercise 
 
With the prevalence of type II diabetes expected to double in the next 25 years (Dunstan 
et al., 2002; Agarwal et al., 2005), healthcare resources need to be spent on preventive 
care.  Focusing on environmental and behavioural factors such as a sedentary lifestyle 
and obesity, the major determinants of the increasing rates of diabetes, offers an 
opportunity for preventing diabetes (Zimmet et al., 2001).  When thinking prevention, 
there is always a tendency to concentrate on diet. Whilst this is important, particularly in 
reducing dietary fats, the overwhelming evidence is that the main cause of positive 
energy balance in weight gain is due to inactivity (Wei et al., 2000; Tuomilehto et al., 2001; 
Knowler et al., 2002; Troiano, 2002). 
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It has been well documented that with regular exercise emerge physiological and 
biochemical benefits.  Studies have shown exercise training improves insulin sensitivity 
and increases insulin-stimulated skeletal muscle glucose transport in insulin resistant 
animal models and type II diabetics (Ivy et al., 1989; Perseghin et al., 1996).  Acute bouts 
of exercise only provide temporary improvements in insulin sensitivity with benefits 
lasting up to 48 hours (Ivy et al., 1983; Etgen et al., 1993), however increasing evidence 
shows chronic exercise training induces metabolic adaptations that cause improved 
insulin action in insulin resistant skeletal muscle (Hawley, 2004).  
 
Several studies have also demonstrated an increase in Na+K+-ATPase concentration with 
exercise in skeletal muscle of lean animal models (Kjeldsen et al., 1986; Tsakiridis et al., 
1996) and healthy individuals (Green et al., 1993; McKenna et al., 1993; Madsen et al., 
1994).  However, no one has investigated the potential benefits of exercise on Na+K+-
ATPase in skeletal muscle of insulin resistant animals or Type II diabetics.  
 
2.7.1 Acute Response 
Na+K+-ATPase is rapidly activated within seconds following excitation and contraction 
in skeletal muscle through a combination of electrical, ionic and hormonal factors.  
Previous studies have shown the up-regulation of Na+K+-ATPase activity however the 
mechanism is not clear.  Studies using electrical stimulation at 60 or 120 Hz for 10 
seconds in rat soleus muscle found an increase in Na+K+-ATPase activity by 12 to 22-
fold (Everts & Clausen, 1994; Nielsen & Clausen, 1997).  After electrical stimulation, 
there is an initial rise in intracellular [Na+] due to leakage but this is then followed by an 
'undershoot' below the resting level.  This may indicate that Na+K+-ATPase activation is 
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elicited by a rise in it’s affinity for intracellular Na+ (Juel, 1986; Buchanan et al., 2002).  
Some studies have claimed the increase in activity is due to acute subunit translocation 
to the membrane from an unidentified intracellular location (Tsakiridis et al., 1996; Juel 
et al., 2000; Juel et al., 2001).  In humans, a short high intensity bout of exercise 
significantly increased the plasma membrane content of the ∝2-, total ∝ and β1-subunits 
(Juel et al., 2000).  Similar findings have been found in animal studies (Juel et al., 2001).  
Murphy and colleagues showed a single bout of prolonged submaximal exercise 
increased mRNA expression of ∝1, ∝3 and β2 isoforms, and protein abundance of the 
∝3 (Murphy et al., 2006).  One study showed 1 hour of treadmill running in rats caused a 
significant increase in the plasma membrane content of ∝1- and ∝2-subunits and 
elevation of the ∝1- and β2-subunit mRNAs, however no difference in subunit content 
was found in the internal membrane fraction or total membranes (Tsakiridis et al., 1996).  
However, more recently, McKenna and colleagues have challenged this theory, 
reporting conflicting results that indicate subunit translocation to the membrane does 
not take place (McKenna et al., 2003).   
 
2.7.2 Long term Effect 
Na+K+-ATPase is regulated in a physical activity dependant manner, in which exercise 
training causes upregulation and inactivity leads to down-regulation of Na+K+-ATPase 
concentration (Clausen, 1998).  Chronic exercise training has been shown to increase 
Na+K+-ATPase content in skeletal muscle whereby a relatively intense level of physical 
activity is required (Madsen et al., 1994; Evertsen et al., 1997).  Elevated sarcolemma 
Na+K+-ATPase content would increase K+ uptake and help alleviate exercise induced 
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hyperkalemia, therefore enhance muscle performance and delay fatigue.  A study by 
Harmer et al, showed improved K+ regulation with exercise training, whereby 
hyperkalemia was reduced during intense exercise after sprint training (Harmer et al., 
2000) and other studies have reported a 16% increase in the concentration of Na+K+-
ATPase in human skeletal muscle with sprint training (McKenna et al., 1993) and 
approximately 15% with endurance training (Green et al., 1993; Madsen et al., 1994; 
Fraser et al., 2002).   
 
However the effect of exercise training can be reversed as inactivity causes down-
regulation of Na+K+-ATPase content.  In a rat study by Kjeldsen et al, detraining after 6 
weeks of endurance training caused a decrease in Na+K+-ATPase content to pre-training 
levels in skeletal muscle (Kjeldsen et al., 1986).  The study also reported a 20% reduction 
in the [3H]-ouabain binding site content in rat muscle when inactivity was induced by 
limb immobilization (Kjeldsen et al., 1986).  In humans, a 26.6% decrease was reported 
in the Na+K+-ATPase content of the deltoid muscle from patients with shoulder 
impingement (Leivseth & Reikeras, 1994). 
 
2.7.3 Exercise and Diabetes 
The effect of insufficient Na+K+-ATPase activity and raised extracellular [K+] was well 
demonstrated by Clausen and colleagues in isolated rat skeletal muscle, when 
extracellular [K+] was raised to 12.5mM and there was a 95% loss in contractile force 
(Clausen et al., 1993).  Early muscular fatigue can compromise exercise capacity and is 
likely to impact on the ability to perform activities of daily living.  Type II diabetics have 
been known to have reduced exercise capacity, with impaired maximal oxygen 
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consumption (VO2max) and increased submaximal VO2 during exercise compared to 
healthy controls (Schneider et al., 1984; Regensteiner et al., 1995; Baldi et al., 2003).  
The mechanism by which exercise improves skeletal muscle insulin action with respect 
to glucose metabolism are fairly well described, including increases in GLUT4 protein 
(Houmard et al., 1993). 
 
2.8 Animal Models of Insulin Resistance 
 
The progressive nature of insulin resistance and its associated chronic metabolic 
changes have been made easier to study with the use of suitable animal models of 
insulin resistance. The appropriate experimental animal model is required to depict the 
inevitable progression of increased weight (obesity) and insulin resistance, impaired 
glucose tolerance and on to frank diabetes with associated cardiovascular risk factors.  
Given that dietary factors are important in the aetiology of both insulin resistance and 
obesity in humans, an over-eating or high-fat fed rat model can be used to simulate the 
disease in humans.   
 
2.8.1 Obese Zucker Rat 
The obese Zucker rat is a well established experimental model of insulin resistance and 
morbid obesity that increases the likelihood of Type II diabetes.  The autosomal 
homozygous recessive genotype (fa/fa) of the obese Zucker causes the rat to develop 
faulty leptin receptors (Phillips et al., 1996; Tirabassi et al., 2004).  Leptin is an adipose-
specific hormone that contributes to appetite regulation.  Obese Zucker rats acquire 
hyperphagia, hyperinsulinemia, insulin resistance, glucose intolerance and ultimately type 
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II diabetes (Shafrir, 1992).  The rats also develop other associated features of type II 
diabetes such as hyperlipidemia and hypertension.  Defects in insulin receptor signalling 
have been described at both receptor and post-receptor sites (Ahmad & Goldstein, 
1995).  
 
2.8.2 High Fat Fed Rats 
Rats that are fed high fat diets, are generally well accepted as a valid rodent model for 
insulin resistance, obesity and dyslipidemia.  High levels of some dietary fats can cause 
insulin resistance in rats in as little as 4 weeks.  Storlien et al, compared the effect of 
different high-fat diets on insulin sensitivity in rats and found that diets high in 
saturated, monounsaturated and omega-6 PUFAs induced severe insulin resistance, 
whilst a diet including long chained omega-3 PUFAs normalised insulin action (Storlien 
et al., 1991).  Another study also demonstrated the importance of omega-3 by reporting 
a diet deficient in omega-3 fed to rats induced insulin resistance, hypertension and 
obesity (Barnard et al., 1998).  High-fat feeding in rats displays skeletal muscle defects in 
insulin signalling and disregulated metabolism that are seen in insulin resistant humans 
(Kraegen et al., 1991).  Limited research has been done involving Na+K+-ATPase and 
diet induced models of diabetes, however, Na+K+-ATPase activity has been found to be 
compromised in skeletal muscle and liver from lard-fed rats (Takeuchi et al., 1995).  The 
growing prevalence of this disease and its strong association with obesity indicate that 
lifestyle factors make an important contribution to its onset and thus, the high fat fed 
rat represents a well suited model for studying insulin resistance. 
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2.8.3 Other Insulin Resistant Rat models 
Sugar-enriched diets also produce hepatic insulin resistance in rats.  Chronic feeding of 
sucrose or fructose to normal rats causes impaired glucose tolerance, loss of tissue 
sensitivity to insulin, hyperinsulinemia and hypertension independently of obesity 
(Thirunavukkarasu et al., 2004).  Fructose infusion in humans has been shown to result 
in impaired insulin regulation of glucose production (Wei & Pagliassotti, 2004). 
 
An injection of streptozotocin (STZ) (80-90 mg/kg body weight) into neonatal rats 
causes glucose intolerance when these animals reach adulthood (Portha et al., 1989).  
However, a faster alternative and easier approach to the study of type II diabetes is the 
administration of a single sub-diabetogenic amount of streptozotocin (40 mg/kg body 
weight) to the adult rat (Rasschaert & Malaisse, 1993; Ramesh & Pugalendi, 2006).  All 
the same, both models represent an unnatural mode of acquiring type II diabetes and do 
not simulate the natural progression of insulin resistance and hyperinsulinemia in the 
human population.  Therefore the drug induced model was not chosen for use in this 
project. 
 
Glucocorticoid treatment causing insulin resistance to cellular glucose uptake is a well 
known phenomenon.  Recently, a study showed Dexamethasone, a synthetic 
glucocorticoid provoked insulin resistance to cellular uptake of K+ in rat skeletal muscle 
despite a significant increase in Na+K+-ATPase ∝2 isoform levels (Rhee et al., 2004).  
Nevertheless, acquiring obesity related insulin resistance through a pharmacological 
approach is not physiological in many respects. 
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2.9 Aims and Hypotheses 
 
 
2.9.1 General Aims 
This thesis investigated the effect of insulin resistance on Na+K+-ATPase function in 
skeletal muscle, and the effect of rosiglitazone and/or exercise training on Na+K+-
ATPase function in insulin resistant skeletal muscle.  Biochemistry techniques used to 
measure Na+K+-ATPase activity and content were maximal K+-stimulated 3-O-MFPase 
activity in crude muscle homogenates and vanadate facilitated [3H]-ouabain binding site 
using whole tissue, respectively.  Since insulin is a major regulator of Na+-K+-ATPase 
function, the first study of the thesis investigated the effect of insulin resistance on  
 
Na+K+-ATPase function in skeletal muscle using 2 animal models of insulin resistance 
and morbid obesity, the obese zucker rat and high fat fed Sprague Dawley (Chapter 4).  
Rosiglitazone is an oral antidiabetic drug that improves hyperglycaemia and 
hyperinsulinemia in insulin resistant and type II diabetic patients via insulin sensitising 
mechanisms (Lebovitz et al., 2001; Hung et al., 2005) but may also have a detrimental 
effect on membrane lipids which is integral to the functioning of Na+-K+-ATPase.  
Therefore the second study (Chapter 5) investigated the effects of rosiglitazone on Na+-
K+-ATPase function in obese zucker skeletal muscle.  Chronic exercise training has 
been shown to decrease skeletal muscle insulin resistance in insulin resistant animal 
models (Ivy et al., 1989) and diabetics (Perseghin et al., 1996) as well as upregulate Na+-
K+-ATPase content in lean skeletal muscle (Green et al., 1993; Evertsen et al., 1997).  
However no study has investigated the effect of exercise on Na+-K+-ATPase in insulin 
resistant skeletal muscle.  The third study (Chapter 6) investigated the effect of  
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rosiglitazone treatment and exercise training on Na+-K+-ATPase function in insulin 
resistant skeletal muscle of high fat fed Sprague Dawley rats.  This study aimed to 
determine whether exercise or rosiglitazone would alleviate the detrimental effect of 
insulin resistance on Na+-K+-ATPase function and since exercise and rosiglitazone 
treatment improve insulin sensitivity via different mechanisms,  whether the two effects 
of the therapeutic treatments would be additive. 
 
 
2.9.2 Hypotheses 
The hypotheses tested in this thesis were: 
1. Na+K+-ATPase activity and concentration assessed by maximal in vitro 3-O-
MFPase activity and [3H]-ouabain binding site content, respectively would be 
depressed with insulin resistance in rat skeletal muscle (Chapter 4). 
2. Rosiglitazone will increase maximal in vitro Na+K+-ATPase activity and 
membrane content in healthy and insulin resistant rat skeletal muscle via its 
insulin sensitising effect (Chapter 5). 
3. Exercise training will alleviate depressed maximal in vitro Na+K+-ATPase activity 
and membrane content with insulin resistance in rat skeletal muscle (Chapter 6). 
4. Rosiglitazone and exercise will have an additive affect on Na+K+-ATPase activity 
and content in insulin resistant rat skeletal muscle (Chapter 6). 
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C h a p t e r  3  
 
GENERAL METHODOLOGY 
3.1 Study Design 
 
This thesis investigated Na+K+-ATPase function in insulin resistant skeletal muscle 
from 2 experimental animal models. Genetically predisposed obese Zucker rats with 
their age matched lean controls and high fat fed Sprague Dawley rats with their standard 
chow fed controls.  Chapter 4 compares the Na+K+-ATPase function investigated in 
skeletal muscle from 15 week old obese Zucker rats and in basal and insulin stimulated 
muscle of high-fat fed 17 week old Sprague Dawley rats.  In the second study (Chapter 
5), the effect of insulin resistance on Na+K+-ATPase function is further examined with 
more insulin resistant animals, 25 week old obese Zucker rats.  This study also explored 
the effects of the anti-diabetic drug, Rosiglitazone, on Na+K+-ATPase function in 
skeletal muscle.  The third study (Chapter 6) examined the effects of rosiglitazone and 
exercise on Na+K+-ATPase function in skeletal muscle using high-fat fed rats.  
 
3.2 Experimental Animals 
 
Two different animal models were used to complete this dissertation.  The availability of 
obese Zucker rats became critically low in the early stages of the final research study and 
proposed a severe delay in the completion of this research.  This problem offered the 
opportunity to investigate Na+K+-ATPase function in another insulin resistant animal 
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model.  The high-fat fed model was chosen as it represents a significant dietary change 
that has occurred in Western society, an unhealthy fast food culture.  This study was 
undertaken at the California State University of Northridge (CSUN) in the United 
States. 
 
3.2.1 Lean & Obese Zucker Rats  
All obese (fa/fa) and age matched lean (fa/?) Zucker rats were obtained from Monash 
Animal Laboratory (Melbourne, Australia).  On arrival, rats were housed 4 per plastic 
cage in an environmentally controlled room, at a temperature of 22±1°C and relative 
humidity of 50±2%, on a 12-hour fixed light-dark cycle and were allowed ad libitum 
access to water and rat chow (67.5% carbohydrate, 11.7% fat, 20.8% protein; Barastock 
Ltd. Victoria, Australia).  Care and treatment of these animals was in accordance with 
procedures outlined by the Australian National Health and Medical Research Council 
guidelines and all surgical and experimental procedures performed were approved by the 
Animal Experimentation Ethics Committee of RMIT University.   
 
3.2.2 Sprague Dawley Rats 
All Sprague Dawley rats were obtained from Harlan Sprague Dawley, Inc., 
(Indianapolis, IN).  On arrival, rats were housed 3 per cage in a temperature controlled 
animal room (21±1°C) maintained on a 12-hour fixed light-dark cycle.  Rats were 
allowed ad libitum access to water and standard rat chow (73% carbohydrate, 11% fat, 
16% protein, D12328; Research Diets Inc., New Brunswick, NJ).  Care and treatment of 
these animals complied with guidelines for laboratory animal use as published by the 
U.S Department of Health and Human Resources and all surgical and experimental 
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procedures performed were approved by the Institutional Animal Care and Use 
Committee at CSUN.  
 
3.3 Muscle Analysis 
 
The focal tissue of interest for this thesis was skeletal muscle as it is the major tissue for 
insulin-stimulated glucose uptake and disposal and is therefore considered the major site 
of insulin resistance. Skeletal muscle also contains the majority of Na+K+-ATPase in the 
body.  The gastrocnemius was the muscle of choice as it contains both red oxidative and 
white glycolytic fibres which can be easily separated based on visible colour differences.  
However this thesis concentrated on red oxidative muscle as these fibres respond to 
endurance exercise training and contain a larger percentage of Na+K+-ATPase ∝2-
subunits than white glycolytic muscle (Bray et al., 1977).  This subunit is ouabain 
sensitive (Repke et al., 1995) and can be quantitatively measured by radioactive labelled 
[3H]-ouabain, and displays a higher degree of plasticity making it more susceptible to 
insulin induced changes (Al-Khalili et al., 2003). 
 
3.3.1 Animal Sacrifice 
In brief, for study 1, lean and obese Zucker rats at 15 weeks of age were anaesthetised 
with pentobarbital (6.5 mg/100g body wt) before being sacrificed by cardiac injection of 
pentobarbital.  For study 2, Zucker rats were sacrificed by asphyxiation with CO2 
inhalation followed by decapitation.  All Sprague Dawley rats were anaesthetised with 
pentobarbital (6.5 mg/100g body wt) before preparation for single hind limb perfusion 
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(described in detail in Chapter 4) and then finally rats were sacrificed via intracardiac 
injection of pentobarbital.  
 
3.3.2 Muscle Collection 
The hind limb muscle, gastrocnemius was rapidly excised and immediately divided into 
red and white portions to represent red gastrocnemius (RG) and white gastrocnemius 
(WG) respectively.  Muscle groups were snap frozen in liquid nitrogen, and stored at -
80°C until further preparation and/or analysis.   
 
3.3.3 Muscle Homogenisation 
Muscle samples weighing 20±2 mg were homogenised for Na+-K+-ATPase activity 
analysis using the 3-OMFPase assay (Fraser & McKenna, 1998).  They were 
homogenised in the appropriate volume of homogenate buffer (5% w/v), containing 
250 mM sucrose, 2 mM EDTA and 10 mM Tris (pH 7.40).  Muscle was homogenised 
on ice for 4°C for 2 x 20 sec at 20,000 rpm using an Omni 1000 (Omni International, 
Marietta, GA).  Muscle homogenates were immediately frozen in liquid nitrogen, and 
stored at -80°C until 3-OMFPase activity analysis. 
 
3.3.4 3-OMFPase Assay  
The rate of Na+K+-ATPase enzyme activity can be determined using a synthetic 
substrate called 3-O-methlylfluorescein phosphate (3-OMFP).  The 3-OMFP can be 
hydrolysed by Na+K+-ATPase in the presence of K+ to yield a phosphate group and a 
fluorescent compound, 3-O-methlylfluorescein (3-OMF) (Huang & Askari, 1975).  This 
compound can be measured to quantify Na+K+-ATPase activity.  Fluorescence was 
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measured by a Jasco FP-750 spectrofluorometer containing a temperature controlled 
chamber with a fluid injection port.   
 
The Na+-K+-ATPase activity was measured using maximal K+ stimulated in vitro 3-O-
methlylfluorescein phosphatase (3-O-MFPase) activity (Fraser & McKenna, 1998).  This 
technique was optimised for human skeletal muscle however these condition also gave 
optimal conditions for  rat skeletal muscle (Fraser & La Vita unpublished observations). 
Muscle samples were made permeable by four freeze-thaw cycles, exposing the binding 
sites for Na+, K+, and ATP.  Samples were then diluted 1/5 in cold homogenate buffer 
and placed on ice waiting analysis.  30µl of chilled sample was added to 2.5ml of pre-
heated assay medium containing 5 mM MgCl2, 1.25 mM EDTA and 100 M Tris buffer 
and 0.04 µM 3-OMF (pH 7.40) and incubated to 37°C.  40µl of 10 mM 3-OMFP was 
added through the injection port to initiate the reaction.  After 80 seconds, 10µl of 2.58 
mM KCl (final concentration 10 mM) was added through the injection port to stimulate 
K+-dependent phosphatase activity and fluorescence was measured for another 80 
seconds.  The assay solution in the cuvette was continuously stirred throughout the 
reaction time.  The maximal K+-stimulated 3-OMFPase activity was determined by the 
increase in activity after the addition of KCl.  3-O-MFPase activity was resolved by the 
difference in slope gradient before and after the addition of KCl and was also based on 
the average of 3-4 successive trials.  Na+-K+-ATPase activity was first determined as 
nmol• min-1•g-1 wet weight but later expressed as pmol• min-1• mg-1 muscle protein to 
correct for any connective tissue present in rat skeletal muscle that could not be 
removed during muscle dissection.  
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3.3.5 Muscle Protein Analysis   
Muscle protein content of the homogenate was determined spectrophotometrically by 
the micro bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL).  A water-
soluble purple colored reaction product is formed by the interaction of two molecules 
of BCA with one Cu1+ ion that exhibits a strong absorbance at 562 nm and is linear with 
increasing protein concentrations.  Hence, the amount of reduction is proportional to 
the protein present. The BCA assay was selected to measure protein content because it 
is faster, easier and more sensitive than the Lowry method (Stoscheck, 1990) and has a 
larger linear working range than the Bradford assay (Zor & Selinger, 1996).  The BCA 
assay was applied to the microtiter plate method using bovine serum albumin (0-2000 
µg/ml) for the standard curve.  
 
3.3.6 Vanadate Facilitated 3H-ouabain Binding Method 
Ouabain is a cardiac glycoside which can be used at low concentrations to treat 
congestive heart failure via partial inhibition of cardiac muscle Na+K+-ATPase (Schoner, 
2001).  However, it is a complete inhibitor if given in high enough concentrations.  Due 
to ouabain’s ability to specifically bind at a one to one ratio with Na+K+-ATPase, 
radioactive labelled [3H]-ouabain is commonly used to quantify the content of Na+K+-
ATPase in skeletal muscle.  In rat skeletal muscle, the number of [3H]-ouabain binding 
sites depends on many factors but at a mature age of 16 weeks, is approximately 300-
400 pmol per gram of wet tissue weight and slightly higher in slow-twitch muscles 
compared with fast-twitch muscles (Fowles et al., 2004).   
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Pump content in muscle tissue samples was quantified using the [3H]-ouabain binding 
method.  The standard ouabain binding assay (using 1000 nM [ouabain]) is known to 
measure the content of α2 isoforms in rat skeletal muscle solely because the α1 isoform is 
highly ouabain resistant (Kjeldsen et al., 1986).  For this assay muscle samples were cut 
into triplicate pieces weighing approximately 5 mg each.  Muscle pieces were pre-washed 
twice for 10 min in a Tris-Vanadate-Sucrose (TVS) buffer containing 10 mM Tris-HCl, 
3 mM MgSO4, 1 mM NaVO3 and 250 mM sucrose (pH 7.3) at 37°C before being 
incubated in TVS buffer containing a saturating concentration of [3H]-ouabain (1000 
nM, 0.6 µCi/ml) for 120 min at 37°C.   Vanadate facilitates the binding of [3H]-ouabain 
and allows quantification of the Na+K+-ATPase content in skeletal muscle (Hansen, 
1982).  Unbound ouabain was removed by 4 x 30 min washouts using TVS buffer at 
0°C.  Muscle pieces were blotted, weighed and placed in 0.5 ml 5% trichloroacetic acid 
with 0.1 mM ouabain solution, overnight at 4°C. Samples were then counted for 3H 
radioactivity in a scintillation mixture (Opti-Fluor, Packard).  The content of 
[3H]ouabain binding sites was determined and expressed as picomoles per gram wet 
weight (for details, see Clausen & Hansen, 1977). 
 
3.3.7 Membrane Phospholipid Analysis   
Membranes phospholipid analysis was completed in a collaborative study Wollongong 
University / Garvan Institute of Medical Research (NSW). 15-30mg portions of the RG 
was prepared for analysis and sent to Wollongong University for determination of the 
phospholipid fatty acid (FA) profile by gas-liquid chromatography performed by Dr 
Nigel Turner. 
 
 64
All solvents used in the lipid analysis were of ultra-pure grade and were from Merck Pty 
(Kilsyth, Victoria, Australia). Analytical grade butylated hydroxytoluene was from Sigma 
Aldrich (Castle Hill, NSW, Australia).  Skeletal muscle lipids were extracted by standard 
methods (Folch et al., 1957) using chloroform-methanol (2:1 vol/vol) containing 
butylated hydroxytoluene (0.01% wt/vol) as an antioxidant.  Phospholipids were 
separated by solid-phase extraction on Strata SI-2 silica cartridges (Phenomenex, 
Pennant Hills, NSW, Australia).  FA analysis of the phospholipid fraction was 
determined, as described in detail previously (Pan & Storlien, 1993).  Briefly, 
phospholipid fractions were transmethylated with 14% (wt/vol) boron trifluoride in 
methanol, and FA methyl esters were separated by gas-liquid chromatography on a 
Shimadzu GC 17A gas chromatograph (Shimadzu Oceania, Sydney, Australia) with 
FAMEWAX column. 
 
Individual FAs were identified by comparing each peak's retention time to those of 
external standards. The relative amount of each FA (percentage of total FA) was 
determined by integrating the area under the peak and dividing the result by the total 
area for all FAs.  The sum of saturates, monounsaturates, and polyunsaturates was 
calculated, and total proportions of n-6 and n-3 FAs were also determined.  
Unsaturation index, which represents the average number of double bonds per 100 FA 
molecules, was calculated by summing the products of the proportion (mol%) of each 
unsaturated FA multiplied by its number of double bonds.  The product-precursor ratio 
of several FAs was used to gain an indication of enzyme activity.  The estimated enzyme 
activities included those of elongase, calculated as the stearic acid (18:0)-to-palmitic acid 
 65
(16:0) ratio; ∆5 desaturase, calculated as the arachidonic acid [20:4(n-6)]-to-di-homo--
linolenic acid [20:3(n-6)] ratio; ∆6 desaturase, calculated as the di-homo--linolenic acid 
[20:3(n-6)]-to-linoleic acid [18:2(n-6)] ratio (assuming that ∆6 desaturase and not 
elongase is rate limiting); and ∆9 desaturase, calculated as the oleic acid [18:1(n-9)]-to-
stearic acid (18:0) ratio. 
3.4 Blood Analysis 
 
Blood samples were collected in each study.  Collection and analysis varied between 
studies however where possible consistency was maintained.   
 
3.4.1 Blood Collection   
For study 1, fasting blood was collected via cardiac puncture into a serum separating 
tube.  Blood was immediately centrifuged and serum frozen for later analysis of glucose, 
ions and lipids.  For study 2, mixed arteriovenous blood was collected in heparinised 
tubes for analysis of risk factors, plasma insulin and lipids, and blood glucose.  For study 
3, fasting blood was collected via cardiac puncture in an eppendorf tube, immediately 
centrifuged and plasma separated and frozen. 
  
3.4.2 Blood Analysis   
For study 1, I performed all blood analysis on a Modular Analytic SWA P module 
(Roche Diagnostics, Mannheim, Germany).  Serum total cholesterol was analysed with 
the enzymatic colorimetric CHOD-PAP method on the Modular system.  A 
homogenous enzymatic colorimetric test was used for the determination of serum  
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HDL cholesterol on the Modular system.  Serum triglycerides were measured applying 
the colorimetric enzymatic GPO-PAP assay at the Modular system.  LDL cholesterol 
was calculated utilising the Friedewald equation (Friedewald et al., 1972): 
 
      LDL-Cholesterol = Total Cholesterol – (HDL-Cholesterol + Triglycerides/5). 
 
Non-fasting serum glucose was measured on the Modular system with the 
glucose/hexokinase method. Creatinine was measured using a colorimetric enzymatic 
assay on the Modular system while Sodium, Potassium and Chloride were measured by 
an ion-selective electrode (ISE) (Roche Diagnostics).   
 
Our collaborators performed the blood analysis in study 2, where plasma insulin was 
measured by enzyme immunoassay kits (Ultra-sensitive Rat Insulin Elisa, Mercodia AB, 
Uppsala, Sweden).  Plasma levels of total cholesterol and triglycerides were measured 
using enzymatic assays CHOD-PAP and GPO-PAP (Roche, Basel, Switzerland), 
respectively.  Blood glucose was measured using a MediSense® glucometer (MediSense, 
Australia). 
 
All Sprague Dawley blood was analysed as fasting serum by a colleague.  Insulin was 
measured by enzyme radioimmunoassay kits (Sensitive Rat Insulin RIA kit, Linco 
Research).  Free fatty acid concentration was determined using an enzymatic 
colorimetric method (NEFA C test kit; Wako Chemicals, USA, Inc) and serum glucose 
was measured using an automated analyser (2300 Stat Plus Glucose and L-Lactate 
Analyzer; Yellow Springs Instruments, Yellow Springs, OH). 
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3.5 Statistical Anlaysis 
 
Statistical analysis was performed on SPSS version 11.5 software (SPSS Inc, 2002).  
Descriptive statistics included means and standard error (SE).  Significance was accepted 
at p<0.05.    
 
Independent T test was used to determine statistical significance between non paired 
data, (ie. lean vs obese Zucker rats Chapter 4) while one-way analysis of variance 
(ANOVA) was used to determine statistical significance between groups when more 
than 2 existed, followed by Tukey's honestly significant difference test. 
3.6 Limitations  
 
There were several limitations to the thesis as a whole, in addition to the limitations of 
the individual studies.  The main factor causing disruption to the flow of the thesis was 
supply shortage of the male obese Zucker rat after research had commenced.  This 
limitation arose as a result of breeding problems within the Zucker colony at Monash 
Animal Laboratory (Melbourne, Australia) and since there had been no prior warning or 
knowledge of this occurrence, it was unavoidable.   
 
3.6.1 Study 1  
The supply of the male old obese Zucker rat became critically low during the first study 
which prevented the sequence of studies to be completed using one animal model of the 
same sex.  Consequently, another insulin resistant animal model had to be chosen and 
the high fat fed rat model was preferred.  Although the housing and treatment of the 
two animal models were identical, they could not be compared as the research involving 
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the two different animal groups were taken place at different times and in different 
places.  Therefore the two groups were investigated separately.   The shortage of male 
obese Zucker rats also prevented the investigation of insulin stimulated muscle in this 
group.  The insulin concentration used in insulin stimulation of the Sprague Dawley rat 
hindlimbs did not produced the expected results in Na+K+-ATPase activity and content.  
This may have been because a low physiological dose of insulin was used. 
 
3.6.2 Study 2  
Study 2 was a collaborative study, which presented the opportunity to investigate the 
effect of rosiglitazone on skeletal muscle of a diabetic rat model.  However the choice to 
use female experimental animals was decided by the collaborators and therefore 
presented the main limitation of study 2.  These older female Zucker rats could not be 
compared to the younger male rats from the previous study and hence an aging effect 
could not also be examined.   The mixed arterial venous blood collection was decided 
by the collaborators introducing another variation between study 1 and 2.  
 
3.6.3 Study 3  
In study 3, the high fat fed model was used to determine the effects of rosiglitazone at a 
more therapeutic dose and investigate the effects of exercise training on Na+K+-ATPase 
in insulin resistant skeletal muscle.  In view of the fact that the study using high fat fed 
Sprague Dawley rats was so large, labour was reduced by sharing rat training and 
laboratory work.  This it self became a limitation as the entire study was not under our 
constant supervision.  Any discrepancies were reported and therefore this limitation was 
minimised.  The second limitation of this study was that rats treated with rosiglitazone, 
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obtained the drug through their intake of food.  The food was weighed to monitor the 
ingested amount however four rats shared a cage and therefore, each rat’s intake of 
rosiglitazone was averaged and could not be strictly controlled.       
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C h a p t e r  4  
STUDY 1:   INSULIN RESISTANCE DEPRESSES NA+K+-ATPASE FUNCTION IN 
RAT SKELETAL MUSCLE 
4.1 Introduction 
 
Insulin resistance is clinically defined as the body’s relative inability to increase glucose 
uptake and utilisation by a known quantity of insulin that would otherwise occur in a 
normal individual (Lebovitz, 2001).  The body compensates for this deficiency by 
increasing insulin secretion from the pancreas.  However when the body fails to respond 
to the elevated insulin levels, high plasma glucose levels persist and type II diabetes 
prevails.  Type II diabetes is also associated with decreased exercise capacity and hence 
can predispose sufferers to early onset of fatigue (Schneider et al., 1984; Regensteiner et 
al., 1995; Baldi et al., 2003).  Muscle fatigue is a highly complex and multifactorial event, 
occurring via a variety of mechanisms at numerous sites within the cell (Fitts, 1994; 
Allman & Rice, 2002).  One mechanism contributing to fatigue during intense exercise 
is the impairment of sarcolemma excitability, induced by diminishing transmembrane 
Na+ and K+ gradients as a result of inadequate Na+K+-ATPase activity (Nielsen & 
Overgaard, 1996; Overgaard et al., 1997; Fraser et al., 2002).  
 
At rest, skeletal muscles use less than 10% of Na+K+-ATPase maximal activity to 
maintain ionic concentration gradients (James et al., 1999a).  During muscle contraction, 
the passing of an action potential causes Na+ and K+ leakage across the sarcolemma and 
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a pronounced decrease in transmembrane Na+ and K+ gradients.  Intense exercise can 
cause extracellular K+ concentrations to rise up to 10mmol/L (Vyskocil et al., 1983).   
 
If the ion gradients are not reinstated, there is loss of membrane excitability (Nielsen & 
Overgaard, 1996).  Insufficient Na+K+-ATPase activity has also been suggested to play a 
role in the development of diabetic complications such as neuropathy, nephropathy and 
retinopathy (Winegrad, 1987; Raccah et al., 1992).  In addition, there is also evidence to 
suggest altered Na+K+-ATPase function is also involved in the development of diabetic 
myopathy (Kjeldsen et al., 1987). 
 
Since insulin is a known activator of Na+K+-ATPase, it would be important to know the 
effects of insulin resistance and elevated levels of circulating insulin on Na+K+-ATPase 
function.  Previous studies have investigated the effects of type II diabetes on Na+K+-
ATPase, however disagreement exists with numerous studies showing conflicting or no 
change in various tissue types of both diabetic humans and rats (refer to Table 4.1).   
Compromised Na+K+-ATPase activity with type II diabetes has been reported in human 
erythrocytes (Baldini et al., 1989; Kiziltunc et al., 1997), platelets (Rabini et al., 1998) and 
nerve tissue (Scarpini et al., 1993; Sima et al., 2000), and also in rat nerve tissue (Wada et 
al., 1999; Kitahara et al., 2002) and retinal cells (Ottlecz et al., 1993).  However other 
studies have reported no change in rat (Levy et al., 1990; Zemel et al., 1990) or human 
erythrocytes (De La Tour et al., 1998; Jannot et al., 2002), and rat skeletal muscle 
(Banyasz & Kovacs, 1996; Ferrer-Martinez et al., 1996).  
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Table 4.1   Previous Na
+
K
+
-ATPase studies with insulin resistance or diabetes. 
 
 
 
Tissue 
Na
+
K
+
-ATPase 
activity 
(change, % of 
control) 
Na
+
K
+
-ATPase 
content 
(change, % of 
control) 
 
Reference 
Skeletal Muscle 
Rat 
Rat 
Human 
 
0 
- 
- 
 
- 
0 
30% decrease 
 
Ferrer-Martinez et al., 1996 
Banyasz et al., 1996 
Djurhuus et al., 2001 
Platelets 
Human  
 
33% decrease 
 
- 
 
Rabini et al., 1998 
Retinal cells  
Rat  
 
14 % decreased 
 
- 
 
Ottlecz et al., 1993 
Erythrocytes 
Rat 
Rat 
Human 
Human 
Human 
Human  
 
0 
0 
15 % decrease  
62 % decrease 
0 
0 
 
- 
- 
- 
70 % decrease 
- 
- 
 
Zemel et al., 1990 
Levy et al., 1990 
Kiziltunc et al., 1997 
Baldini et al, 1989  
Jannot et al., 2002  
De La Tour et al., 1998  
Nerve tissue 
Rat  
Rat 
Human  
Human 
 
80 % decrease 
20 % decrease 
35 % decrease 
59% decrease 
 
- 
- 
- 
- 
 
Kitahara et al., 2002 
Wada et al., 1999 
Sima et al., 2000  
Scarpini et al., 1993  
 
 
A study involving identical twins discordant for type II diabetes found the diabetic twin 
group demonstrated an approximate 20% reduction in muscle [3H]-ouabain binding 
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capacity compared to the healthy twin group (Djurhuus et al., 2001).  An inverse 
correlation was found between the differences in [3H]-ouabain binding capacity between 
the twin pairs and corresponding differences in waist/hip ratio.  This indicated that 
reduced muscle Na+K+-ATPase concentration was associated with the development of 
abdominal fat in type II diabetics.   
 
This chapter investigated Na+K+-ATPase function in skeletal muscle of 15 week old 
lean and obese Zucker rats, and in basal and insulin stimulated skeletal muscle of high-
fat fed and chow fed Sprague Dawley rats aged 14 weeks.  The hypotheses tested were 
(1) Insulin resistant skeletal muscle from obese Zucker rats will have depressed Na+K+-
ATPase function and (2) Insulin resistant skeletal muscle from high fat fed Sprague 
Dawley rats will have depressed Na+K+-ATPase function and not respond to insulin 
stimulation. 
 
4.2 Methods 
 
Two different animal models of insulin resistance were used in this study, genetically 
predisposed obese Zucker (OZ) rats with their age matched lean Zucker (LZ) controls 
and high fat fed Sprague Dawley rats with their standard chow fed controls.  All animal 
handling and experimental procedures for muscle extraction and blood sampling and 
analysis have been fully described earlier (Chapter 3).   
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4.2.1 Obese Zucker Rats   
Red oxidative gastrocnemius muscle was analysed for 3-O-MFPase activity and [3H]-
ouabain binding site content.  Blood samples were analysed for glucose, lipids and ions.  
The availability of obese Zucker rats became critically low in the early stages the final 
research study and proposed a severe delay in the completion of this research.  This 
problem offered the opportunity to investigate Na+K+-ATPase function in another 
insulin resistant or diabetic animal model.  This time round, a high-fat fed rodent model 
was chosen.  Given that dietary factors are important in the etiology of both insulin 
resistance and obesity in humans and high-fat feeding in rats displays skeletal muscle 
defects in insulin signalling and disregulated metabolism that are seen in insulin resistant 
humans (Kraegen et al., 1991), a high-fat fed rat model was considered an appropriate 
substitute.  
 
4.2.2 High Fat Fed Sprague Dawley Rats  
At California State University of Northridge (CSUN), United States, 80 male Sprague 
Dawley rats were ordered at 4 weeks of age, 32 of which will be discussed in this 
chapter, the remaining 48 will be discussed in Chapter 6.  The 32 rats were acclimatised 
for 2 weeks, allowed ad libitum access to water and standard rat chow (73% 
carbohydrate, 11% fat, 16% protein, D12328; Research Diets Inc., New Brunswick, NJ)   
before being randomly assigned to either a very high fat diet containing hydrogenated 
coconut oil (58% of calories as fat and 26% as carbohydrate, D12330N; Research Diets) 
or normal chow for an 8 week period.  The caloric density of the chow diet was 4.1 
kcal/g and that of the high fat was 5.6 kcal/g.  This resulted in lower daily food 
consumption in grams for the rats fed the high fat diet however there was no difference 
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in caloric intake (244.3 ± 4.4 versus 261.0 ± 9.2 kcal/kg of body mass per day) between 
chow and high fat diet fed rats.  At the end of their respective diets, animals were fasted 
for 8-12 h prior to undergoing hind limb perfusion for the measurement of insulin-
stimulated 3-O-methylglucose transport, whereby 8 rats received perfusate without 
insulin and 8 rats received perfusate containing insulin.   
 
4.2.2.1 Hind limb Perfusion preparation 
Rats were anaesthetised with pentobarbital (6.5 mg/100g body wt) and body weight 
recorded.  All rat surgery for hindlimb perfusion was performed by Dr Ben Yaspelkis.  
Left and right epididymal fat pad were quickly dissected out before preparing rats for 
single hind limb perfusion as previously described (Herr et al., 2005).  Briefly, cannulas 
were inserted into the abdominal aorta and vena cava, blood was collected and the 
animals were killed via an intracardiac injection of pentobarbital as the hind limbs were 
washed out with 30 mL of Krebs-Henseleit buffer (KHB, pH 7.55). The basic perfusate 
medium contained 30% washed time-expired human erythrocytes (Ogden Medical 
Center, Ogden, UT, USA) and was continuously gassed with a mixture of 95% O2- 5% 
CO2 and warmed to 37
oC.  Perfusate flow rate was set at 7.5 mL/min during the 
stabilisation period and subsequent perfusion, during which rates of glucose transport 
uptake were determined.  
  
4.2.2.2 Insulin stimulated 3-O-methylglucose transport 
The cannulas were placed in line with a non-recirculating perfusion system and the hind 
limbs were allowed to stabilise during a 5 min washout period.  After the washout 
period, 8 minutes of hind limb perfusion was performed with a perfusate containing 8 
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mM of the non-metabolised glucose analogue 3-O-methylglucose (3-MG; 32 µCi 3-[3H-
O-MG/mM, PerkinElmer Life Sciences, Boston, MA, USA) and 2 mM mannitol (60 
µCi-[1-14C] mannitol/ mM, PerkinElmer Life Sciences) as an intracellular space marker.    
 
Immediately following the glucose transport perfusion, portions of the red oxidative 
gastrocnemius were excised from both hind limbs, blotted on gauze dampened with 
cold KHB, freeze clamped in liquid N2 and stored at -80
oC for later transport to RMIT 
for further analysis.  Rates of insulin stimulated skeletal muscle 3-MG transport were 
calculated as previously described (Yaspelkis et al., 2004).      
 
RG extracted from 8 chow fed, (normal control NC) and 8 high fat fed (HF) were 
classed as basal tissue.  Insulin stimulated RG was extracted from another 8 chow fed 
(NCIns) and 8 high fat fed (HFIns) rats following hindlimb perfusion with the same 
perfusate but containing a physiological concentration of insulin at 500 µU/ml.  Basal 
and insulin stimulated muscle were  analysed for 3-O-MFPase activity and [3H]-ouabain 
binding site content of Na+K+-ATPase.  Blood samples were immediately centrifuged 
and serum analysed for insulin, glucose and FFA.  
 
4.3 Results – Lean v’s Obese Zucker Rats 
 
Despite not all rats having their weights measured and recorded due to methological 
issues, at aged 15 weeks, the male OZ were 34% heavier (P < 0.001) than LZ (OZ 415 
± 7 grams, n=6; LZ 309 ± 9 grams, n=5).   
 
 77
4.3.1 Blood Analysis 
Data from the blood analysis is shown in Table 4.2.  Blood could not be collected from 
1 OZ and 1 LZ, hence reducing n to 7.  OZ were hyperglycaemic, displaying elevated 
glucose levels (OZ 19.9 ± 3.1 mmol/L, P < 0.01 compared with LZ).  OZ also suffered 
hyperlipidemia with their total cholesterol and triglycerides significantly higher than LZ 
(P < 0.001).  The HDL:LDL ratio was significantly lower in the OZ compared with the 
LZ.  Electrolytes were in the normal ranges for both groups with no differences 
between groups. 
 
Table 4.2    Blood analysis in lean and obese Zucker rats. 
 
 
 LZ OZ 
Glucose (mM) 6.9 ± 0.9 19.9 ± 3.1
#
 
Total cholesterol (mM) 1.29 ± 0.04 3.57 ± 0.19
†
 
Triglycerides (mM) 0.46 ± 0.06 3.74 ± 0.23
†
 
HDL:LDL ratio 3.96 ± 0.49 1.69 ± 0.22
†
 
Serum Potassium (mM) 5.8 ± 0.7 5.6 ± 0.6 
Serum Sodium (mM) 140 ± 1 141 ± 1 
Urea (mM) 7.8 ± 0.5 8.6 ± 0.3 
Creatinine (mM) 0.034 ± 0.003 0.039 ± 0.004 
 
 
Values are means ± SE; n=7; Significance for LZ v’s OZ is # at p<0.001 and † at 
p<0.001. 
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4.3.2 3-O-MFPase activity  
To determine the effects of insulin sensitivity on Na+K+-ATPase activity in skeletal 
muscle, we measured maximal 3-O-MFPase activity in red oxidative gastrocnemius.   
There appeared to be a decrease in 3-O-MFPase activity in OZ compared to LZ in RG.  
This difference became significant (29%) when activity was expressed relative to muscle 
protein content (LZ 7212 ± 497, OZ 5110 ± 404 pmol.min-1.mg-1 protein, P < 0.01). 
Results are shown in Figure 4.1.   
 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
RG
p
m
o
l.
m
in
-1
.m
g
-1
 p
ro
te
in
LZ
OZ
 
Figure 4.1    Na
+
K
+
-ATPase activity measured by 3-O-MFPase assay in RG from LZ and 
OZ rats. Data are means ± SE for 8 rats per group. # p<0.01. 
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4.3.3 Na+K+-ATPase content  
The content of Na+K+-ATPase were determined using vanadate facilitated [3H]-ouabain 
binding method on whole muscle samples.  In red gastrocnemius, there was a 22% (P < 
0.001) decrease in the number of Na+K+-ATPase in OZ when compared with LZ rats.  
Results are displayed in Figure 4.2. 
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Figure 4.2    Na
+
K
+
-ATPase content measured by Vanadate facilitated [
3
H]-ouabain 
binding assay in RG of LZ and OZ rats. Data are means ± SE for 8 rats per 
group. † Significance for OZ<LZ at p<0.001. 
 
 
4.3.4 Relationships between Na+K+-ATPase content and activity  
It was anticipated that Na+K+-ATPase content in OZ and LZ would be related to  
maximal Na+K+-ATPase activity.  A significant correlation was found however it held a 
moderate correlation value (r=0.5, P <0.05). 
 
 
 
 † 
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Figure 4.3    The relationship between Na
+
K
+
-ATPase content and maximal activity in 
RG. n =16 
 
 
 
 
 
4.3.5 Relationships between Na+K+-ATPase content and serum diabetic markers  
To determine whether Na+K+-ATPase content in rat skeletal muscle was influenced by 
diabetic status, the relationship between ouabain binding sites and diabetic markers, 
serum glucose, triglycerides, total cholesterol and HDL:LDL ratio was examined.  
Na+K+-ATPase content was found to be negatively correlated with serum glucose levels 
(Figure 4.4a, P < 0.01), triglycerides (Figure 4.4b, P < 0.01) and total cholesterol (Figure 
4.4c, P < 0.01), while positively correlated with HDL:LDL ratio (Figure 4.4d, P < 0.01). 
 
 81
 
y = -6.3236x + 516.99
r = -0.75, P<0.001
300
350
400
450
500
550
600
0 10 20 30
Glucose (mM)
[3
H
]-
o
u
a
b
a
in
 c
o
n
te
n
t
(p
m
o
l/
g
 w
e
t 
w
t)
A
 
y = -34.453x + 504.6
r = -0.8, P<0.001
300
350
400
450
500
550
600
0.0 1.0 2.0 3.0 4.0 5.0
Triglyceride (mM)
[3
H
]-
o
u
a
b
a
in
 c
o
n
te
n
t
(p
m
o
l/
g
 w
e
t 
w
t)
B
 
 
 
 
y = -51.999x + 558.54
r = -0.9, P<0.001
300
350
400
450
500
550
600
0.0 1.0 2.0 3.0 4.0 5.0
Total Cholesterol (mM)
[3
H
]-
o
u
a
b
a
in
 c
o
n
te
n
t
(p
m
o
l/
g
 w
e
t 
w
t)
C
  
y = 34.705x + 334.23
r = 0.7, P<0.001
300
350
400
450
500
550
600
0.0 1.0 2.0 3.0 4.0 5.0
HDL:LDL ratio
[3
H
]-
o
u
a
b
a
in
 c
o
n
te
n
t
(p
m
o
l/
g
 w
e
t 
w
t)
D
 
 
 
Figure 4.4    Rat Na
+
K
+
-ATPase content in RG as a function of serum glucose (A), 
triglycerides (B), total cholesterol (C) and HDL:LDL ratio (D). n =14 (NB 
not all bloods were obtained) 
 
4.3.6 Rat Na+K+-ATPase activity and content as a function of body weight  
To determine whether the reduction in Na+K+-ATPase activity and content in OZ may 
be related to characteristic features of insulin resistance, we investigated the association 
 82
between 3-O-MFPase activity or [3H]-ouabain binding content with body weight.  There 
was a significant inverse relationship between the activity and content of Na+K+-
ATPase in skeletal muscle and rat body weight (Figure 4.5a and 4.5b, P < 0.01).   
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Figure 4.5    The relationship between Na
+
K
+
-ATPase content (a) and activity (b) in RG 
and rat body weight. n =11 (NB not all rat body weights were obtained) 
 
4.4 Results – Chow Fed v’s High Fat Fed Sprague Dawley Rats 
 
4.4.1 General and metabolic characteristics  
Clinical and metabolic characteristics for the two groups are shown in Table 4.3. At 14 
weeks, the male HF rats did not appear to gain appreciable amounts of weight, however 
they were 7% heavier than NC (HF 460 ± 10, n=16; NC 430 ± 6 grams, n=15, P < 
0.05).  Epididymal fat pad weight increased by 1.9 fold in HF rats (HF 10.6 ± 0.8, NC 
5.7 ± 0.2 grams, n=16 P < 0.001).  The epididymal fat pads were used as an indicator of 
body fat percentage as epididymal fat pad weight correlate well with total body fat in 
rodents (Eisen & Leatherwood, 1981; Levy et al., 2000). 
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Blood could not be collected from 1 HF rat, hence reducing n to 7.  Serum glucose 
concentrations were elevated due to haemolysis and along with insulin and FFA were 
not different between rat groups.  
 
Table 4.3   General and metabolic characteristics in chow fed controls and high fat fed 
Sprague Dawley rats.   
 
 NC HF 
Body Mass (g) 430 ± 6 460 ± 10
*
 
Epididymal Fat Pad mass (g) 5.7 ± 0.2 10.6 ± 0.8
†
 
Blood Glucose (mM) 17.5 ± 1.5 16.4 ± 1.0 
Plasma Insulin (ng/ml) 1.23 ± 0.25 1.21 ± 0.24 
Free Fatty Acids (mM) 0.89 ± 0.16 0.60 ± 0.10 
 
Values are means ± SE; Significance for NC v’s HF is at *p<0.05, † p<0.001. 
 
4.4.2 Glucose Uptake  
Glucose uptake was measured using [14C]-glucose and calculated from the arteriovenous 
difference, the perfusate flow rate and the weight of the muscle perfused.  As expected, 
glucose uptake was significantly different between NC and NCIns (NC 2.34 ± 0.54, 
NCIns 6.17 ± 0.44 µmol.g-1.hr-1, P = 0.001).  No difference was found between HF and 
HFIns (HF 2.32 ± 0.85, HFIns 4.11 ± 0.56 µmol.g-1.hr-1), indicating insulin resistance. 
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4.4.3 3-O-MFPase activity  
Maximal 3-O-MFPase activity in basal RG appeared to be reduced in the HF compared 
to NC and these results became significantly different when activity was expressed 
relative to muscle protein content (NC 6392 ± 397, HF 4041 ± 254 pmol.min-1.mg-1 
protein, P = 0.001).  Results are shown in Figure 4.6.  The submaximal concentration of 
insulin stimulation did not have an effect on 3-O-MFPase activity in the NCIns group 
(5800 ± 422 pmol.min-1.mg-1 protein), however caused an elevation in maximal activity 
of the HFIns (HF 4041 ± 254, HFIns 5581 ± 420 pmol.min-1.mg-1 protein, P < 0.05).   
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Figure 4.6    Na
+
K
+
-ATPase activity measured by 3-O-MFPase assay in basal and insulin 
stimulated RG from NC and HF rats. Data are means ± SE for 8 rats per 
group. Significance for NC > HF † P =0.001, HFIns > HF at * P <0.05,  
 
 
4.4.4 Na+K+-ATPase content  
Na+K+-ATPase content was 23% lower in red gastrocnemius of basal HF when 
compared to NC rats (HF 307 ± 18, NC 395 ± 18 pmol.g-1.wet wt P < 0.01, figure 4.7).  
Insulin stimulation with submaximal insulin concentrations had no effect on Na+K+-
ATPase content in either HF or NC. 
 † 
 * 
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Figure 4.7    Na
+
K
+
-ATPase concentration measured by Vanadate facilitated [
3
H]-
ouabain binding assay in RG of LZ and OZ rats. Data are means ± SE for 8 
rats per group. # Significance for NC v’s HF at p<0.01. 
                 
4.5 Discussion 
 
The underlying objective of this study was to analyse the effect of insulin resistance or 
type II diabetes on Na+K+-ATPase function in skeletal muscle.  The findings of this 
study supported the two hypotheses that Na+K+-ATPase activity and concentration, 
respectively would be depressed with insulin resistance or type II diabetes in rat skeletal 
muscle. 
 
4.5.1 Effect of Insulin Resistance on Na+K+-ATPase Function  
One of the two most important findings from this study was that Na+K+-ATPase 
activity was depressed with insulin resistance and type II diabetes in rats when expressed 
relative to muscle protein content.  This effect was evident in both the diabetic obese 
 # 
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Zucker rats and insulin resistant high fat fed Sprague Dawley rats.  The other significant 
finding was the similar decrease in Na+K+-ATPase content in skeletal muscle of both 
animal models.  These findings support the study involving identical twins discordant 
for type II diabetes (Djurhuus et al., 2001) but oppose other previous findings in the 
literature for rat skeletal muscle (Banyasz & Kovacs, 1996; Ferrer-Martinez et al., 1996).  
 
4.5.1.1 Obese Zucker Rat 
In the present study, obese Zucker rats displayed typical characteristics of obesity 
related type II diabetes, suffering from severe weight gain, hyperglycemia and 
dyslipidemia with elevated cholesterol, triglycerides and decreased HDL:LDL ratio.  
Obese Zucker rats also displayed a 29% drop in maximal 3-O-MFPase activity in 
skeletal muscle indicating depressed Na+K+-ATPase activity.  In addition to this 
significant result, the content of functional Na+K+-ATPase measured in the sarcolemma 
was also decreased by 22% in obese Zucker rats.  The reduced content offers an 
obvious explanation for the reduced Na+K+-ATPase activity found.  Together, these 
findings suggest that Na+K+-ATPase function in skeletal muscle was compromised with 
type II diabetes.  This opposes the “no change” result found in obese Zucker rats in a 
study conducted by Ferrer-Martinez and colleagues, however their study did show a 
non-significant decrease in Na+K+-ATPase activity using a small sample size (n=5) 
(Ferrer-Martinez et al., 1996).   
 
Structural alterations in the kinetics of the enzyme and/or the membrane lipids in which 
the protein is embedded may have contributed to the reduced activity but the decreased 
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Na+K+-ATPase content implies the membrane protein would have been compromised 
at either an earlier stage such as at gene transcription or translation, translocation to 
and/or insertion into the membrane or later on with a higher rate of enzyme 
degradation.   
 
Decreased Na+K+-ATPase content with insulin resistance may be the result of 
prolonged elevated levels of circulating insulin and consequently insulin resistant 
diabetes itself.  Therefore, it seemed reasonable to determine whether any association 
exists between muscle [3H]-ouabain binding content and characteristic serum markers of 
type II diabetes.  After plotting the [3H]-ouabain binding content as a function of the 
serum markers, Na+K+-ATPase content was negatively correlated with glucose, 
triglycerides and total cholesterol, but positively correlated with the HDL:LDL ratio.  
These relationships suggest that the reduction in Na+K+-ATPase content could be 
associated with the development of insulin resistance and type II diabetes.  Therefore, 
since Na+K+-ATPase is important for cell function in diverse tissues, this supports the 
literature implicating the Na+K+-ATPase in the development of diabetic complications 
such as neuropathy, nephropathy, retinopathy and myopathy.  In addition, 
compromised Na+K+-ATPase function in skeletal muscle may offer a partial explanation 
for reduced exercise capacity and increased muscle fatigue associated with type II 
diabetes (Schneider et al., 1984; Regensteiner et al., 1995; Baldi et al., 2003).  
 
The fundamental cause for the alterations could not be narrowed down to the lack of 
insulin action as insulin stimulated muscle was not investigated in the obese Zucker 
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model.  In addition, obese Zucker rats also display markedly elevated circulating leptin 
levels (Hardie et al., 1996; Wang et al., 1999) and decreased T3 serum levels (Katzeff & 
Selgrad, 1993).  These may offer other possible explanation for the decreased pump 
activity observed in these rats as leptin has been negatively associated with Na+K+-
ATPase function in a variety of tissues (Cha & Jones, 1998; Sweeney & Klip, 2001; 
Beltowski et al., 2004)  and T3 is known to be a chronic pump regulator and decreased 
levels are associated with decreased Na+K+-ATPase concentrations (Kjeldsen et al., 
1984c).   
 
Compromised Na+K+-ATPase function in obesity related type II diabetes might lower 
cellular energy consumption, since Na+K+-ATPase is one of the biggest consumers of 
cellular ATP.  It has been estimated that in resting humans, Na+K+-ATPase hydrolyses 
23% of all cytoplasmic ATP (Lingrel & Kuntzweiler, 1994).  Increased usage of ATP by 
the Na+K+-ATPase would influence resting metabolic rate which is a key factor in body 
weight maintenance.  Therefore compromised Na+K+-ATPase function may lower 
metabolic rate thus increasing the likelihood of body fat accumulation.  For that reason, 
we chose to examine any association that existed between rat muscle [3H]-ouabain 
binding content and/or 3-O-MFPase activity and body weight, as an indicator of fat 
accumulation.  Both Na+K+-ATPase activity and content were inversely correlated with 
body weight, indicating that Na+K+-ATPase function has a possible association with the 
development of obesity.  On the other it may be that the obesity is causing reduced 
physical activity which may in turn be down regulating the Na+K+-ATPase function.  It 
has been previously shown that reduced physical activity and muscle disuse will decrease 
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enzyme content (Kjeldsen et al., 1986; Leivseth & Reikeras, 1994).  Unfortunately the 
movement/physical activity of the rats was not measured and therefore the role of 
physical activity induced changes in pump function cannot be ruled out.  Future studies 
might consider assessing the level of physical activity through the use of accelerometry 
or video movement analysis techniques.  
 
4.5.1.2 High Fat Fed Rat 
Insulin resistance was induced in Sprague Dawley rats with a high fat diet containing 
saturated fats.  HF rats did not gain considerable weight but were still heavier than the 
lean chow fed controls.  Epididymal fat pads were notably larger in HF rats indicating a 
substantial increase in body fat.  HF rats did not have elevated serum insulin, glucose or 
FFA levels but were confirmed as insulin resistant, pre-diabetic phenotype, as insulin 
administration in HFIns rats did not significantly increase glucose uptake.  Glucose 
uptake appeared to increase in the HFIns rats but not significantly.  There was no 
difference in glucose uptake between diet groups in the basal states.   
 
In agreement with the Zucker data, similar results were found with Na+K+-ATPase 
function in skeletal muscle from insulin resistant HF rats.  HF rats had a 37% decrease 
in Na+K+-ATPase activity in basal skeletal muscle and a 23% reduction in Na+K+-
ATPase content.  Again, physical activity was not measured and therefore could not be 
ruled out as the cause of reduced Na+K+-ATPase function in the HF skeletal muscle.  
These results will be further discussed in Chapter 6.  
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4.5.2 Effect of Insulin Stimulation on Na+K+-ATPase in Insulin resistant skeletal muscle  
Up regulation of Na+K+-ATPase activity upon insulin stimulation with large insulin 
concentrations (80-100 mM) is well known and documented (Weil et al., 1991; Sampson 
et al., 1994).  However, no study has investigated the effect of insulin on Na+K+-ATPase 
function at a physiological concentration (500 µU/ml).  Submaximal concentrations of 
insulin had no effect on Na+K+-ATPase activity in skeletal muscle of the NC rats.  This 
result was not expected as insulin is a known acute activator of the pump.  The in vitro 
assay appears to be sensitive to insulin stimulation as the HF rats showed a 38% 
increase in 3-O-MFPase activity.  Logically one would expect to see the opposite result.  
The discrepancy between the two groups in Na+K+-ATPase response to insulin 
stimulation is confounding and potentially warrants further investigation.  Future studies 
investigating the role of insulin stimulation of the pump need to consider the effect of 
insulin on phosphorylation status and Na+K +-ATPase enzyme kinetics. 
 
The detrimental effect on Na+K+-ATPase activity seen with the HF rats could not be 
the result of deficient insulin action as seen with glucose uptake, and would appear to 
involve a different mechanism of inhibition.  Na+K+-ATPase content was unaltered 
with insulin stimulation in both NC and HF rats, so the effect of insulin on maximal 
activity in HF group could not be due to an increase in enzyme translocation of to the 
sarcolemma.  Instead, insulin’s effect would be more of a direct alteration on the 
structure of the enzyme, such as phosphorylation of the ∝-subunit (Al-Khalili et al., 
2004) or enzyme kinetics by alleviating a potential inhibitor of the Na+K+-ATPase 
(McGill & Guidotti, 1991).  
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4.5.3 Conclusion  
In summary, the results of this study demonstrate depression in maximal in vitro Na+K+-
ATPase activity and content with insulin resistance in rat skeletal muscle.  This was 
shown in both, the genetically predisposed and high fat diet induced animal models.  
The findings indicate compromised Na+K+-ATPase function causing a reduced reserve 
for Na+K+-ATPase activation in insulin resistant skeletal muscle.  This may predispose 
diabetics to early muscle fatigue with associated impaired exercise tolerance.  Whether 
the altered pump function is due to insulin resistance itself or due to obesity/reduced 
physical activity, the reduced exercise tolerance may further progress the development 
of type II diabetes and its associated complications as exercise is a well known 
antidiabetic treatment.  The findings of the current study might also suggest that the 
altered Na+K+-ATPase function contributes to the development of obesity related 
insulin resistance and type II diabetes as the Na+K+-ATPase is one of the biggest ATP 
consumers in the body and reduced ATP consumption may increase fat accumulation.  
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 C h a p t e r  5  
 
STUDY 2:   ROSIGLITAZONE COMPROMISES NA+K+-ATPASE FUNCTION IN 
SKELETAL MUSCLE OF LEAN ZUCKER RATS. 
5.1 Introduction 
 
The treatment of obesity related insulin resistance involves a combination of diet, 
exercise and pharmacologic approaches. Thiazolidinediones (TZDs) are a group of oral 
antidiabetic compounds that function as insulin sensitisers (Saltiel & Olefsky, 1996).  
TZDs are agonists for peroxisome proliferator-activated receptor-γ, a nuclear hormone 
receptor, which when activated by natural ligands, fatty acids and their derivatives, 
regulates the transcription of genes involved in lipid and carbohydrate metabolism 
(Ricote et al., 1998; Spiegelman, 1998; Wahli, 2002).  TZD receptors are expressed in 
insulin target tissues; adipose tissue, liver and at low levels in skeletal muscle.  Many 
studies have shown administration of TZDs improves hyperglycaemia and 
hyperinsulinemia in insulin resistant rodent models and Type II diabetic patients (Saltiel 
& Olefsky, 1996; Olefsky, 2000).  Sensitised skeletal muscle might increase insulin-
induced Na+-K+-ATPase function (Al-Khalili et al., 2003), however, TZDs have also 
been shown to alter membrane phospholipids and fluidity (Kurebayashi et al., 1997; 
Clore et al., 2000; Wahl et al., 2002).  Since the Na+K+-ATPase is a membrane-embedded 
protein, the surrounding membrane phospholipids are important for the intrinsic 
function of the enzyme (Komers & Vrana, 1998).  
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Rosiglitazone, a TZD derivative, has been shown to restore insulin’s ability to suppress 
hepatic gluconeogenesis and improve peripheral glucose uptake, without stimulating 
insulin production (Miyazaki et al., 2001; Wagstaff & Goa, 2002).  In addition, 
rosiglitazone has been shown to reduce circulating free fatty acids by promoting their 
uptake and storage in adipocytes (Mayerson et al., 2002).  However other TZDs, such as 
troglitazone and pioglitazone have been shown to repress the gene expression of 
stearoyl-CoA desaturase 1, a key enzyme involved in the biosynthesis of 
monounsaturated fatty acids, components of membrane phospholipids and maintenance 
of the fluidity of biological membranes (Kurebayashi et al., 1997).  Alterations in 
membrane fatty acyl chains and phospholipid compositions have been shown to 
influence membrane permeability, ion channels and transport, and cause changes in 
membrane-bound enzyme activities (Spector & Yorek, 1985). 
 
Past experiments have demonstrated that the function and intrinsic activity of the 
membrane ion transporter, Na+-K+-ATPase is influenced by the lipid milieu in which it 
exists (Storch & Schachter, 1984; Else & Wu, 1999).  However it is unclear whether the 
lipid-protein interactions are effective via direct contact and binding or indirectly by 
means of order and fluidity.  Modifications that can affect protein function are alteration 
of the phospholipid head group, acyl chain length and unsaturation, and insertion of 
cholesterol (Cantor, 1999).  The degree of unsaturation and length of acyl chains in 
adjacent phospholipids affects lateral movement and conformational change of an 
integral protein (Wu et al., 2001).  While the length of acyl chains simply increases bilayer 
thickness, the double bonds in unsaturated acyl chains inhibit freedom of rotation about 
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the bond and prevent phospholipids from compacting themselves, improving efficiency 
of ligand binding and activity of membrane-bound enzymes (Hollan, 1996).  A study 
using hepatocyte membranes reported an increase in lipid fluidity which was 
accompanied by an increase in Na+K+-ATPase specific activity (Storch & Schachter, 
1984).  In a species membrane cross-over experiment, toad Na+K+-ATPase which was 
reconstituted in more unsaturated rat membrane showed a 30-40% increase in activity 
while rat Na+K+-ATPase positioned in toad membrane significantly decreased (~40%) 
enzyme activity in both kidney and brain (Else & Wu, 1999).  Another double crossover 
study by Wu and colleagues used the same technique to show that membrane 
phospholipids play a significant role in determining the molecular activity of the Na+K+-
ATPase (Wu et al., 2004). 
 
Membrane fluidity is increased by phospholipids composed of polyunsaturated fatty 
acids (PUFAs), in particular omega-3 PUFAs.  Specifically, docosahexaenoic acid 
(DHA) contains 22 carbons and 6 double bonds and is the longest and most 
unsaturated fatty acid commonly present in biological membranes. DHA plays an 
important structural role in the cytoplasmic membrane of cells and has been shown to 
increase the unsaturation index, disordering and fluidity (Hashimoto et al., 1999; 
Petrache et al., 2001).  Omega-6 PUFAs have been associated with inhibiting the 
absorbance of omega-3 PUFAs, in a competitive nature (Iritani & Fujikawa, 1982).  The 
net result is an increase in omega-6/omega-3 ratio, which is associated with reduced 
membrane fluidity (Farkas et al., 2002).   
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There is also evidence to suggest a high omega-6/omega-3 ratio is deleterious on insulin 
action in skeletal muscle (Storlien et al., 1996).  Dietary omega-3 and PUFAs have been 
shown to increase insulin binding to sarcolemma (Liu et al., 1994), suggesting that 
changes in fatty acyl composition of phospholipids neighbouring the insulin receptor 
might be responsible for altered insulin sensitivity.  The effect of membrane lipid 
composition on Na+K+-ATPase function may also explain irregular Na+ ion transport 
observed in disease states with abnormal lipid metabolism such as hypertension, obesity 
and diabetes (Mazzanti et al., 1990; Modan & Halkin, 1991; Zicha et al., 1997). 
 
Obesity-related insulin resistance and Type II diabetes are characterised by elevated 
plasma insulin and glucose levels (Goldstein, 2003), and frequently accompanied by 
altered regulation of the Na+-K+-ATPase enzyme (Jannot et al., 2002).  Individuals 
suffering obesity related insulin resistance or diabetes have compromised exercise 
capacity which could be partly due to inadequate Na+K+-ATPase function.  Reduced 
Na+K+-ATPase function can cause hyperkalemia and contribute to early onset of 
fatigue, limiting the ability of these individuals to exercise as part of their treatment 
strategy. 
 
In the previous study (Chapter 4), we showed a down regulation in Na+-K+-ATPase 
activity and concentration in skeletal muscle of two different rodent animal models of 
insulin resistance.  The present study investigated Na+-K+-ATPase function and 
membrane phospholipids in skeletal muscle of more mature Zucker rats, aged 25 weeks.  
The effect of rosiglitazone on Na+-K+-ATPase function in skeletal muscle has not been 
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addressed, therefore the other purpose of the present study was to evaluate the effects 
of rosiglitazone on Na+-K+-ATPase function and membrane phospholipids in skeletal 
muscle of obese Zucker rats.   
 
5.2 Methods 
 
5.2.1 Animals and Drug treatment  
This study used 25 week-old female obese Zucker rats and age-matched female lean 
Zucker rats.  At 19 weeks of age, 7 obese Zucker rats (OZR) and 7 lean, littermates 
(LZR) received, via oral gavage, rosiglitazone (3 mg/kg/day suspended in 1% 
carboxymethylcellulose, CMC) for 6 weeks.  This dose was chosen as it has previously 
been shown to protect against myocardial infarction in normal rats (Yue Tl et al., 2001), 
is the threshold dose for lowering plasma triglycerides in dietary obese rats (Pickavance 
et al., 1999) and improves insulin sensitivity without ill effects in obese Zucker rats 
(Sidell et al., 2002).  Another 7 obese Zucker (OZ) and 7 lean, littermate controls (LZ) 
received only vehicle (1% CMC) for 6 weeks.   All animal handling procedures have 
been fully described earlier (Chapter 3).   
 
5.2.2 Physiological & Biochemical Parameters  
At the end of the 6-week treatment, body weight and blood pressure (tail-cuff 
plethysmography measured in conscious rats using Harvard rat tail blood pressure 
apparatus, Hadland Phototonics Pty Ltd, Australia) were recorded.  An oral glucose 
tolerance test (OGTT) was performed where glucose 70% weight/volume was 
administered by oral gavage, 2.5 g/kg body weight.  Non-fasting blood was drawn from 
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a cut at the tip of the tail at 0 and 10, 15, 30, 60, and 90 minutes after the glucose feed 
for blood glucose determinations (MediSense® glucometer with Precision Plus© blood 
glucose electrodes; MediSense Australia).  24 hours post last dose, rats were sacrificed 
by asphyxiation with CO2 inhalation followed by decapitation. Mixed arteriovenous 
blood was collected in heparinised tubes for analysis of risk factors associated with 
diabetes, plasma insulin and lipids, and blood glucose.   
 
5.2.3 Muscle analysis  
All experimental procedures for muscle extraction and analysis have been fully 
described earlier (Chapter 3).  Briefly, red gastrocnemius (RG) was extracted from the 
rat hind limb and analysed for 3-O-MFPase activity and [3H]-ouabain binding site 
content.  RG was further analysed for determination of the phospholipid fatty acid (FA) 
profile via gas chromatography. 
 
5.2.4 Data Analysis  
Descriptive statistics included means and standard error (SE).  One-way analysis of 
variance (ANOVA) was used to determine significance between groups.  Significance 
was accepted at p<0.05. 
5.3 Results 
5.3.1 General Characteristics  
Clinical and metabolic characteristics for the four groups are shown in table 5.1.  OZ 
were 77% heavier (P < 0.001) than LZ which was 17% (P < 0.01) further exacerbated 
with rosiglitazone treatment (OZR).  Systolic blood pressure was significantly (P < 0.01) 
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higher in OZ compared with LZ, rosiglitazone caused a noticeable drop in systolic 
blood pressure in OZR, though this was not statistically significant.  Despite the 
untreated OZ having normal glucose levels, they were considerably hyperinsulinemic 
(946 ± 292µM), consistent with an insulin resistant, pre-diabetic state.  Rosiglitazone 
reduced plasma insulin by 88% (P < 0.001) in OZR.  Total cholesterol (P < 0.05) and 
triglycerides (P < 0.001) were significantly higher in OZ compared to LZ.  Rosiglitazone 
treatment had no effect on cholesterol levels but significantly (P < 0.05) improved 
triglyceride concentrations in OZR (see table 5.1).  OZ displayed considerable glucose 
intolerance with a greater than 2 fold increase in the area under the curve (AUC) when 
compared to LZ (P < 0.001), while rosiglitazone completely restored normal glucose 
tolerance in OZR (P < 0.001).   
 
Table 5.1  General and metabolic characteristics in lean and obese Zucker control and 
rosiglitazone treated rats. 
 LZ OZ LZR OZR 
Body Mass (g) 212 ± 7 376 ± 7
†
 221 ± 5 440 ± 19
#
 
Mean Arterial Blood 
Pressure (mmHg)
 
134 ± 5 174 ± 8
#
 141± 6 152 ± 8 
Blood Glucose (mM) 6.7 ± 0.4 6.6 ± 0.4 6.0 ± 0.3 6.5 ± 0.2 
Plasma Insulin (µM) 62 ± 18 946 ± 292
†
 45 ± 12 113 ± 30
†
 
Total cholesterol (mM) 1.13 ± 0.06 1.58 ± 0.06* 1.46 ± 0.17 1.84 ± 0.11 
Triglycerides (mM) 0.42 ± 0.07 2.52 ± 0.56
†
 0.48 ± 0.08 1.15 ± 0.19* 
OGTT AUC (mM*min) 248 ± 22 529 ± 72
†
 225 ± 28 251 ± 29
†
 
 
Values are means ± SE; n=7 with the exception of Blood pressure, n=5; Significance 
for LZ v’s OZ; LZ v’s LZR and OZ v’s OZR at *p<0.05, # p<0.01, † p<0.001. 
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5.3.2 Na+K+-ATPase activity  
To determine the effects of obesity-related insulin resistance and rosiglitazone on 
Na+K+-ATPase activity in skeletal muscle, maximal 3-O-MFPase activity in red 
gastrocnemius was measured.   There was no difference between genotypes when 3-O-
MFPase activity was expressed per gram of wet weight.  However, after measuring 
protein levels in RG and expressing the results per mg of muscle protein, a significant 
35% decrease was found with OZ (LZ 6814 ± 690, OZ 4428 ± 359 pmol.min-1.g-1 
protein, P < 0.01) (Figure 5.1).   When calculating the activity of an enzyme, the amount 
of muscle protein in the sample needs to be taken into account as added weight due to 
fluid or connective tissue, which does not contain Na+K+-ATPase, will underestimate 
the enzyme’s activity level.  Rosiglitazone treatment induced, again, a significant 35% 
decrease in 3-O-MFPase activity (LZ 6814 ± 690, LZR 4416 ± 404 pmol.min-1.g-1 
protein, P < 0.01) (Figure 5.1).  There was no change in OZR with treatment.  
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Figure 5.1    Na
+
K
+
-ATPase activity measured by 3-O-MFPase assays in RG.  Data are 
means ± SE for 7 rats per group. Significance for LZ v’s OZ and LZ v’s 
LZR # p<0.01.   
  #                  #  
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5.3.3 Na+K+-ATPase content  
The concentration of Na+K+-ATPase was determined using the Vanadate facilitated 
[3H]-ouabain binding method on whole muscle samples.  Results are displayed in Figure 
5.2.  There was no detectable change in Na+K+-ATPase content between OZ and LZ 
rats, nor did rosiglitazone treatment have any affect on content.   
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Figure 5.2    Na
+
K
+
-ATPase concentration measured by Vanadate facilitated [
3
H]-
ouabain binding assay in RG of control LZ and OZ rats and rosiglitazone 
treated LZR and OZR. Data are means ± SE for 7 rats per group.   
 
5.3.4 Membrane Phospholipid analysis  
The phospholipid fatty acid (FA) composition in RG membranes was determined by 
measuring the content of individual FA types and representing them as a percentage of 
the total FA content.  Results are shown in Table 5.3.  Saturated fatty acids, palmitic 
acid [16:0] and stearic acid [18:0] contents were not different across all groups.  The 
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monounsaturated omega-9, oleic acid [18:1(n-9], was also unchanged.  As a result, there 
were no differences found in percentage of saturated and mono-unsaturated FA (see 
Table 5.3). In contrast, variations were identified with different PUFA species, 
specifically between omega types.  Of the omega-6 PUFAs, only linoleic acid [18:2(n-6)] 
was not significantly changed between animal groups, however there was a significant 
increase in the levels of dihomo-gamma-linolenic acid [20:3(n-6)] (P < 0.001) and 
arachidonic acid [20:4(n-6)] (P < 0.01) in OZ compared to LZ.  Eicosapentaenoic acid 
(EPA) [20:5(n-3)], docosapentaenoic acid (DPA) [22:5 (n-3)] and docosahexaenoic acid 
(DHA) [22:6(n-3)] are long chained omega-3 PUFA.  There was a significant (P < 0.001) 
decrease in DHA in the OZ compared to LZ, but only an indicated decrease in the 
content of EPA (non significant), while DPA was increased (P < 0.01).  Together, the 
findings led to an increase in % omega-6 (n-6) and a decrease in % omega-3 (n-3), and 
therefore an overall 45% increase in the n-6/n-3 ratio (P < 0.001) in OZ compared with 
LZ.     
 
Rosiglitazone only had a significant effect on membrane phospholipids in OZR, 
displaying lower arachidonic acid (P < 0.001) but elevated EPA (P < 0.001) (see Table 
5.2).  The OZR also had decreased % PUFA and % omega-6, resulting in a significant 
decrease in the unsaturation index (P < 0.05) compared to OZ.   
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Table 5.2    Phospholipid fatty acid composition of RG.   
Fatty acid LZ OZ LZR OZR 
16:0 Palmitic 13.2 ± 0.8 13.4 ± 0.8 14.9 ± 1.4 16.7 ± 1.3 
18:0 Stearic 10.8 ± 0.5 10.9 ± 0.2 10.8 ± 0.3 11.1 ± 0.3 
18:1(n-9)  Oleic 6.1 ± 0.3 6.7 ± 0.3 6.3 ± 0.1 7.3 ± 0.3 
18:2(n-6) Linoleic 22.3 ± 0.4 23.5 ± 0.5 21.7 ± 0.8 24.8 ± 1.2 
20:3(n-6) DHLA 0.70 ± 0.07 1.20 ± 0.04
†
 0.82 ± 0.04 1.20 ± 0.08 
20:4(n-6) Arachidonic 14.3 ± 0.2 17.7 ± 0.7
#
 14.7 ± 0.5 12.7 ± 0.9
†
 
20:5(n-3) EPA 0.78 ± 0.07 0.53 ± 0.03 1.00 ± 0.05 1.07 ± 0.14
†
 
22:5(n-3) DPA 1.53 ± 0.07 2.04 ± 0.13 
#
 1.43 ± 0.06 1.89 ± 0.11 
22:6(n-3)  DHA 27.7 ± 0.7 20.8 ± 0.8
†
 25.1 ± 0.6 19.8 ± 1.1 
% Saturated FA 23.9 ± 0.9 24.3 ± 0.9 25.7 ± 1.4 27.8 ± 1.4 
% MUFA 8.3 ± 0.3 9.4 ± 0.4 9.0 ± 0.2 10.3 ± 0.4 
% PUFA 67.7 ± 1.0 66.3 ± 1.0 65.3 ± 1.2 61.9 ± 1.2
* 
% n-6 37.8 ± 0.5 42.9 ± 0.9
†
 37.8 ± 0.8 39.2 ± 1.1
*
 
% n-3 30.0 ± 0.7 23.4 ± 0.8
†
 27.5 ± 0.6 22.7 ± 1.0 
% Unsaturated FA  76.1 ± 0.9 75.7 ± 0.9 74.3 ± 1.4 72.2 ± 1.4 
Unsaturation index 292 ± 5 271 ± 5* 279 ± 6 251 ± 6
*
 
n-6/n-3 1.26 ± 0.03 1.85 ± 0.08
†
 1.38 ± 0.03 1.75 ± 0.10 
 
Values are means ± SE; n=7; Fatty acid composition is expressed as mole percentage of 
total fatty acids; DHLA, Dihomo gamma-linolenic acid; EPA, Eicosapentaenoic acid; 
DPA, Docosapentaenoic acid; DHA, Docosahexaenoic acid; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids; Unsaturation index is the number of 
double bonds per 100 fatty acid chains; Significance for LZ v’s OZ; LZ v’s LZR and OZ 
v’s OZR at *p<0.05, # p<0.01, † p<0.001. 
 103 
The ratios of 20:4 to 20:3, 20:3 to 18:2, 18:1 to 18:0 and 18:0 to 16:0 are product-
precursor ratios for the reactions catalysed by delta(sup 5)-desaturase (∆5desaturase), 
delta(sup 6)-desaturase (∆6desaturase), delta(sup 9)-desaturase (∆9desaturase) and 
elongase respectively.  The estimated activity of ∆5desaturase was significantly (P < 0.01) 
decreased in OZ compare to LZ, while ∆6desaturase activity was significantly (P < 0.01) 
increased.  Refer to Table 5.3. 
 
Table 5.3    Estimated activity of desaturase and elongase enzymes in RG.   
 
Enzyme LZ OZ LZR OZR 
20:4/20:3 ∆
5
desaturase 21.26 ± 1.49 14.75 ± 0.51
#
 21.26 ± 1.49 21.26 ± 1.49 
20:3/18:2 ∆
6
desaturase 0.032 ± 0.003 0.051 ± 0.002
†
 0.038 ± 0.003 0.049 ± 0.003 
18:1/18:0  ∆
9
desaturase 0.57 ± 0.02 0.61 ± 0.02 0.58 ± 0.02 0.66 ± 0.03 
18:0/16:0 Elongase 0.84 ± 0.07 0.83 ± 0.05 0.77 ± 0.08 0.69 ± 0.06 
 
Values are means ± SE; n=7; Significance for LZ v’s OZ; at # p<0.01, † p<0.001. 
 
5.4 Discussion 
 
Obesity-related insulin resistance is a characteristic feature of type II diabetes and often 
the persistence of obesity interferes with conventional therapy.  In these cases, a 
pharmacological approach is commonly used to reinstate normoglycemia.  In this study, 
rosiglitazone substantially improved peripheral insulin sensitivity by decreasing insulin 
levels and improving glucose tolerance.  However, as expected, rosiglitazone treatment 
also promoted weight gain and increased fat deposition.  Na+K+-ATPase function was 
 104 
found to be depressed with insulin resistance in the mature obese Zucker rats.  
Rosiglitazone’s action on Na+K+-ATPase function in skeletal muscle of the lean Zucker 
rat was detrimental however in the obese Zucker rat, no drug effect was seen.  
 
5.4.1 Effect of Insulin Resistance 
In the present study, Na+K+-ATPase activity was, again, found to be depressed with 
insulin resistance in skeletal muscle of obese Zucker rats.  However, in contrast to the 
previous study, Na+K+-ATPase content was found to be unaltered between the 25 week 
old lean and obese rat groups used for this study.  This could possibly be explained by 
the use of much older rats as study 1 involved 15 week old rats.  It may be that skeletal 
muscle attempts to rectify the Na+K+-ATPase disregulation seen in younger rats by 
upregulating the number of pumps in the membrane, just as excess insulin is produced 
when insulin resistance occurs.  In addition, female obese Zucker rats are also known to 
be less susceptible to insulin resistant changes than their male equivalent and could also 
offer an explanation for this discrepancy.  Finally it is also possible that the known age 
lowering effect on Na+K+-ATPase could mask any content differences between the 
groups (Kjeldsen et al., 1984a). Nevertheless, these results indicate that the membrane 
protein is not compromised at a gene or protein level but at a functional level.  On the 
other hand, many studies have shown different ∝-isoforms of the Na+K+-ATPase can 
display varying turnover rates in a variety of different tissues (Maixent & Berrebi-
Bertrand, 1993; Segall et al., 2001).  Therefore, reduced Na+K+-ATPase activity without 
a change in content may be representing a change in Na+K+-ATPase isoenzymes,  
whereby the α1 isoenzymes may have been reduced but not detected by the content 
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assay as this α isoform is ouabain resistant (Kjeldsen et al., 1986).  However, as reduced 
Na+K+-ATPase function can cause hyperkalemia and contribute to early onset of 
fatigue, the reduced exercise capacity seen with insulin resistant or diabetic patients may 
be, in part, explained by the compromised Na+K+-ATPase function as seen in obese 
Zucker rats.   
 
The function of membrane enzymes, such as Na+K+-ATPase, is known to depend on 
membrane fluidity and lipidic components (Storch & Schachter, 1984).  Specifically, 
DHA plays an important structural role in the plasma membrane and has been shown to 
increase fluidity (Hashimoto et al., 1999; Petrache et al., 2001).  OZ had a reduced 
percentage of omega-3 PUFA, principally from decreased DHA content.  In addition 
the percentage of omega-6 PUFAs was elevated.  Omega-6 PUFA have been associated 
with inhibiting the absorbance of omega-3 PUFA, in a competitive nature (Iritani & 
Fujikawa, 1982).  The net result was an increase in n-6/n-3 ratio, which is associated 
with reduced membrane fluidity (Farkas et al., 2002).   Na+K+-ATPase function in 
skeletal muscle from insulin resistant OZ rats may have been compromised due to the 
phospholipid profile, which indicated reduced fluidity in the plasma membrane.  This is 
in agreement with other researchers who have used obese animal models and have 
found similar results with the n-6/n-3 ratio and Na+K+-ATPase activity in other insulin 
sensitive tissues (Izpisua et al., 1989).  PUFAs also allow a higher incorporation of 
cholesterol (rigidness) in the membranes to balance their fluidity, which would 
contribute to lower blood cholesterol levels (Colin et al., 2003), which was found with 
the OZ compared with LZ.   
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In this study, the estimated activity determined for ∆5desaturase was also found to be 
significantly decreased in the OZ when compared to the LZ.  ∆5desaturase is 
responsible for catalysing the addition of a double bond into a FA, and it’s product-
precursor ratio has been previously correlated with insulin sensitivity (Borkman et al., 
1993).   Another enzyme responsible for inserting double bonds, ∆6desaturase also 
displayed reduced activity in the OZ skeletal muscle.  This is again in accordance with 
Borkman’s study which found ∆6desaturase to be negatively correlated with insulin 
sensitivity, although this was not statistically significant (Borkman et al., 1993).  Other 
studies of insulin deficiency have also shown that insulin has an effect on fatty-acid 
desaturase activity (Tilvis & Miettinen, 1985; el Boustani et al., 1989).  This could 
possibly suggest that reduced levels of unsaturated fatty acids in the membrane may be a 
result of reduced insulin action, caused by either insulin resistance or insulin deficiency. 
 
It is also known that several protein kinases affect the function of Na+K+-ATPase.  In 
particular, protein kinase C (PKC) has also been associated with the development of 
insulin resistance in skeletal muscle (Qu et al., 1999).  With insulin resistance, increased 
diacylglycerol-protein kinase C (DAG-PKC) signalling has been associated with reduced 
glucose transport and metabolism.  However, several DAG-PKC isoforms were 
measured in muscle from these animals in an associated study and were shown to be not 
elevated (Lessard et al., 2004). 
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5.4.2 Effect of Rosiglitazone  
Rosiglitazone had a detrimental effect on Na+K+-ATPase function in skeletal muscle of 
lean Zucker rats.  Na+K+-ATPase activity in LZR was reduced by the same degree that 
was seen with that of OZ.  Maximal activity of OZR did not further decrease with 
rosiglitazone but remained similar to that of OZ.  Rosiglitazone, therefore, had either no 
effect on Na+K+-ATPase in skeletal muscle of obese Zucker rats or, its effect was not 
seen because it was not additive to the decrease already observed with insulin resistance 
alone.    Na+K+-ATPase content was unaltered with rosiglitazone treatment so the drop 
in maximal activity could not be due to lack of enzyme concentration but as a result of 
activation or functional inhibition, or isoenzyme changes.   
 
Analysis of the phospholipids in LZR showed rosiglitazone had no significant effect.  
Rosiglitazone did significantly increase EPA content and percentage of omega-6 
PUFAs, and decrease Arachnidonic acid content, the percentage of PUFA and 
unsaturation index in OZR when compared to the OZ.  However, upon closer 
inspection of LZR lipid results, most of the FA’s and composite parameters do appear 
to change in the same direction as the OZ despite the lack of statistical significance, for 
example DHLA, Arachnidonic acid and DHA content, percentages of FA groups, the 
unsaturation index and n-6/n-3 ratio.  Nevertheless, we cannot conclude FA’s or the 
degree of saturation in the sarcolemma was responsible for rosiglitazone’s effect, and 
the inhibitory effect may involve a different mechanism to that of insulin resistance.   
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Rosiglitazone is thought to have its primary effects in adipose tissue and therefore any 
effect seen in muscle may be secondary.  Leptin, an adipose-derived hormone, 
stimulates thermogenesis by its direct effects on leptin receptors in skeletal muscle 
(Friedman & Halaas, 1998; Dulloo et al., 2002) and has been negatively correlated with 
Na+K+-ATPase function in kidney (Beltowski et al., 2002; Beltowski & Wojcicka, 2002; 
Beltowski et al., 2004), liver (Cha & Jones, 1998) and fibroblast cells (Sweeney & Klip, 
2001).  Obese Zucker rats display markedly elevated circulating leptin levels due to a 
mutation in the gene for the leptin receptor and the lack of auto-regulation (Hardie et al., 
1996; Wang et al., 1999) which may offer a possible explanation for the decreased pump 
activity observed in these rats.  Rosiglitazone has been shown to transcriptionally inhibit 
leptin expression in adipocytes (De Vos et al., 1996) and decrease serum leptin levels 
(Boden et al., 2003; Toruner et al., 2004), however, in obese or diabetic Zucker (fa/fa) 
rats, leptin levels remain unchanged (Wang et al., 1997; Cai et al., 2000).  This may 
explain why LZR responded to rosiglitazone and in OZR, where leptin signalling is 
dysfunctional, Na+K+-ATPase function remained unaffected. 
 
Another possible explanation involves AMP-activated protein kinase (AMPK), a 
regulatory protein that monitors energy consumption and down-regulates ATP-
consuming processes when activated, including enzyme activity.  AMPK has been 
shown to be activated by rosiglitazone in cultured skeletal muscle cells (Fryer et al., 2002) 
and by pioglitazone in rat liver and adipose tissue (Saha et al., 2004).  AMPK also has 
been shown to inhibit activity of a specific ATP-dependent Cl- channel which also 
requires ATP hydrolysis by Na+K+-ATPase for chloride secretion (Hardie et al., 2003).  
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Therefore, inhibition of Na+K+-ATPase by rosiglitazone may be secondary via AMPK 
activation.  The AMPK activity in skeletal muscle of obese Zucker rats was shown to be 
normalised with chronic rosiglitazone treatment (Lessard et al., 2006). 
 
5.4.3 Conclusion  
In conclusion, this study found Na+K+-ATPase activity, but not content, to be altered in 
insulin resistant obese Zucker rats and that this may be due to altered membrane 
phospholipid composition and desaturase activity as seen with this phenotype.  Other 
possible explanations could involve PKC signalling or leptin concentrations.  Despite 
insulin sensitivity increasing through rosiglitazone, Na+K+-ATPase activity was reduced 
only in the lean rats.  This was not found to be due to decreased enzyme content or 
alterations in membrane lipids but may possibly be due to elevated leptin levels or 
AMPK activation, leading to inhibition of the membrane bound Na+K+-ATPase.  
Therefore, the treatment of insulin resistance with rosiglitazone may increase insulin 
sensitivity but may also affect Na+K+-ATPase, which may limit skeletal muscle function. 
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C h a p t e r  6  
STUDY 3:   EFFECT OF ROSIGLITAZONE AND EXERCISE ON NA+K+-ATPASE 
FUNCTION IN INSULIN RESISTANT SKELETAL MUSCLE. 
6.1 Introduction 
 
Type II diabetics receive a range of treatment options to relieve the insulin resistance 
and or help reduce the associated risk factors for cardiovascular disease (Rennert & 
Charney, 2003).  The treatment options include diet and exercise before the option of 
medication such as insulin sensitisers, such as Rosiglitazone, are administered (Rennert 
& Charney, 2003).  The previous chapter showed that diabetic rats had lower Na+K+-
ATPase activity and that rosiglitazone lowered Na+K+-ATPase activity in lean controls.  
It is postulated that exercise training would increase Na+K+-ATPase content and activity 
in diabetic rats.  Further, exercise may counter any deleterious effects that rosiglitazone 
has on Na+K+-ATPase function.  Therefore the third study of this dissertation 
examined the individual effects of rosiglitazone and exercise and their combined effect 
on the Na+K+-ATPase function in skeletal muscle of high-fat fed rats.  
 
It has been well documented that regular exercise promotes physiological and health 
benefits (Karacabey, 2005).  Studies have shown exercise training improves insulin 
sensitivity and increases insulin-stimulated skeletal muscle glucose transport in insulin 
resistant animal models (Wallberg-Henriksson & Holloszy, 1984; Ivy et al., 1989; Cortez 
et al., 1991) and Type II diabetics (Ivy et al., 1989; Perseghin et al., 1996).  The increased 
insulin sensitivity with exercise training is mostly attributed to increased expression and 
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or activity of signalling proteins involved in the regulation of skeletal muscle glucose 
uptake (Zierath, 2002).  These proteins include Glut 4 (Henriksen, 2002; Holloszy, 
2005) and increased expression of PI-3 kinase activity (Houmard et al., 1999) or AMPK 
protein (Sriwijitkamol et al., 2006).   
 
Chronic exercise training increases skeletal muscle Na+K+-ATPase concentration in 
both lean animal models (Kjeldsen et al., 1986; Tsakiridis et al., 1996) as well as healthy 
individuals (Green et al., 1993; McKenna et al., 1993; Madsen et al., 1994; Fraser et al., 
2002).  However, no one has investigated the potential benefits of exercise training on 
Na+K+-ATPase function in skeletal muscle of insulin resistant animals or Type II 
diabetics.  These diabetic animals have impaired Na+K+-ATPase (see Chapter 4 and 5) 
so the beneficial effects of exercise training warrant investigation.  The potential benefit 
of exercise training might be countered by any deleterious effects that co administered 
medication might have.  Rosiglitazone increases insulin sensitivity and peripheral 
glucose uptake, without stimulating insulin production (Miyazaki et al., 2001; Wagstaff & 
Goa, 2002).  The intrinsic activity of the ion transporter, Na+-K+-ATPase is dependant 
upon the membrane lipid milieu.  These TZDs such as rosiglitazone may also affect 
membrane fluidity and the function of membrane transport proteins (Kurebayashi et al., 
1997).  This present study will investigate the effect of rosiglitazone and exercise on 
Na+-K+-ATPase function and membrane phospholipids in skeletal muscle of the high 
fat fed Sprague Dawley rat, an animal model of insulin resistance that develops type II 
diabetes.   
 
 112 
6.2 Methods 
 
6.2.1 Animals and Treatment groups  
This study involved the use of 80 Sprague Dawley rats ordered at 4 weeks of age, 32 of 
which have already been described in Chapter 4.  Of those the high fat (HF) group will 
represent the control group for the remaining 48 rats.  48 male rats were acclimatised 
for 2 weeks and allowed ad libitum access to water and standard rat chow (73% 
carbohydrate, 11% fat, 16% protein, D12328; Research Diets Inc., New Brunswick, NJ) 
before commencing a high fat diet containing hydrogenated coconut oil (58% of 
calories as fat and 26% as carbohydrate, D12330N; Research Diets).  4 weeks into the 
diet, 16 rats were randomly assigned to a rosiglitazone treatment group (HFR), an 
exercise treatment group (HFX) or a rosiglitazone plus exercise group (HFRX).  At the 
end of their respective treatments, each group of 16 rats were divided into 2, one group 
receiving basal perfusate and the other group, insulin perfusate (500 µU/ml insulin 
concentration) for hind limb perfusion to measure insulin stimulated glucose uptake as 
previously described (Herr et al., 2005).    
 
Rats assigned to the rosiglitazone treatment groups had their high fat (D12330) diet 
replaced with high fat mixed with rosiglitazone maleate (SmithKline Beecham, Harlow, 
UK) diet (D04110901).  The mixture was made into coloured pellets and dried by the 
manufacturer (Research Diets, Inc., New Jersey, US).  The concentration of 
rosiglitazone in the food was 50 ppm. Drug-treated rats ingested an average daily dose 
of 2.08 ± 0.06 mg/kg body mass of rosiglitazone, a more therapeutic dose than the one 
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used in the previous study however the dose is still considered high when compared to 
doses used in humans.  
 
Animals appointed to the exercise training groups underwent an endurance exercise 
training regime, carried out on a rodent treadmill.  Rats were run 5 days per week for a 
period of 4 weeks.  The work rates were gradually increased in the first week of training 
until the rats could run for a total time of 60 min at speed of 32 m/min on a 15% 
incline. 
 
6.2.2 Physiological & Biochemical Parameters  
All animal handling procedures have been fully described earlier (Chapter 3).  At the end 
of their respective diets, animals were fasted for 8-12 h and exercised animals undertook 
their last acute training bout 36-48 h prior to undergoing hind limb perfusion.  Rats 
were anaesthetised with pentobarbital (6.5 mg/100g body wt) and body weight was 
recorded.  Left and right epididymal fat pad were quickly dissected out before preparing 
rats for hind limb perfusion, as previously described (Chapter 4).  Blood was collected 
via cardiac puncture and rats were sacrificed via intracardiac injection of pentobarbital.  
After a stabilising washout period, 8 minutes of hind limb perfusion with a perfusate 
containing 8 mM of the non-metabolised glucose analogue 3-O-methylglucose (3-MG; 
32 µCi 3-[3H-O-MG/mM, PerkinElmer Life Sciences, Boston, MA, USA) and 2 mM 
mannitol (60 µCi-[1-14C] mannitol/ mM, PerkinElmer Life Sciences) as an intracellular 
space marker, to measure glucose uptake.  Red oxidative gastrocnemius was extracted 
from the perfused hind limb and classed as basal (HF, HFR, HFX or HFRX) or insulin 
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stimulated (HFIns, HFRIns, HFXIns or HFRXIns) tissue if perfusate contained 
500µU/ml of insulin.  Blood samples were immediately centrifuged and serum collected 
and frozen at -80ºC for later analysis of insulin, glucose and FFA concentrations. 
 
6.2.3 Muscle analysis  
All experimental procedures for muscle extraction and analysis have been fully 
described (Chapter 3).  Briefly, basal and insulin stimulated RG was analysed for 3-O-
MFPase activity and [3H]-ouabain binding site content.  Basal RG of all groups including 
the normal chow fed (NC, previously discussed in Chapter 4) group was further 
analysed for determination of the phospholipid fatty acid (FA) profile via gas 
chromatography. 
 
6.3 Results 
 
6.3.1 General Characteristics  
Clinical and metabolic characteristics for the four high fat groups are shown in table 6.1.  
Rosiglitazone treatment did not have the expected detrimental effect on body or 
epididymal fat pad weight with no significant difference found after treatment.  
However exercise training caused a significant decrease in both body mass and 
epididymal fat pad weight.  Body mass was reduced by 10% (P < 0.01) and 12% (P < 
0.001) in the HFX and HFRX group respectively compared to the control HF group 
(HF 460 ± 10, HFX 413 ± 7 grams, HFRX 403 ± 8 grams, n=16) while epididymal fat 
pad weight were decreased by approximately 36% in HFX and HFRX (HF 10.6 ± 0.8, 
HFX 6.9 ± 0.6 grams, HFRX 6.7 ± 0.3 grams, n=16 P < 0.001).  There was no 
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significant difference between HFX and HFRX but a significant decrease between HFR 
and HFRX in body mass and epididymal fat pad weights, indicating the reducing effect 
in the HFRX group was due to the exercise training and not rosiglitazone treatment.   
 
There was no difference between glucose and insulin levels between groups.  Glucose 
concentrations were elevated due to haemolysis (Kilpatrick et al., 1995), caused when 
samples were collected via intracardiac puncture.  Free fatty acids were significantly (P < 
0.05) decreased in both exercised groups compared to the untreated HF group (HF 0.60 
± 0.10, HFX 0.33 ± 0.05 and HFRX 0.29 ± 0.4 mmol/L).  
 
Table 6.1   General and metabolic characteristics in lean and obese Zucker control and 
rosiglitazone treated rats. 
 
 HF HFR HFX HFRX 
Body Mass (g) 460 ± 10 458 ± 9
§
 413 ± 7
#
 403 ± 8
†  
Epidydimal Fat Pads 10.6 ± 0.8 9.7 ± 0.5
¶
 6.9 ± 0.6
†
 6.7 ± 0.3
† 
 
Blood Glucose (mM) 16.4 ± 1.0 15.7 ± 1.3 16.2 ± 1.0 11.8 ± 1.3 
Plasma Insulin (ng/ml) 1.21 ± 0.24 1.25 ± 0.21 0.84 ± 0.16 0.88 ± 0.20 
Free Fatty Acids (mM) 0.60 ± 0.10 0.50 ± 0.05 0.33 ± 0.05* 0.29 ± 0.4* 
 
Values are means ± SE; n=16 with the exception of blood parameters, n=7-8; 
Significance for HF v’s HFX and HFRX is at * p<0.05, # p<0.01, † p<0.001 and for 
HFRX v’s HFX and HFR is at, ¶ p<0.01, § p<0.001. 
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6.3.2 Glucose Uptake  
Glucose uptake was measured using 3-O-methylglucose and calculated from the 
arteriovenous difference, the perfusate flow rate and the weight of the muscle perfused.  
As expected, glucose uptake in basal muscle did not differ between treatment groups.  
As previously stated in Chapter 4, insulin stimulation did not cause a significant increase 
in glucose uptake in RG in the high-fat fed control group (HF 2.32 ± 0.85 and HFIns 
4.11 ± 0.56 µmol.g-1.hr-1), confirming established insulin resistance.  However, all 
treatment groups showed significant increases in glucose uptake upon insulin 
stimulation.  Rosiglitazone treatment caused a 3.6 fold increase (HFR 1.39 ± 0.31, 
HFRIns 5.05 ± 0.63 µmol.g-1.hr-1, P < 0.01), chronic exercise caused a 3.8 fold increase 
(HFX 2.11 ± 0.56, HFXIns 8.09 ± 1.22 µmol.g-1.hr-1, P < 0.01) and both treatments 
caused a 2.0 fold increase (HFRX 2.92 ± 0.65, HFRXIns 6.02 ± 0.77 µmol.g-1.hr-1, P < 
0.01). 
 
Table 6.2 3-O-methylglucose uptake in RG. 
 
 Glucose Uptake (µmol.g-1.hr-1) 
HF HFR HFX HFRX Basal 
2.32 ± 0.85 1.39 ± 0.31 2.11 ± 0.56 2.97 ± 0.65 
HFIns HFRIns HFXIns HFRXIns 500 µU/ml 
Insulin  4.11 ± 0.56 5.05 ± 0.63
#
 8.09 ± 1.22
#
 6.02 ± 0.77
# 
 
Values are means ± SE; n=8; Significance for HFR v’s HFRIns; HFX v’s 
HFXIns; and HFRX v’s HFRXIns is at # P <0.01. 
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6.3.3 Na+K+-ATPase activity  
To determine the effects of rosiglitazone or exercise and their combined effect on 
Na+K+-ATPase activity in skeletal muscle, maximal 3-O-MFPase activity was measured 
in red gastrocnemius collected from treatment groups.   There was a significant increase 
in 3-O-MFPase activity when insulin resistant rats were endurance exercise trained.  
Compared to the HF control group, exercise training caused a significant 58% (P < 
0.001) and 46% (P < 0.01)  rise in maximal 3-O-MFPase activity in HFX and HFRX 
groups respectively (HF 412 ± 27, HFX 652 ± 38 and HFRX  600 ± 24 nmol.min-1.g-1 
wet wt,  refer to Figure 6.1).   The difference between groups was also seen when 
activity was made relative to muscle protein.  Maximal 3-O-MFPase activity was 
significant 83% (P < 0.01) and 62% (P < 0.05) higher in HFX and HFRX groups 
respectively compared to HF controls (HF 4041 ± 254, HFX 7389 ± 687 and HFRX 
6553 ± 558 pmol.min-1.mg-1 protein).  Treating rats with rosiglitazone did not cause any 
significant change in 3-O-MFPase activity (HF 4041 ± 254 and HFR 5168 ± 785 
pmol.min-1.g-1 protein).  Insulin stimulation did not have the anticipated effect on 
Na+K+-ATPase with no significant difference in maximal activity compared to basal 
tissue. 
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Figure 6.1    Na
+
K
+
-ATPase activity measured by 3-O-MFPase assays in basal RG.  
Data are means ± SE for 8 rats per group. Significance for HF v’s HFX 
and HF v’s HFRX at * p< 0.05 and # p<0.01. 
 
6.3.4 Na+K+-ATPase content  
The concentration of Na+K+-ATPase was determined using the Vanadate facilitated 
[3H]-ouabain binding method on whole muscle samples.  Exercise training had a 
significant effect on rats with HFX and HFRX having 53% (P < 0.001)  and 79% (P < 
0.001)  respective increases in Na+K+-ATPase content when compared to HF control 
(HF 307 ± 18, HFX 471 ± 28 and HFRX 549 ± 23 pmol.g-1 wet wt).  Rosiglitazone 
treatment did not seem to have an effect on content as there was no significant 
difference between HF and HFR but a significant difference between HFR and HFRX 
(HFR 328 ± 17 and HFRX 549 ± 23 pmol. g-1 wet wt, P<0.01). Results are displayed in 
Figure 6.2.  There was no difference between basal and insulin stimulated muscle, 
indicating the insulin concentration used did not have the expected effect.   
 
  #                 
                      * 
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Figure 6.2.    Na
+
K
+
-ATPase concentration measured by Vanadate facilitated [
3
H]-
ouabain binding assay in RG. Data are means ± SE for 8 rats per group.  
Significance for HF v’s HFX and HF v’s HFRX at † p< 0.001 and HFR 
v’s HFRX is at § p<0.01 
 
6.3.5  Membrane Phospholipid analysis 
 
6.3.5.1 Effect of High-Fat Diet 
The effect of the high-fat diet was investigated by comparing NC and HF groups.  The 
content of saturated fatty acid palmitic acid [16:0] was significantly decreased (P < 0.05) 
while stearic acid [18:0] (P < 0.001) was increased in the HF group.  All 
monounsaturated FA’s were significantly decreased; palmitoleic [16:1(n-7)], vaccenic 
[18:1(n-7)] and oleic [18:1(n-9] acid, and of the omega 6 PUFAs, only dihomo-gamma-
linolenic acid [20:3(n-6)] was significantly increased (P < 0.001) in HF compared to NC.  
No differences were found in the long chained omega 3 PUFA.   
 
   § 
                     † 
   † 
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As a result, there were significant differences found in the percentages of saturated, 
mono-unsaturated, polyunsaturated and unsaturated FA but overall unsaturation index 
remained unchanged (refer to Table 6.3).  No significant differences were found 
between omega groups. 
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Table 6.3    Phospholipid fatty acid composition of RG in NC and HF rats. 
Fatty acid NC HF 
16:0 Palmitic 19.4 ± 0.6 16.9 ± 1.0* 
18:0 Stearic 17.2 ± 0.7 22.4 ± 0.7
† 
16:1(n-7) Palmitoleic 1.22 ± 0.13 0.34 ± 0.04
†
 
18:1(n-7) Vaccenic 4.51 ± 0.33 1.93 ± 0.08
† 
18:1(n-9)  Oleic 5.1 ± 0.2 3.8 ± 0.1
†
 
18:2(n-6) Linoleic 24.0 ± 0.7 25.1 ± 0.5 
20:3(n-6) DGLA 0.61 ± 0.01 0.82 ± 0.04
†
 
20:4(n-6) Arachidonic 12.8 ± 0.3 13.3 ± 0.4 
22:5(n-3) DPA 2.53 ± 0.09 2.51 ± 0.07 
22:6(n-3)  DHA 11.7 ± 0.5 12.0 ± 0.5 
% Saturated FA 36.6 ± 0.3 39.3 ± 0.4
†
 
% MUFA 10.8 ± 0.6 6.1 ± 0.2
†
 
% PUFA 52.6 ± 0.5 54.6 ± 0.5
#
 
% n-6 38.4 ± 0.5 40.1 ± 0.7 
% n-3 14.2 ± 0.5 14.5 ± 0.5 
% Unsaturated FA  63.4 ± 0.3 60.7 ± 0.4
†
 
Unsaturation index 199 ± 2 201 ± 2 
n-6/n-3 2.73 ± 0.12 2.80 ± 0.12 
 
Values are means ± SE; n=8; Fatty acid composition is expressed as mole percentage 
of total fatty acids; DGLA, Dihomo gamma-linolenic acid; DPA, Docosapentaenoic 
acid; DHA, Docosahexaenoic acid; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; Unsaturation index is the number of double bonds per 
100 fatty acid chains; Significance for NC v’s HF at *p<0.05, # p<0.01, † p<0.001. 
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The ratios of 20:4 to 20:3, 20:3 to 18:2, 18:1 to 18:0 and 18:0 to 16:0 are product-
precursor ratios for the reactions catalysed by delta(sup 5)-desaturase (∆5desaturase), 
delta(sup 6)-desaturase (∆6desaturase), delta(sup 9)-desaturase (∆9desaturase) and 
elongase respectively.  The estimated activities of ∆5desaturase and ∆9desaturase were 
significantly (P < 0.001) decreased, while activities of ∆6desaturase and elongase were 
significantly (P < 0.01) increased in HF compared to NC group.  Refer to Table 6.4. 
 
Table 6.4        Estimated activity of desaturase and elongase enzymes in RG.   
 
Enzyme NC HF 
20:4/20:3 ∆
5
desaturase 21.00 ± 0.62 16.37 ± 0.54
†
 
20:3/18:2 ∆
6
desaturase 0.026 ± 0.002 0.033 ± 0.002
#
 
18:1/18:0  ∆
9
desaturase 0.30 ± 0.02 0.17 ± 0.01
†
 
18:0/16:0 Elongase 0.90 ± 0.07 1.38 ± 0.14
#
 
 
Values are means ± SE; n=8. Significance for NC v’s HF at # p<0.01 and † p<0.001. 
  
 
6.3.5.2 Effect of Exercise 
Chronic exercise training had a mixed effect on the membrane phospholipid profile, 
results are shown in Table 6.5.  No change was seen in saturated and monounsaturated 
fatty acids.  Of the omega 6 PUFAs, the essential linoleic acid [18:2(n-6)] was 
significantly (P < 0.001) increased while arachidonic acid [20:4(n-6)] was significantly (P 
< 0.001) decreased in HFX compared to HF.  Overall there was a significant (P < 0.05) 
decrease and (P < 0.05) increase in the % of saturated and unsaturated fatty acids 
respectively.  However, when unsaturation was expressed as the number of double 
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bonds per 100 fatty acid chains, unsaturation index was significantly (P < 0.05) 
decreased.  Together, the findings led to an increase in % omega-6 (n-6) and a decrease 
in % omega-3 (n-3), and therefore an overall 19% increase in the n-6/n-3 ratio (P < 
0.05) in HFX compared with HF.   
 
6.3.5.3 Effect of Rosiglitazone 
Rosiglitazone treatment significantly (P<0.01) increased the monounsaturated omega 9, 
oleic acid [18:1(n-9] leading to a significant (P<0.05) increase in the % of 
monounsaturated fats (see Table 6.5). The % of omega 3 fatty acids was significantly 
(P<0.05) decreased however the n-6/n-3 ratio was unchanged. 
 
6.3.5.4 Effect of Combined treatments 
In the HFRX group, treatments had an added effect on the phospholipid composition 
with changes displayed by the HFR and HFX groups repeated in the HFRX group 
when compared to HFC (refer to Table 6.5).  Oleic and linoleic acid were significantly 
(P<0.01) increased and arachidonic acid was significantly (P < 0.001) decreased.  A 
significant (P<0.001) decrease in docosapentaenoic acid (DPA) was also seen.  Overall, 
there was a significant (P < 0.05) decrease in % of saturated FAs and significant (P < 
0.001) increase in % of monounsaturated FAs.  Like the HFX group, the % of 
unsaturated FA was significantly (P < 0.05) increased but then significantly (P < 0.05) 
decreased when expressed as the unsaturation index.  In addition, the % of omega 3 
fatty acids was significantly (P<0.05) decreased and an overall 19% increase in the n-
6/n-3 ratio (P < 0.05) was seen in HFRX compared with HF. 
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Table 6.5    Phospholipid fatty acid composition of RG.   
Fatty acid HF HFR HFX HFRX 
16:0 Palmitic 16.9 ± 1.0 16.5 ± 0.6 15.2 ± 0.5 15.4 ± 0.5 
18:0 Stearic 22.4 ± 0.7 22.2 ± 0.4 22.7 ± 0.4 22.6 ± 0.3 
16:1(n-7) Palmitoleic 0.34 ± 0.04 0.43 ± 0.06 0.34 ± 0.03 0.40 ± 0.03 
18:1(n-7) Vaccenic 1.93 ± 0.08 1.84 ± 0.03 1.91 ± 0.05 1.97 ± 0.07
 
18:1(n-9)  Oleic 3.8 ± 0.1 4.6 ± 0.2
#
 4.3 ± 0.1
‡
 4.9 ± 0.2
†
 
18:2(n-6) Linoleic 25.1 ± 0.5 27.2 ± 0.6 29.6 ± 0.6
†
 29.0 ± 0.7
†
 
20:3(n-6) DGLA 0.82 ± 0.04 0.94 ± 0.04 0.84 ± 0.03 0.86 ± 0.07 
20:4(n-6) Arachidonic 13.3 ± 0.4 12.6 ± 0.3
‡
 11.3 ± 0.2
†
 11.3 ± 0.3
†
 
22:5(n-3) DPA 2.51 ± 0.07 2.30 ± 0.08 2.28 ± 0.08 2.03 ± 0.08
†
 
22:6(n-3)  DHA 12.0 ± 0.5 10.6 ± 0.3 10.6 ± 0.3 10.7 ± 0.4 
% Saturation 39.3 ± 0.4 38.6 ± 0.3 37.9 ± 0.2* 37.9 ± 0.3* 
% MUFA 6.1 ± 0.2 6.9 ± 0.2* 6.5 ± 0.1
‡
  7.3 ± 0.2
†
 
% PUFA 54.6 ± 0.5 54.5 ± 0.4 55.5 ± 0.3 54.8 ± 0.3
 
% n-6 40.1 ± 0.7 41.7 ± 0.5 42.6 ± 0.5* 42.0 ± 0.5 
% n-3 14.5 ± 0.5 12.9 ± 0.2* 12.9 ± 0.3* 12.8 ± 0.4* 
% Unsaturation  60.7 ± 0.4 61.4 ± 0.3 62.1 ± 0.2* 62.1 ± 0.3* 
Unsaturation index 201 ± 2 193 ± 2 192 ± 2* 192 ± 2* 
n-6/n-3 2.80 ± 0.12 3.25 ± 0.09 3.33 ± 0.12* 3.33 ± 0.16* 
Values are means ± SE; n=8; Fatty acid composition is expressed as mole percentage 
of total fatty acids; DGLA, Dihomo gamma-linolenic acid; DPA, Docosapentaenoic 
acid; DHA, Docosahexaenoic acid; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids; Unsaturation index is the number of double bonds per 
100 fatty acid chains; Significance for HF v’s HFR; HFX and HFRX at *p<0.05, # 
p<0.01, † p<0.001 and HFRX v’s HFR and HFX is at ‡ p<0.05. 
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6.3.5.5 Estimated enzyme activities 
The estimated activity of ∆5desaturase was significantly (P < 0.05) decreased in all 
treatment groups compared to HF control group while ∆9desaturase activity was 
significantly (P < 0.01) increased in rosiglitazone treated groups.  ∆6desaturase and 
elongase activities were unchanged.  Refer to Table 5.3. 
 
Table 6.6    Estimated activity of desaturase and elongase enzymes in RG.   
 
Enzyme HF HFR HFX HFRX 
20:4/20:3 ∆
5
desaturase 16.37 ± 0.54 13.63 ± 0.59*  13.64 ± 0.43* 13.55 ± 0.84* 
20:3/18:2 ∆
6
desaturase 0.033 ± 0.002 0.035 ± 0.002 0.028 ± 0.001 0.030 ± 0.003 
18:1/18:0  ∆
9
desaturase 0.17 ± 0.01 0.21 ± 0.01
#
 0.19 ± 0.00 0.22 ± 0.01
#
 
18:0/16:0 Elongase 1.38 ± 0.14 1.36 ± 0.07 1.51 ± 0.07 1.48 ± 0.06 
 
Values are means ± SE; n=8; Significance for HF v’s HFR; HF v’s HFX and HF v’s 
HFRX at *p<0.05. 
 
6.4 Discussion 
 
The most important finding from this study was the positive effect exercise training had 
on the down regulation of Na+K+-ATPase found with insulin resistance.  However the 
antidiabetic drug, rosiglitazone did not have the same desired effect in this study.  
 
6.4.1 Effect of Exercise Training 
The benefits of exercise training to treat insulin resistance are well known (Ivy et al., 
1989; Perseghin et al., 1996).  As expected this study showed, exercise significantly 
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reduced body mass and epididymal fat pad weight, and increased insulin-stimulated 
skeletal muscle glucose uptake in the high fat fed animal model of insulin resistance.  
There was no effect on blood glucose and insulin concentrations as the HF rats were 
still in the early stages of developing insulin resistance and hence parameters were 
already normal.  Only FFA levels significantly improved with exercise.  However, the 
effect of exercise training on Na+K+-ATPase function in skeletal muscle has never been 
studied.  In Chapter 4 and 5, insulin resistance was repeatedly shown to down regulate 
Na+K+-ATPase activity.  Exercise training is known to increase Na+K+-ATPase content 
in healthy rats and humans (Kjeldsen et al., 1986; McKenna et al., 1993; Madsen et al., 
1994).  This study found moderate exercise training for a period of 4 weeks caused a 
significant increase in Na+K+-ATPase content in the sarcolemma, plus a corresponding 
significant increase in Na+K+-ATPase maximal activity.  It may be safe to assume the 
rise in content was ultimately the reason for an increase in maximal Na+K+-ATPase 
activity.   
 
Surprisingly, insulin stimulation of exercise trained muscle did not have the anticipated 
effect on Na+K+-ATPase activity or content.  This may have been a result of the 
submaximal insulin concentration used, as the muscle did show a significant increase in 
insulin stimulated glucose uptake into red gastrocnemius.  Further, the amount of insulin 
exposure (dose 500uU/ml and duration 8 min) may have been sufficient to stimulated 
glucose uptake but not affect Na+K+-ATPase function.   
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Chronic exercise training had a mixed effect on the membrane phospholipid profile.  No 
change was seen in saturated and monounsaturated fatty acids however with respect to 
the omega 6 PUFAs, only the content of linoleic acid was increased while arachidonic 
acid was decreased compared to the high fat diet group.  The overall effect resulted in a 
decrease in the percentage of saturated fatty acids and an increase in the percentage of 
unsaturated fatty acids.  These changes appear to be beneficial however, when 
unsaturation was expressed as the number of double bonds per 100 fatty acid chains, 
there was a decrease in the unsaturation index.  Exercise training, also, had the opposite 
effect on omega PUFA percentages than what was expected.  An increase in the 
percentage of omega-6 PUFA and a decrease in the percentage of omega-3 PUFA, 
leading to an overall increase in the n-6/n-3 ratio in HFX compared with HF.  This 
effect in the omega ratio is known to reflect reduced membrane fluidity (Farkas et al., 
2002).   
 
6.4.2 Effect of Rosiglitazone 
Rosiglitazone is currently used as an antidiabetic drug to treat hyperglycemia, 
hyperlipidemia without causing further secretion of insulin (Miyazaki et al., 2001; 
Wagstaff & Goa, 2002). This study showed rosiglitazone improved insulin stimulated 
glucose uptake in skeletal muscle of insulin resistant rats.  As reported in our previous 
study (Chapter 5), rosiglitazone did not significantly alter Na+K+-ATPase activity or 
content in insulin resistant muscle.  Na+K+-ATPase maximal activity did seem to display 
a trend to suggest increased activity.  The mean activity in skeletal muscle from 
rosiglitazone treated rats was 28% greater than the high fat fed control rats.  However, 
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this difference was not found to be statistically significant, probably due to the large 
variation within the treatment group.   
 
Similarly to the exercised muscle, insulin stimulation of rosiglitazone treated muscle did 
not have any effect on Na+K+-ATPase activity or content. 
 
Rosiglitazone treatment had little effect on membrane phospholipid composition of the 
HF rats which was consistent with those found with the obese Zuckers in study 2 
(Chapter 5).  The content of only one fatty acid, oleic acid was altered when 
rosiglitazone treatment was taken at this dosage.  This fatty acid was most likely 
responsible for the increase in the percentage of monounsaturated fatty acids.  The 
overall percentage of omega 3 PUFA was significantly decreased but this was not 
reflected in the n-6/n-3 ratio.   
 
6.4.3 Combined effect of Rosiglitazone & Exercise Training 
Since the effect of rosiglitazone treatment alone was found to be non-significant but 
exercise training alone caused significant improvements in Na+K+-ATPase activity and 
content, the effect seen in the group of rats receiving both treatments was most likely 
due to the exercise training.  In some instances, the combined treatment group was 
found to be significantly different from the rosiglitazone treated group, confirming the 
effect to be as a result of the exercise training regime.  Like the exercise trained rats, rats 
undergoing both treatments showed a significant increase in Na+K+-ATPase content in 
the sarcolemma and a matching increase in Na+K+-ATPase maximal activity.   
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Phospholipid analysis of the sarcolemma in these rats showed most of the changes seen 
with the individual treatments.  Hence the combined treatment group showed an 
increase in oleic acid and the percentage of monounsaturated fatty acids when compared 
to the normal control rats.  These two measures were also significantly decreased when 
compared to the exercise group, supporting the notion these changes were due to the 
rosiglitazone treatment.  Mimicking the alterations seen in the exercise group, the 
combined treatment group also displayed increased linoleic acid, percentage of 
unsaturated fatty acids and percentage of omega-6 PUFA, decreased arachidonic acid, 
percentage of saturated fatty acids, unsaturation index and percentage of omega-3 
PUFA, and the net increase in n-6/n-3 ratio compared with HF.     
 
6.4.4 Membrane Phospholipid Analysis 
The high-fat diet consumed by the rats contained hydrogenated coconut oil, of which 
93.3% was saturated fatty acids, 2.4% monounsaturated fatty acids, and 4.3% 
polyunsaturated fatty acids.   Although, it contains seven different saturated fatty acids 
in total, it contains primarily 44.3% lauric acid, 16.7% myristic acid and 8.8% palmitic 
acid.  The only monounsaturated and polyunsaturated fatty acid present is oleic acid and 
linoleic acid respectively.  Therefore, a significant increase in percentage of saturated FA 
was expected.  From the content analysis, the fall in palmitic acid may have caused the 
rise in stearic acid, as it is the direct elongase product of palmitic acid.  The other 
products of palmitic acid, palmitoleic and vaccenic acid were significantly lower in the 
HF group, however the contents of these FA’s are so low, they would not have much  
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impact.  Two elongase reactions with linoleic acid produce linolenic acid, which is 
turned into Arachidonic acid by ∆5desaturase were present in the diet, they also were 
present in low amounts and would not significantly affect overall results.  The overall 
affect of the diet on the rats was a significant decrease in unsaturated FA. 
 
6.4.5 Conclusion 
Based upon previous results from this thesis, we demonstrated that maximal Na+K+-
ATPase function in skeletal muscle is compromised with insulin resistance.  The present 
study demonstrated chronic exercise training significantly increased Na+K+-ATPase 
content and activity, restoring maximal function in insulin resistant skeletal muscle, and 
this increase may have beneficial effects on the exercise capacity and reducing the 
fatiguing effects of exercise for diabetic patients as well as helping to reduce the 
associated risk factors for cardiovascular disease.  Although no effect was demonstrated 
on Na+K+-ATPase function with rosiglitazone, a larger study may be required to 
confirm this observation.  This study indicates that exercise has beneficial effects on 
Na+K+-ATPase function as well as glucose disposal in this diabetic population.  
Therefore it strengthens the recommendation that exercise is the preferable treatment 
option for diabetic patients. 
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C h a p t e r  7  
GENERAL SUMMARY 
7.1 Introduction 
 
Na+K+-ATPase function is vital to the preservation of membrane excitability and 
impaired function has been implicated with insulin resistance and diabetes, and 
associated complications.  In this thesis, the first study investigated Na+K+-ATPase 
activity and content in skeletal muscle of two insulin resistant animal models, genetically 
predisposed obese Zucker rats and high fat diet induced Sprague Dawley rats.  The 
subsequent studies investigated the effects of two therapeutic treatments for type II 
diabetes, rosiglitazone and exercise training, on Na+K+-ATPase function and membrane 
phospholipids in insulin resistant skeletal muscle.   
 
7.2 Major Findings 
 
7.2.1 Decreased Na+K+-ATPase activity and content with insulin resistance in rat skeletal muscle  
One of the most important findings from this thesis was that Na+K+-ATPase function 
was compromised with insulin resistance in rat skeletal muscle.  Maximal in vitro Na+K+-
ATPase activity, expressed relative to muscle protein content, was decreased by 29% in 
15 week old obese Zucker rats and 37% in 14 week old high fat fed Sprague Dawley 
rats.  A similar decrease was found in sarcolemmal Na+K+-ATPase content of both 
animal models.  The content of functional Na+K+-ATPase was reduced by 21.5% in 
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obese Zucker rats and 23% in high fat fed Sprague Dawley rats.  Structural alterations in 
the kinetics of the enzyme and/or the membrane lipids in which the protein is 
embedded may have contributed to the reduced activity but the reduced content implies 
Na+K+-ATPase is compromised at gene transcription or translation, translocation to or 
insertion into the membrane, or has a higher rate of enzyme degradation.   
 
Despite high fat fed Sprague Dawley rats showing deficient insulin action as seen with 
glucose uptake, insulin stimulation with submaximal concentrations of insulin increased 
Na+K+-ATPase activity by 38%.  Hence, the compromised Na+K+-ATPase function 
seen with insulin resistant Sprague Dawley rats could not have been caused by the lack 
of insulin action and would appear to involve a different mechanism of inhibition.  
Possibly reduced physical activity in obese or diabetic rats contributes to a 
downregulation in Na+K+-ATPase function.  To investigate this further, the level of 
physical activity of rats in future studies would need to be measured with the use of 
accelerometry or video movement analysis techniques. 
 
Together, these findings indicate Na+K+-ATPase content is compromised in insulin 
resistant skeletal muscle, resulting in a reduced reserve capacity for Na+K+-ATPase 
activation.   To some degree, this may help explain the predisposition to early onset of 
fatigue and reduced exercise capacity seen with type II diabetics, however, this outcome 
is not the result of reduced insulin action on the Na+K+-ATPase.  Unfortunately the 
movement/physical activity of the rats was not measured and therefore the role of 
physical activity induced changes in Na+K+-ATPase function cannot be ruled out.   
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Na+K+-ATPase function in skeletal muscle from insulin resistant obese zucker rats may 
have been compromised due to reduced fluidity in the sarcolemma, as indicated by 
membrane phospholipid profile analysis, reported in Chapter 5.  The estimated activity 
for ∆5desaturase, which catalyses the addition of a double bond into a FA, was also 
found to be decreased in the obese Zucker rat.  Studies of insulin deficiency have shown 
insulin to have an effect on fatty-acid desaturase activity, suggesting that reduced levels 
of unsaturated fatty acids in the membrane may be a result of reduced insulin action, 
caused by either insulin resistance or insulin deficiency. 
 
7.2.2 Relationships of Na+K+-ATPase activity and content with blood parameters and body mass of rats 
As discussed in Chapter 4, Na+K+-ATPase content in Zucker rats had strong inverse 
correlations with type II diabetic serum markers; glucose (r = -0.75, P < 0.001), 
triglycerides (r = -0.8, P < 0.001) and total cholesterol (r = -0.9, P < 0.001).  These 
relationships and the positive correlation between Na+K+-ATPase content and 
HDL:LDL ratio (r = 0.7, P < 0.001) suggest that the reduction in Na+K+-ATPase 
content could be associated with the development of type II diabetes.  Na+K+-ATPase 
activity also had moderate correlations with serum triglycerides and cholesterol, but no 
relationship was found with glucose or HDL:LDL ratios.  This thesis also examined any 
association between rat muscle [3H]-ouabain binding content or 3-O-MFPase activity 
and body weight, as an indicator of fat accumulation.  Both, Na+K+-ATPase activity (r = 
-0.8, P < 0.001) and content (r = -0.7, P < 0.01) had a strong negative correlation with 
body weight, indicating that Na+K+-ATPase function has a possible association with the 
development of obesity in the obese Zucker rats.   
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7.2.3 Rosiglitazone depresses maximal Na+K+-ATPase activity in lean rat skeletal muscle  
Chronic rosiglitazone treatment had a detrimental affect on the Na+K+-ATPase function 
in skeletal muscle of lean Zucker rats.  Maximal in vitro 3-O-MFPase activity was 
decreased by 35%, to the same activity level as seen in obese Zucker rats.  Maximal 
activity of obese Zucker rats did not further decrease with rosiglitazone treatment.  
Rosiglitazone, therefore, had either no effect on Na+K+-ATPase in skeletal muscle of 
obese Zucker rats or, its effect could not seen because it was not additive to the 
decreased activity already observed with insulin resistance.  Na+K+-ATPase content was 
unaltered with rosiglitazone, hence decreased activity could not be due to reduced 
sarcolemmal content but as a result of activation or functional inhibition.  Analysis of 
the membrane phospholipids showed alterations in membrane lipids and the degree of 
saturation was also not responsible for rosiglitazone’s inhibitory effect.  It would appear 
that the detrimental effects of rosiglitazone, involves a different mechanism to that of 
insulin resistance.  Chronic rosiglitazone treatment may increase insulin sensitivity but it 
could also affect Na+K+-ATPase activity which may limit skeletal muscle function.  
Future studies using a therapeutic dose would need to be carried out to determine if the 
same effect would be seen.  Rosiglitazone treatment at more therapeutic doses, although 
still high, did not significantly alter Na+K+-ATPase activity or content in insulin resistant 
skeletal muscle.       
 
7.2.4 Exercise training restores Na+K+-ATPase function in skeletal muscle of insulin resistant rats 
In Chapter 4 and 5, insulin resistance was repeatedly shown to be associated with down 
regulation of Na+K+-ATPase activity.  In the final study, the most important finding was 
the beneficial effect exercise training had on reduced Na+K+-ATPase function 
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associated with insulin resistance.  Moderate exercise caused a 53% increase in Na+K+-
ATPase content in the sarcolemma and an 83% increase in Na+K+-ATPase maximal 
activity in insulin resistant rats.  This is the first report of restored Na+K+-ATPase 
function with exercise training in insulin resistant skeletal muscle.  Comparable with the 
exercise trained rats, rats undergoing both rosiglitazone treatment and exercise training 
showed a 79% increase in Na+K+-ATPase content in the sarcolemma and a subsequent 
62% increase in Na+K+-ATPase maximal activity.  The effect in this group was almost 
certainly due to the exercise training as rosiglitazone treatment alone was no effect.   
 
7.3 Recommendations for further research 
 
Studies conducted in this thesis have raised important questions regarding the effects of 
insulin resistance and obesity, rosiglitazone and exercise training on skeletal muscle  
Na+K+-ATPase function and membrane phospholipids.  Further work is required to 
determine the mechanism(s) responsible for compromised Na+K+-ATPase function in 
skeletal muscle with insulin resistance and type II diabetes.   
 
Insulin resistance or deficiency may be responsible for decrease desaturase enzyme 
activity resulting in reduced unsaturation in membrane phospholipids, which is known 
to affect Na+K+-ATPase function.  However this hypothesis warrants further 
investigation.  Analysis focusing on the expression of Na+K+-ATPase isoforms may be 
of great benefit.  In addition the measurement of rat physical activity or movement 
would be of great benefit to identify its potential role in affecting the Na+K+-ATPase.   
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Research in this area may provide further insight into the mechanisms responsible for 
the effects of the disease.  
 
Another study is required to investigate the mechanism causing the effect of 
rosiglitazone on Na+K+-ATPase in skeletal muscle.  The inhibition of Na+K+-ATPase 
by chronic rosiglitazone treatment, may be secondary to other mechanisms such as 
AMPK  activation. 
 
Taking these finding from animal models and investigating the effects in humans would 
be of great benefit.  The growing epidemic of obesity and diabetes poses may 
challenges. Further research that elucidates the effects of diabetes on skeletal muscle 
function and the interaction with treatment option such as exercise, diet and medication  
is paramount. 
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